<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:alzm="http://alzamend.com/20241031">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_021_US%2DGAAP%2D2024%2D(with%2DECD) -->
<!-- Field: Set; Name: xdx; ID: xdx_03A_alzm_alzamend.com_20241031 -->
<!-- Field: Set; Name: xdx; ID: xdx_04E_20240501_20241031 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_052_edei%2D%2DDocumentFiscalYearFocus_2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DDocumentFiscalPeriodFocus_Q2 -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0wNC0zMA== -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DEntityCentralIndexKey_0001677077 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2024-05-01to2024-10-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-05-01to2024-10-31" id="Fact000004" name="dei:DocumentFiscalYearFocus">2024</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-05-01to2024-10-31" id="Fact000005" name="dei:DocumentFiscalPeriodFocus">Q2</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-05-01to2024-10-31" id="Fact000006" name="dei:CurrentFiscalYearEndDate">--04-30</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-05-01to2024-10-31" id="Fact000007" name="dei:EntityCentralIndexKey">0001677077</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2024-10-31" id="xdx2ixbrl0071" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-10-31_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0099" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-04-30_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0101" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-10-31_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0119" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-04-30_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0121" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:DividendsOnPreferredShares" contextRef="From2023-08-012023-10-31" id="xdx2ixbrl0200" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:DividendsOnPreferredShares" contextRef="From2023-05-012023-10-31" id="xdx2ixbrl0202" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-07-31_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0241" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-07-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0242" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-07-31_custom_NoteRecievableForCommonStockRelatedPartyMember" id="xdx2ixbrl0245" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts" contextRef="From2024-08-012024-10-31_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0255" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts" contextRef="From2024-08-012024-10-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0256" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts" contextRef="From2024-08-012024-10-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0260" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-08-012024-10-31_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0265" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-08-012024-10-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0266" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-08-012024-10-31_us-gaap_CommonStockMember" id="xdx2ixbrl0267" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-08-012024-10-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0268" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-08-012024-10-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0270" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-08-012024-10-31" id="xdx2ixbrl0271" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:IssuanceOfPreferredStockForCashNetOfIssuanceCosts" contextRef="From2024-08-012024-10-31_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0275" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:IssuanceOfPreferredStockForCashNetOfIssuanceCosts" contextRef="From2024-08-012024-10-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0276" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:IssuanceOfPreferredStockForCashNetOfIssuanceCosts" contextRef="From2024-08-012024-10-31_us-gaap_CommonStockMember" id="xdx2ixbrl0277" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:IssuanceOfPreferredStockForCashNetOfIssuanceCosts" contextRef="From2024-08-012024-10-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0280" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:ConversionOfPreferredStockToCommonStock" contextRef="From2024-08-012024-10-31_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0285" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:ConversionOfPreferredStockToCommonStock" contextRef="From2024-08-012024-10-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0286" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:ConversionOfPreferredStockToCommonStock" contextRef="From2024-08-012024-10-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0290" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:ConversionOfPreferredStockToCommonStock" contextRef="From2024-08-012024-10-31" id="xdx2ixbrl0291" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:StockbasedCompensationToEmployeesAndConsultants" contextRef="From2024-08-012024-10-31_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0297" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:StockbasedCompensationToEmployeesAndConsultants" contextRef="From2024-08-012024-10-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0298" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:StockbasedCompensationToEmployeesAndConsultants" contextRef="From2024-08-012024-10-31_us-gaap_CommonStockMember" id="xdx2ixbrl0299" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:StockbasedCompensationToEmployeesAndConsultants" contextRef="From2024-08-012024-10-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0302" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-08-012024-10-31_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0305" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-08-012024-10-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0306" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-08-012024-10-31_us-gaap_CommonStockMember" id="xdx2ixbrl0307" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-08-012024-10-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0308" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-08-012024-10-31_custom_NoteRecievableForCommonStockRelatedPartyMember" id="xdx2ixbrl0309" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-10-31_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0313" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-10-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0314" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-10-31_custom_NoteRecievableForCommonStockRelatedPartyMember" id="xdx2ixbrl0317" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-07-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0327" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-07-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0334" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts" contextRef="From2023-08-012023-10-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0338" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts" contextRef="From2023-08-012023-10-31_us-gaap_CommonStockMember" id="xdx2ixbrl0339" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts" contextRef="From2023-08-012023-10-31_custom_NoteRecievableForCommonStockRelatedPartyMember" id="xdx2ixbrl0341" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts" contextRef="From2023-08-012023-10-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0342" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-08-012023-10-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0347" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-08-012023-10-31_us-gaap_CommonStockMember" id="xdx2ixbrl0348" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-08-012023-10-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0349" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-08-012023-10-31_custom_NoteRecievableForCommonStockRelatedPartyMember" id="xdx2ixbrl0350" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-08-012023-10-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0351" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-08-012023-10-31" id="xdx2ixbrl0352" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:SubscriptionReceivablePaymentReceived" contextRef="From2023-08-012023-10-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0356" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:SubscriptionReceivablePaymentReceived" contextRef="From2023-08-012023-10-31_us-gaap_CommonStockMember" id="xdx2ixbrl0357" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:SubscriptionReceivablePaymentReceived" contextRef="From2023-08-012023-10-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0360" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:SubscriptionReceivablePaymentReceived" contextRef="From2023-08-012023-10-31" id="xdx2ixbrl0361" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:StockbasedCompensationToEmployeesAndConsultants" contextRef="From2023-08-012023-10-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0363" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:StockbasedCompensationToEmployeesAndConsultants" contextRef="From2023-08-012023-10-31_us-gaap_CommonStockMember" id="xdx2ixbrl0364" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:StockbasedCompensationToEmployeesAndConsultants" contextRef="From2023-08-012023-10-31_custom_NoteRecievableForCommonStockRelatedPartyMember" id="xdx2ixbrl0366" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:StockbasedCompensationToEmployeesAndConsultants" contextRef="From2023-08-012023-10-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0367" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-08-012023-10-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0370" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-08-012023-10-31_us-gaap_CommonStockMember" id="xdx2ixbrl0371" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-08-012023-10-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0372" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-08-012023-10-31_custom_NoteRecievableForCommonStockRelatedPartyMember" id="xdx2ixbrl0373" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-10-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0377" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-10-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0384" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-04-30_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0388" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-04-30_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0389" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-04-30_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0395" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts" contextRef="From2024-05-012024-10-31_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0401" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts" contextRef="From2024-05-012024-10-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0402" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts" contextRef="From2024-05-012024-10-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0405" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-05-012024-10-31_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0410" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-05-012024-10-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0411" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-05-012024-10-31_us-gaap_CommonStockMember" id="xdx2ixbrl0412" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-05-012024-10-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0413" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-05-012024-10-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0414" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-05-01to2024-10-31" id="xdx2ixbrl0415" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:IssuanceOfPreferredStockForCashNetOfIssuanceCosts" contextRef="From2024-05-012024-10-31_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0419" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:IssuanceOfPreferredStockForCashNetOfIssuanceCosts" contextRef="From2024-05-012024-10-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0420" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:IssuanceOfPreferredStockForCashNetOfIssuanceCosts" contextRef="From2024-05-012024-10-31_us-gaap_CommonStockMember" id="xdx2ixbrl0421" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:IssuanceOfPreferredStockForCashNetOfIssuanceCosts" contextRef="From2024-05-012024-10-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0423" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:ConversionOfPreferredStockToCommonStock" contextRef="From2024-05-012024-10-31_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0428" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:ConversionOfPreferredStockToCommonStock" contextRef="From2024-05-012024-10-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0429" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:ConversionOfPreferredStockToCommonStock" contextRef="From2024-05-012024-10-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0432" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:ConversionOfPreferredStockToCommonStock" contextRef="From2024-05-01to2024-10-31" id="xdx2ixbrl0433" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:ConversionOfNotePayableAndInterestToPreferredStock" contextRef="From2024-05-012024-10-31_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0439" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:ConversionOfNotePayableAndInterestToPreferredStock" contextRef="From2024-05-012024-10-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0440" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:ConversionOfNotePayableAndInterestToPreferredStock" contextRef="From2024-05-012024-10-31_us-gaap_CommonStockMember" id="xdx2ixbrl0441" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:ConversionOfNotePayableAndInterestToPreferredStock" contextRef="From2024-05-012024-10-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0443" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:StockbasedCompensationToEmployeesAndConsultants" contextRef="From2024-05-012024-10-31_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0446" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:StockbasedCompensationToEmployeesAndConsultants" contextRef="From2024-05-012024-10-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0447" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:StockbasedCompensationToEmployeesAndConsultants" contextRef="From2024-05-012024-10-31_us-gaap_CommonStockMember" id="xdx2ixbrl0448" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:StockbasedCompensationToEmployeesAndConsultants" contextRef="From2024-05-012024-10-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0450" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-05-012024-10-31_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0453" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-05-012024-10-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0454" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-05-012024-10-31_us-gaap_CommonStockMember" id="xdx2ixbrl0455" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-05-012024-10-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0456" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-10-31_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0460" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-10-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0461" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-04-30_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0473" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-04-30_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0480" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts" contextRef="From2023-05-012023-10-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0484" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts" contextRef="From2023-05-012023-10-31_us-gaap_CommonStockMember" id="xdx2ixbrl0485" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts" contextRef="From2023-05-012023-10-31_custom_NoteRecievableForCommonStockRelatedPartyMember" id="xdx2ixbrl0487" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts" contextRef="From2023-05-012023-10-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0488" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-05-012023-10-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0493" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-05-012023-10-31_us-gaap_CommonStockMember" id="xdx2ixbrl0494" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-05-012023-10-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0495" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-05-012023-10-31_custom_NoteRecievableForCommonStockRelatedPartyMember" id="xdx2ixbrl0496" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-05-012023-10-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0497" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-05-012023-10-31" id="xdx2ixbrl0498" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:SubscriptionReceivablePaymentReceived" contextRef="From2023-05-012023-10-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0502" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:SubscriptionReceivablePaymentReceived" contextRef="From2023-05-012023-10-31_us-gaap_CommonStockMember" id="xdx2ixbrl0503" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:SubscriptionReceivablePaymentReceived" contextRef="From2023-05-012023-10-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0506" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:SubscriptionReceivablePaymentReceived" contextRef="From2023-05-012023-10-31" id="xdx2ixbrl0507" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:StockbasedCompensationToEmployeesAndConsultants" contextRef="From2023-05-012023-10-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0509" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:StockbasedCompensationToEmployeesAndConsultants" contextRef="From2023-05-012023-10-31_us-gaap_CommonStockMember" id="xdx2ixbrl0510" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:StockbasedCompensationToEmployeesAndConsultants" contextRef="From2023-05-012023-10-31_custom_NoteRecievableForCommonStockRelatedPartyMember" id="xdx2ixbrl0512" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:StockbasedCompensationToEmployeesAndConsultants" contextRef="From2023-05-012023-10-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0513" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-05-012023-10-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0516" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-05-012023-10-31_us-gaap_CommonStockMember" id="xdx2ixbrl0517" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-05-012023-10-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0518" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-05-012023-10-31_custom_NoteRecievableForCommonStockRelatedPartyMember" id="xdx2ixbrl0519" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-10-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0523" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-10-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0530" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2023-05-012023-10-31" id="xdx2ixbrl0547" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:IncreaseDecreaseInPrepaidExpensesRelatedParty" contextRef="From2024-05-01to2024-10-31" id="xdx2ixbrl0558" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="From2023-05-012023-10-31" id="xdx2ixbrl0583" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:ConversionOfSeriesConvertiblePreferredStock" contextRef="From2023-05-012023-10-31" id="xdx2ixbrl0604" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:FairValueOfWarrantsIssuedInConnectionWithSeriesConvertiblePreferredStock" contextRef="From2023-05-012023-10-31" id="xdx2ixbrl0607" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:ConversionOfNotePayableAndAccruedInterestIntoSeriesBConvertiblePreferredStock" contextRef="From2023-05-012023-10-31" id="xdx2ixbrl0610" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:PrepaidClinicalTrialExpenses" contextRef="AsOf2024-04-30" id="xdx2ixbrl0693" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="alzm:SharesAvailableForGrantOptionsGranted" contextRef="From2024-05-01to2024-10-31" id="xdx2ixbrl0729" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-05-01to2024-10-31" id="xdx2ixbrl0731" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-05-01to2024-10-31" id="xdx2ixbrl0733" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="alzm:SharesAvailableForGrantOptionsExercised" contextRef="From2024-05-01to2024-10-31" id="xdx2ixbrl0735" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2024-05-01to2024-10-31" id="xdx2ixbrl0737" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2024-05-01to2024-10-31" id="xdx2ixbrl0739" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-05-01to2024-10-31" id="xdx2ixbrl0780" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-05-01to2024-10-31" id="xdx2ixbrl0782" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2024-05-01to2024-10-31" id="xdx2ixbrl0788" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2024-05-01to2024-10-31" id="xdx2ixbrl0790" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-08-012024-10-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="xdx2ixbrl0803" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-08-012023-10-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="xdx2ixbrl0805" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-05-012024-10-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="xdx2ixbrl0807" unitRef="USD" xs:nil="true"/>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="alzm-20241031.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2024-05-01to2024-10-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-10">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-30_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-30_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-012024-10-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-012023-10-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-01</xbrli:startDate>
        <xbrli:endDate>2023-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-012023-10-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-01</xbrli:startDate>
        <xbrli:endDate>2023-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-31_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-31_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-31_custom_NoteRecievableForCommonStockRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:NoteRecievableForCommonStockRelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-31_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-31_custom_NoteRecievableForCommonStockRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:NoteRecievableForCommonStockRelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-30_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-30_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-30_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-30_custom_NoteRecievableForCommonStockRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:NoteRecievableForCommonStockRelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-012024-10-31_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-012024-10-31_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-012024-10-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-012024-10-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-012024-10-31_custom_NoteRecievableForCommonStockRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:NoteRecievableForCommonStockRelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-012024-10-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-012023-10-31_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-01</xbrli:startDate>
        <xbrli:endDate>2023-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-012023-10-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-01</xbrli:startDate>
        <xbrli:endDate>2023-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-012023-10-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-01</xbrli:startDate>
        <xbrli:endDate>2023-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-012023-10-31_custom_NoteRecievableForCommonStockRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:NoteRecievableForCommonStockRelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-01</xbrli:startDate>
        <xbrli:endDate>2023-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-012023-10-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-01</xbrli:startDate>
        <xbrli:endDate>2023-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-10-31_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-10-31_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-10-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-10-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-10-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-012023-10-31_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-01</xbrli:startDate>
        <xbrli:endDate>2023-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-012023-10-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-01</xbrli:startDate>
        <xbrli:endDate>2023-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-012023-10-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-01</xbrli:startDate>
        <xbrli:endDate>2023-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-012023-10-31_custom_NoteRecievableForCommonStockRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:NoteRecievableForCommonStockRelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-01</xbrli:startDate>
        <xbrli:endDate>2023-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-012023-10-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-01</xbrli:startDate>
        <xbrli:endDate>2023-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_custom_NoteRecievableForCommonStockRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:NoteRecievableForCommonStockRelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-31_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-31_custom_NoteRecievableForCommonStockRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:NoteRecievableForCommonStockRelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-10-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-012023-10-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-01</xbrli:startDate>
        <xbrli:endDate>2023-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-10-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-012023-10-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-01</xbrli:startDate>
        <xbrli:endDate>2023-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-10-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-012023-10-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-01</xbrli:startDate>
        <xbrli:endDate>2023-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-22_custom_AL001LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AL001LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-14_us-gaap_DirectorsAndOfficersLiabilityInsuranceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:DirectorsAndOfficersLiabilityInsuranceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-04-30_custom_StockIncentivePlan2016Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alzm:StockIncentivePlan2016Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-02-282019-03-01_custom_StockIncentivePlan2016Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alzm:StockIncentivePlan2016Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-02-28</xbrli:startDate>
        <xbrli:endDate>2019-03-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-292016-04-30_srt_MaximumMember_custom_StockIncentivePlan2016Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alzm:StockIncentivePlan2016Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-29</xbrli:startDate>
        <xbrli:endDate>2016-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-252019-11-26_custom_PerformanceContingentStockOptionsMember_custom_KeyEmployeesAndDirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alzm:PerformanceContingentStockOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alzm:KeyEmployeesAndDirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-25</xbrli:startDate>
        <xbrli:endDate>2019-11-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_custom_UnamortizedStockBasedCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">alzm:UnamortizedStockBasedCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-10-31_custom_StockBasedCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">alzm:StockBasedCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-012024-10-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-012023-10-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-01</xbrli:startDate>
        <xbrli:endDate>2023-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-10-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-012023-10-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-01</xbrli:startDate>
        <xbrli:endDate>2023-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-012024-10-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-012023-10-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-01</xbrli:startDate>
        <xbrli:endDate>2023-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-10-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-012023-10-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-01</xbrli:startDate>
        <xbrli:endDate>2023-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-10-31_custom_Warrant2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:Warrant2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_custom_Warrant2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:Warrant2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-012024-08-19_custom_Warrant2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:Warrant2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-01</xbrli:startDate>
        <xbrli:endDate>2024-08-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-19_custom_Warrant2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:Warrant2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-012024-08-21_custom_Warrant2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:Warrant2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-01</xbrli:startDate>
        <xbrli:endDate>2024-08-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-21_custom_Warrant2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:Warrant2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-09-012024-09-11_custom_Warrant2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:Warrant2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-01</xbrli:startDate>
        <xbrli:endDate>2024-09-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-11_custom_Warrant2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:Warrant2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_custom_ExercisePrice1Member_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">alzm:ExercisePrice1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_custom_ExercisePrice1Member_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">alzm:ExercisePrice1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_custom_ExercisePrice1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">alzm:ExercisePrice1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_custom_ExercisePrice3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">alzm:ExercisePrice3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_custom_ExercisePrice4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">alzm:ExercisePrice4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_custom_ExercisePrice5Member_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">alzm:ExercisePrice5Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_custom_ExercisePrice5Member_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">alzm:ExercisePrice5Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_custom_ExercisePrice5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">alzm:ExercisePrice5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-012018-07-02_custom_AL001LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AL001LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2018-07-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-012018-07-02_custom_AL001LicenseMember_custom_FirstAnniversaryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AL001LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:GuaranteedInsuranceContractTypeOfGuaranteeAxis">alzm:FirstAnniversaryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2018-07-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-012018-07-02_custom_AL001LicenseMember_custom_SecondAnniversaryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AL001LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:GuaranteedInsuranceContractTypeOfGuaranteeAxis">alzm:SecondAnniversaryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2018-07-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-012018-07-02_custom_AL001LicenseMember_custom_ThirdAnniversaryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AL001LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:GuaranteedInsuranceContractTypeOfGuaranteeAxis">alzm:ThirdAnniversaryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2018-07-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-292016-05-02_custom_ALZN002LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:ALZN002LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-29</xbrli:startDate>
        <xbrli:endDate>2016-05-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-292016-05-02_custom_ALZN002LicenseMember_custom_FirstAnniversaryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:ALZN002LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:GuaranteedInsuranceContractTypeOfGuaranteeAxis">alzm:FirstAnniversaryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-29</xbrli:startDate>
        <xbrli:endDate>2016-05-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-292016-05-02_custom_ALZN002LicenseMember_custom_SecondAnniversaryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:ALZN002LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:GuaranteedInsuranceContractTypeOfGuaranteeAxis">alzm:SecondAnniversaryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-29</xbrli:startDate>
        <xbrli:endDate>2016-05-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-292016-05-02_custom_ALZN002LicenseMember_custom_ThirdAnniversaryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:ALZN002LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:GuaranteedInsuranceContractTypeOfGuaranteeAxis">alzm:ThirdAnniversaryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-29</xbrli:startDate>
        <xbrli:endDate>2016-05-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-012019-11-19_custom_AdditionalAL001LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AdditionalAL001LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-01</xbrli:startDate>
        <xbrli:endDate>2019-11-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-012019-11-19_custom_AdditionalAL001LicenseMember_custom_FirstAnniversaryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AdditionalAL001LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:GuaranteedInsuranceContractTypeOfGuaranteeAxis">alzm:FirstAnniversaryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-01</xbrli:startDate>
        <xbrli:endDate>2019-11-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-012019-11-19_custom_AdditionalAL001LicenseMember_custom_SecondAnniversaryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AdditionalAL001LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:GuaranteedInsuranceContractTypeOfGuaranteeAxis">alzm:SecondAnniversaryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-01</xbrli:startDate>
        <xbrli:endDate>2019-11-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-012019-11-19_custom_AdditionalAL001LicenseMember_custom_ThirdAnniversaryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AdditionalAL001LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:GuaranteedInsuranceContractTypeOfGuaranteeAxis">alzm:ThirdAnniversaryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-01</xbrli:startDate>
        <xbrli:endDate>2019-11-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_custom_PreIndMeetingMember_custom_AL001LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:PreIndMeetingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AL001LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-10-31_custom_PreIndMeetingMember_custom_AL001LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:PreIndMeetingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AL001LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_custom_IndApplicationFilingMember_custom_AL001LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:IndApplicationFilingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AL001LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-10-31_custom_IndApplicationFilingMember_custom_AL001LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:IndApplicationFilingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AL001LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_custom_UponFirstDosingOfPatientInClinicalTrialMember_custom_AL001LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:UponFirstDosingOfPatientInClinicalTrialMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AL001LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-10-31_custom_UponFirstDosingOfPatientInClinicalTrialMember_custom_AL001LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:UponFirstDosingOfPatientInClinicalTrialMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AL001LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_custom_UponCompletionOfFirstClinicalTrialMember_custom_AL001LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:UponCompletionOfFirstClinicalTrialMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AL001LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-10-31_custom_UponCompletionOfFirstClinicalTrialMember_custom_AL001LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:UponCompletionOfFirstClinicalTrialMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AL001LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_custom_UponFirstPatientTreatedInAPhaseIIIClinicalMember_custom_AL001LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:UponFirstPatientTreatedInAPhaseIIIClinicalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AL001LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-10-31_custom_UponFirstPatientTreatedInAPhaseIIIClinicalMember_custom_AL001LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:UponFirstPatientTreatedInAPhaseIIIClinicalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AL001LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_custom_UponFdaApprovalMember_custom_AL001LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:UponFdaApprovalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AL001LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-10-31_custom_UponFdaApprovalMember_custom_AL001LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:UponFdaApprovalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AL001LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_custom_UponINDApplicationFilingMember_custom_ALZN002LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:UponINDApplicationFilingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:ALZN002LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-10-31_custom_UponINDApplicationFilingMember_custom_ALZN002LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:UponINDApplicationFilingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:ALZN002LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_custom_UponFirstDosingOfPatientInFirstPhaseIClinicalTrialMember_custom_ALZN002LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:UponFirstDosingOfPatientInFirstPhaseIClinicalTrialMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:ALZN002LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-10-31_custom_UponFirstDosingOfPatientInFirstPhaseIClinicalTrialMember_custom_ALZN002LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:UponFirstDosingOfPatientInFirstPhaseIClinicalTrialMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:ALZN002LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_custom_UponCompletionOfFirstPhaseIIClinicalTrialMember_custom_ALZN002LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:UponCompletionOfFirstPhaseIIClinicalTrialMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:ALZN002LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-10-31_custom_UponCompletionOfFirstPhaseIIClinicalTrialMember_custom_ALZN002LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:UponCompletionOfFirstPhaseIIClinicalTrialMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:ALZN002LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_custom_UponFirstPatientTreatedInPhaseIIIClinicalTrialMember_custom_ALZN002LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:UponFirstPatientTreatedInPhaseIIIClinicalTrialMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:ALZN002LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-10-31_custom_UponFirstPatientTreatedInPhaseIIIClinicalTrialMember_custom_ALZN002LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:UponFirstPatientTreatedInPhaseIIIClinicalTrialMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:ALZN002LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_custom_UponFDABLAApprovalMember_custom_ALZN002LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:UponFDABLAApprovalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:ALZN002LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-10-31_custom_UponFDABLAApprovalMember_custom_ALZN002LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:UponFDABLAApprovalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:ALZN002LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_custom_UponFirstPatientTreatedInAPhaseIIIClinicalMember_custom_AdditionalAL001LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:UponFirstPatientTreatedInAPhaseIIIClinicalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AdditionalAL001LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-10-31_custom_UponFirstPatientTreatedInAPhaseIIIClinicalMember_custom_AdditionalAL001LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:UponFirstPatientTreatedInAPhaseIIIClinicalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AdditionalAL001LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_custom_FirstCommercialSaleMember_custom_AdditionalAL001LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:FirstCommercialSaleMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AdditionalAL001LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-10-31_custom_FirstCommercialSaleMember_custom_AdditionalAL001LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="alzm:LicenseEventsAxis">alzm:FirstCommercialSaleMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alzm:AdditionalAL001LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-05-08_us-gaap_SeriesAPreferredStockMember_custom_SecuritiesPurchaseAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alzm:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-05-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-05-10_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alzm:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-05-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-10_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alzm:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-05-10_custom_SecuritiesPurchaseAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alzm:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-05-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-10_custom_SecuritiesPurchaseAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alzm:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-012024-06-25_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alzm:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-01</xbrli:startDate>
        <xbrli:endDate>2024-06-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-25_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alzm:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-01-31_custom_SeriesBConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementsMember_custom_AultLendingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alzm:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alzm:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alzm:AultLendingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-01-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-01-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-012024-03-26_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-01</xbrli:startDate>
        <xbrli:endDate>2024-03-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-012024-03-26_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-01</xbrli:startDate>
        <xbrli:endDate>2024-03-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-26_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-04-29_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-04-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-04-29_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-04-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-29_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-012024-12-10">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2024-12-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact000669" toRefs="Footnote000684"/>
  <ix:relationship fromRefs="Fact000671" toRefs="Footnote000684"/>
  <ix:relationship fromRefs="Fact000975" toRefs="Footnote000996"/>
  <ix:relationship fromRefs="Fact000979" toRefs="Footnote000996"/>
  <ix:relationship fromRefs="Fact000983" toRefs="Footnote000996"/>
  <ix:relationship fromRefs="Fact000987" toRefs="Footnote000996"/>
  <ix:relationship fromRefs="Fact001001" toRefs="Footnote001018"/>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<!-- Field: Rule-Page --><div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES<br/>
SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, DC 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_902_edei--DocumentType_c20240501__20241031_z6IvUqdeQgO4"><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" id="Fact000013" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_906_edei--DocumentQuarterlyReport_c20240501__20241031_zEWEAR0tTGI3"><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" format="ixt:booleantrue" id="Fact000014" name="dei:DocumentQuarterlyReport">x</ix:nonNumeric></span></span></td>
    <td style="width: 99%; font-size: 10pt"><b>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the quarterly period ended&#160;<span id="xdx_906_edei--DocumentPeriodEndDate_c20240501__20241031_zuthovX4OaN4"><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" format="ixt:datemonthdayyearen" id="Fact000015" name="dei:DocumentPeriodEndDate">October
31, 2024</ix:nonNumeric></span></b>&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OR</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_902_edei--DocumentTransitionReport_c20240501__20241031_zz3LKB1SCHc7"><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" format="ixt:booleanfalse" id="Fact000016" name="dei:DocumentTransitionReport">&#168;</ix:nonNumeric></span></span></td>
    <td style="width: 99%; font-size: 10pt"><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Commission File Number:&#160;<span id="xdx_904_edei--EntityFileNumber_c20240501__20241031_zUYECUxk8ivb"><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" id="Fact000017" name="dei:EntityFileNumber">001-40483</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3pt; text-align: center; color: #231F20"><b><span id="xdx_903_edei--EntityRegistrantName_c20240501__20241031_zGamMJTRNRCa"><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" id="Fact000018" name="dei:EntityRegistrantName">ALZAMEND NEURO, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of registrant as specified in its
charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 52%; font-size: 10pt; text-align: center"><b><span id="xdx_90E_edei--EntityIncorporationStateCountryCode_c20240501__20241031_z8PNbj3rfab4"><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" format="ixt-sec:stateprovnameen" id="Fact000019" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></td>
    <td style="width: 48%; font-size: 10pt; text-align: center"><b><span id="xdx_900_edei--EntityTaxIdentificationNumber_c20240501__20241031_z0luyVQ3Pp5a"><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" id="Fact000020" name="dei:EntityTaxIdentificationNumber">81-1822909</ix:nonNumeric></span></b></td></tr>
  <tr>
    <td style="font-size: 10pt; text-align: center">(State or other jurisdiction of incorporation or organization)</td>
    <td style="font-size: 10pt; text-align: center">&#160;(I.R.S. Employer Identification Number)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 52%; text-align: center"><b><span id="xdx_904_edei--EntityAddressAddressLine1_c20240501__20241031_zyh2zioG0IVb"><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" id="Fact000021" name="dei:EntityAddressAddressLine1">3480 Peachtree Road NE</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressAddressLine2_c20240501__20241031_zyFdNjiQHqT2"><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" id="Fact000022" name="dei:EntityAddressAddressLine2">Second Floor Suite 103</ix:nonNumeric></span>, <span id="xdx_90D_edei--EntityAddressCityOrTown_c20240501__20241031_zVoM83FLGIcf"><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" id="Fact000023" name="dei:EntityAddressCityOrTown">Atlanta</ix:nonNumeric></span>, <span id="xdx_901_edei--EntityAddressStateOrProvince_c20240501__20241031_zyr2ZRps8PK4"><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" id="Fact000024" name="dei:EntityAddressStateOrProvince">GA</ix:nonNumeric></span></b></td>
    <td style="vertical-align: top; width: 10%; text-align: center"><b><span id="xdx_90F_edei--EntityAddressPostalZipCode_c20240501__20241031_zPPZoLAU2dMc"><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" id="Fact000025" name="dei:EntityAddressPostalZipCode">30326</ix:nonNumeric></span></b></td>
    <td style="vertical-align: top; width: 38%; text-align: center"><b>(<span id="xdx_90F_edei--CityAreaCode_c20240501__20241031_zhzQomBy0GN2"><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" id="Fact000026" name="dei:CityAreaCode">844</ix:nonNumeric></span>) <span id="xdx_907_edei--LocalPhoneNumber_c20240501__20241031_zk5ArXZRc507"><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" id="Fact000027" name="dei:LocalPhoneNumber">722-6303</ix:nonNumeric></span></b></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">(Address of principal executive offices)</td>
    <td style="text-align: center">(Zip Code)</td>
    <td style="text-align: center">(Registrant&#8217;s telephone number, including area code)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered under Section 12(b) of the
Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 42%; text-align: center"><b>Title of Each Class</b></td>
    <td style="vertical-align: top; width: 20%; text-align: center"><b>Trading Symbol</b></td>
    <td style="width: 38%; text-align: center"><b>Name of each exchange on which registered</b></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center"><span id="xdx_90D_edei--Security12bTitle_c20240501__20241031_zx6aUquNdlIc"><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" id="Fact000028" name="dei:Security12bTitle">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_901_edei--TradingSymbol_c20240501__20241031_zwMhTRr7JfJb"><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" id="Fact000029" name="dei:TradingSymbol">ALZN</ix:nonNumeric></span></td>
    <td style="text-align: center"><span id="xdx_90A_edei--SecurityExchangeName_c20240501__20241031_z96UHopzMdg5"><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" format="ixt-sec:exchnameen" id="Fact000030" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Capital Market</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;<b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days.&#160;<span id="xdx_901_edei--EntityCurrentReportingStatus_c20240501__20241031_zMTM2eTgbUXg"><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" id="Fact000031" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>&#160;<span style="font-family: Wingdings">x</span>&#160;No&#160;<span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding
12 months (or for such shorter period that the registrant was required to submit such files).&#160;<span id="xdx_90A_edei--EntityInteractiveDataCurrent_c20240501__20241031_zAqoBWLPSxT9"><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" id="Fact000032" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span>&#160;<span style="font-family: Wingdings">x</span>&#160;No&#160;<span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.
See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221;
and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 25%">Large accelerated filer</td>
    <td style="white-space: nowrap; width: 35%"><span style="font-family: Wingdings">&#168;</span></td>
    <td style="white-space: nowrap; width: 40%; text-align: right">Accelerated filer <span style="font-family: Wingdings">&#168;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span id="xdx_90A_edei--EntityFilerCategory_c20240501__20241031_zZbHxdtsYjE3"><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" format="ixt-sec:entityfilercategoryen" id="Fact000033" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span></td>
    <td style="white-space: nowrap"><span style="font-family: Wingdings">x</span></td>
    <td style="white-space: nowrap; text-align: right">&#160;Smaller reporting company <span style="font-family: Wingdings"><span id="xdx_909_edei--EntitySmallBusiness_c20240501__20241031_z2OYCf006Cjc"><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" format="ixt:booleantrue" id="Fact000034" name="dei:EntitySmallBusiness">x</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">Emerging growth company</td>
    <td style="white-space: nowrap"><span style="font-family: Wingdings"><span id="xdx_904_edei--EntityEmergingGrowthCompany_c20240501__20241031_z2Gbh7ZYCrA8"><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" format="ixt:booleantrue" id="Fact000035" name="dei:EntityEmergingGrowthCompany">x</ix:nonNumeric></span></span></td>
    <td style="white-space: nowrap">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<span style="font-family: Wingdings"><span id="xdx_903_edei--EntityExTransitionPeriod_c20240501__20241031_zCzANpZ91bKk"><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" format="ixt:booleanfalse" id="Fact000036" name="dei:EntityExTransitionPeriod">&#168;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes&#160;<span style="font-family: Wingdings">&#168;</span> <span id="xdx_90F_edei--EntityShellCompany_c20240501__20241031_zWMpZQJ5a8f3"><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" format="ixt:booleanfalse" id="Fact000037" name="dei:EntityShellCompany">No</ix:nonNumeric></span>&#160;<span style="font-family: Wingdings">x</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 10, 2024 there were&#160;<span id="xdx_909_edei--EntityCommonStockSharesOutstanding_iI_c20241210_znd5jvb3wgKk" title="Entity Common Stock, Shares Outstanding"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2024-12-10" id="Fact000039" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,432,797</ix:nonFraction></span>&#160;shares of registrant&#8217;s
common stock, $0.0001 par value per share, outstanding.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"/><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Table of Contents</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: center"><b>Page</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; width: 8%"><b>PART I.</b></td>
    <td style="white-space: nowrap; width: 88%"><b><span style="text-decoration: underline">FINANCIAL INFORMATION</span></b></td>
    <td style="white-space: nowrap; width: 4%; text-align: center">3</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap">Item 1.</td>
    <td style="white-space: nowrap">Financial Statements (unaudited)</td>
    <td style="white-space: nowrap; text-align: center">3</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">Condensed Balance Sheets</td>
    <td style="white-space: nowrap; text-align: center">3</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">Condensed Statements of Operations</td>
    <td style="white-space: nowrap; text-align: center">4</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">Condensed Statements of Stockholders&#8217; (Deficit) Equity</td>
    <td style="white-space: nowrap; text-align: center">5</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">Condensed Statements of Cash Flows</td>
    <td style="white-space: nowrap; text-align: center">9</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">Notes to Condensed Financial Statements</td>
    <td style="white-space: nowrap; text-align: center">10</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap">Item 2.</td>
    <td style="white-space: nowrap">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</td>
    <td style="white-space: nowrap; text-align: center">22</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap">Item 3.</td>
    <td style="white-space: nowrap">Quantitative and Qualitative Disclosures About Market Risk</td>
    <td style="white-space: nowrap; text-align: center">36</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap">Item 4.</td>
    <td style="white-space: nowrap">Controls and Procedures</td>
    <td style="white-space: nowrap; text-align: center">37</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap"><b>PART II.</b></td>
    <td style="white-space: nowrap"><b><span style="text-decoration: underline">OTHER INFORMATION</span></b></td>
    <td style="white-space: nowrap; text-align: center">39</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap">Item 1.</td>
    <td style="white-space: nowrap">Legal Proceedings</td>
    <td style="white-space: nowrap; text-align: center">39</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap">Item 1A.</td>
    <td style="white-space: nowrap">Risk Factors</td>
    <td style="white-space: nowrap; text-align: center">39</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap">Item 2.</td>
    <td style="white-space: nowrap">Unregistered Sales of Equity Securities and Use of Proceeds</td>
    <td style="white-space: nowrap; text-align: center">39</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap">Item 3.</td>
    <td style="white-space: nowrap">Defaults Upon Senior Securities</td>
    <td style="white-space: nowrap; text-align: center">39</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap">Item 4.</td>
    <td style="white-space: nowrap">Mine Safety Disclosures</td>
    <td style="white-space: nowrap; text-align: center">39</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap">Item 5. </td>
    <td style="white-space: nowrap">Other Information</td>
    <td style="white-space: nowrap; text-align: center">39</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap">Item 6.</td>
    <td style="white-space: nowrap">Exhibits</td>
    <td style="white-space: nowrap; text-align: center">40</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">Signatures</td>
    <td style="white-space: nowrap; text-align: center">41</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART I &#8211; FINANCIAL INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 45pt"><b>ITEM 1.</b></td><td style="text-align: justify"><b>FINANCIAL STATEMENTS</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;<b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Alzamend Neuro, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Condensed Balance Sheets</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" id="xdx_305_111_z2dNX9KKmjg" summary="xdx: Statement - Condensed Balance Sheets (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20241031" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20240430" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">October 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">April 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AssetsAbstract_iB_z5NmhPrJmYV" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AssetsCurrentAbstract_i01B_z3U3bl7TtAUf" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CURRENT ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCz0Pz_z9Sw8Yy93x7e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-10-31" id="Fact000047" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,093,073</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-04-30" id="Fact000048" format="ixt:numdotdecimal" decimals="0" unitRef="USD">376,048</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maCz0Pz_zHywEUn3CWzc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-10-31" id="Fact000050" format="ixt:numdotdecimal" decimals="0" unitRef="USD">673,669</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-04-30" id="Fact000051" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79,194</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AssetsCurrent_i02TI_mtCz0Pz_maCztFW_zlGt89oZ4lb1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">TOTAL CURRENT ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-10-31" id="Fact000053" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,766,742</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-04-30" id="Fact000054" format="ixt:numdotdecimal" decimals="0" unitRef="USD">455,242</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentNet_i02I_maCztFW_z9n2nsFcHs5c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Property, plant and equipment, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-10-31" id="Fact000056" format="ixt:numdotdecimal" decimals="0" unitRef="USD">240,976</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-04-30" id="Fact000057" format="ixt:numdotdecimal" decimals="0" unitRef="USD">176,346</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--Assets_i01TI_mtCztFW_zlxYG09deWgf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">TOTAL ASSETS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-10-31" id="Fact000059" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,007,718</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-04-30" id="Fact000060" format="ixt:numdotdecimal" decimals="0" unitRef="USD">631,588</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesCurrentAbstract_i01B_zg7UYAGLQz71" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CURRENT LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AccountsPayableCurrent_i02I_maCzobl_z7OeAX6iNuki" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounts payable and accrued liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-10-31" id="Fact000068" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,254,750</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-04-30" id="Fact000069" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,925,059</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NotesPayableCurrent_i02I_maCzobl_zOrDGbjEfrF8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Note payable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0071">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2024-04-30" id="Fact000072" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,714</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--Liabilities_i02TI_mtCzobl_maLASEzzp4_zFhwLSllOIpa" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">TOTAL LIABILITIES, ALL CURRENT</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-10-31" id="Fact000074" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,254,750</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-04-30" id="Fact000075" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,225,773</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CommitmentsAndContingencies_i01I_zq8GdWQEKbwf" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">COMMITMENTS AND CONTINGENCIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--StatementOfStockholdersEquityAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">STOCKHOLDERS&#8217; EQUITY (DEFICIT)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Series A Convertible Preferred Stock, $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_c20241031__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Preferred stock, par value (in dollars per share)"><span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_c20240430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Preferred stock, par value (in dollars per share)"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-10-31_us-gaap_SeriesAPreferredStockMember" id="Fact000083" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-04-30_us-gaap_SeriesAPreferredStockMember" id="Fact000085" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span>
    stated value per share, <span id="xdx_901_ecustom--PreferredStockSharesDesignated_c20241031__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Preferred stock shares designated"><span id="xdx_90F_ecustom--PreferredStockSharesDesignated_c20240430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Preferred stock shares designated"><ix:nonFraction name="alzm:PreferredStockSharesDesignated" contextRef="AsOf2024-10-31_us-gaap_SeriesAPreferredStockMember" id="Fact000087" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="alzm:PreferredStockSharesDesignated" contextRef="AsOf2024-04-30_us-gaap_SeriesAPreferredStockMember" id="Fact000089" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,000</ix:nonFraction></ix:nonFraction></span></span>
    shares designated; <span id="xdx_903_eus-gaap--PreferredStockSharesIssued_c20241031__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Preferred stock, shares issued"><span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_c20241031__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-10-31_us-gaap_SeriesAPreferredStockMember" id="Fact000091" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-10-31_us-gaap_SeriesAPreferredStockMember" id="Fact000093" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">87.9867</ix:nonFraction></ix:nonFraction></span></span>
    and nil <span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_c20240430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Preferred stock, shares issued"><span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_c20240430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Preferred stock, shares outstanding" style="display: none"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-04-30_us-gaap_SeriesAPreferredStockMember" id="Fact000095" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-04-30_us-gaap_SeriesAPreferredStockMember" id="Fact000097" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></span></span> issued and outstanding as of October 31, 2024 and April 30, 2024, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--PreferredStockValue_pp0p0_maCzJ2l_c20241031__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_za9uWuJLYhml" title="Preferred Stock, Value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0099">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--PreferredStockValue_pp0p0_maCzJ2l_c20240430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zp3JtBLYvlC3" title="Preferred Stock, Value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0101">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Series B Convertible Preferred Stock, $<span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_c20241031__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Preferred stock, par value (in dollars per share)"><span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_c20240430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Preferred stock, par value (in dollars per share)"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-10-31_us-gaap_SeriesBPreferredStockMember" id="Fact000103" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-04-30_us-gaap_SeriesBPreferredStockMember" id="Fact000105" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> stated value per share, <span id="xdx_900_ecustom--PreferredStockSharesDesignated_c20241031__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Preferred stock shares designated"><span id="xdx_90E_ecustom--PreferredStockSharesDesignated_c20240430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Preferred stock shares designated"><ix:nonFraction name="alzm:PreferredStockSharesDesignated" contextRef="AsOf2024-10-31_us-gaap_SeriesBPreferredStockMember" id="Fact000107" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="alzm:PreferredStockSharesDesignated" contextRef="AsOf2024-04-30_us-gaap_SeriesBPreferredStockMember" id="Fact000109" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,000</ix:nonFraction></ix:nonFraction></span></span> designated; <span id="xdx_902_eus-gaap--PreferredStockSharesIssued_c20241031__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Preferred stock, shares issued"><span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_c20241031__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Preferred stock, shares outstanding"><span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_c20240430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Preferred stock, shares issued"><span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_c20240430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-10-31_us-gaap_SeriesBPreferredStockMember" id="Fact000111" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-10-31_us-gaap_SeriesBPreferredStockMember" id="Fact000113" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-04-30_us-gaap_SeriesBPreferredStockMember" id="Fact000115" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-04-30_us-gaap_SeriesBPreferredStockMember" id="Fact000117" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,100</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> issued and outstanding as of
    October 31, 2024 and April 30, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--PreferredStockValue_pp0p0_maCzJ2l_c20241031__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zGBFvp9MeUIb" title="Preferred Stock, Value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0119">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--PreferredStockValue_pp0p0_maCzJ2l_c20240430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zQ9NBQMbHNL3" title="Preferred Stock, Value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0121">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CommonStockValue_iI_maCzJ2l_zyhBBXqOvPyk" style="vertical-align: bottom; background-color: White">
    <td>Common stock, $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_c20241031_pdd" title="Common stock, par value (in dollars per share)"><span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_c20240430_pdd" title="Common stock, par value (in dollars per share)"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-10-31" id="Fact000126" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-04-30" id="Fact000128" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value: <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_c20241031_pdd" title="Common stock, shares authorized"><span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_c20240430_pdd" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-10-31" id="Fact000130" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-04-30" id="Fact000132" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">300,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_906_eus-gaap--CommonStockSharesIssued_c20241031_pdd" title="Common stock, shares issued"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_c20241031_pdd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-10-31" id="Fact000134" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-10-31" id="Fact000136" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,231,254</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_904_eus-gaap--CommonStockSharesIssued_c20240430_pdd" title="Common stock, shares issued"><span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_c20240430_pdd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-04-30" id="Fact000138" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-04-30" id="Fact000140" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">687,999</ix:nonFraction></ix:nonFraction></span></span>&#160;issued and outstanding as of October 31, 2024 and April 30, 2024, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-10-31" id="Fact000123" format="ixt:numdotdecimal" decimals="0" unitRef="USD">523</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-04-30" id="Fact000124" format="ixt:numdotdecimal" decimals="0" unitRef="USD">69</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AdditionalPaidInCapital_iI_maCzJ2l_z8BdvipKWspi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-10-31" id="Fact000142" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,162,478</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-04-30" id="Fact000143" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,426,154</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_maCzJ2l_zdK8jRDjqDTf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Accumulated deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-10-31" id="Fact000145" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">56,410,033</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-04-30" id="Fact000146" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">54,020,408</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--StockholdersEquity_iTI_pp0p0_mtCzJ2l_maLASEzzp4_zBk06tCMbrMj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">TOTAL STOCKHOLDERS&#8217; EQUITY (DEFICIT)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-10-31" id="Fact000148" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,752,968</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-04-30" id="Fact000149" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,594,185</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_pp0p0_mtLASEzzp4_z7RzzvOTAUT1" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-10-31" id="Fact000151" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,007,718</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-04-30" id="Fact000152" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">631,588</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these unaudited condensed financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Alzamend Neuro, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Condensed Statements of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_113_zDTSqAdeDvNf" summary="xdx: Statement - Condensed Statements of Operations (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49B_20240801_20241031" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20230801_20231031" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20240501_20241031" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_494_20230501_20231031" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">For the Three Months Ended<br/>
October 31,</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">For the Six Months Ended<br/>
October 31,</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingExpensesAbstract_iB_zAGVFJjSxzQ8" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">OPERATING EXPENSES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_i01_maCza1M_z7FqUp2o866" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; text-indent: 10pt">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-08-012024-10-31" id="Fact000159" format="ixt:numdotdecimal" decimals="0" unitRef="USD">311,088</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-08-012023-10-31" id="Fact000160" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,996,783</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-05-01to2024-10-31" id="Fact000161" format="ixt:numdotdecimal" decimals="0" unitRef="USD">517,659</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-05-012023-10-31" id="Fact000162" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,362,920</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--GeneralAndAdministrativeExpense_i01_maCza1M_zza01JkIm4xl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-08-012024-10-31" id="Fact000164" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,046,980</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-08-012023-10-31" id="Fact000165" format="ixt:numdotdecimal" decimals="0" unitRef="USD">904,939</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-05-01to2024-10-31" id="Fact000166" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,802,814</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-05-012023-10-31" id="Fact000167" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,064,732</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingExpenses_i01T_mtCza1M_msCzDq8_zloLM7QekLb6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 20pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-08-012024-10-31" id="Fact000169" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,358,068</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-08-012023-10-31" id="Fact000170" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,901,722</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-05-01to2024-10-31" id="Fact000171" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,320,473</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-05-012023-10-31" id="Fact000172" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,427,652</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingIncomeLoss_iT_mtCzDq8_maCzlYN_zOMFqNfEz2j8" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Loss from operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-08-012024-10-31" id="Fact000174" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,358,068</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-08-012023-10-31" id="Fact000175" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,901,722</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-05-01to2024-10-31" id="Fact000176" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,320,473</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-05-012023-10-31" id="Fact000177" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,427,652</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zSGD5M8xNG8f" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">OTHER EXPENSE, NET</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--InterestExpense_iN_di_msCzbTI_zmCDjNLXJdy9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Interest expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2024-08-012024-10-31" id="Fact000184" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,495</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-08-012023-10-31" id="Fact000185" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,311</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2024-05-01to2024-10-31" id="Fact000186" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,501</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-05-012023-10-31" id="Fact000187" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,147</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--NonoperatingIncomeExpense_iT_mtCzbTI_maCzlYN_zeaCDSfa8V7a" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: 10.05pt">Total other expense, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-08-012024-10-31" id="Fact000189" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,495</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-08-012023-10-31" id="Fact000190" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,311</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-05-01to2024-10-31" id="Fact000191" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,501</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-05-012023-10-31" id="Fact000192" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,147</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--ProfitLoss_iT_mtCzlYN_maCznlq_z4pc1IjRjAEd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">NET LOSS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-08-012024-10-31" id="Fact000194" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,361,563</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-08-012023-10-31" id="Fact000195" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,906,033</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-05-01to2024-10-31" id="Fact000196" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,335,974</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-05-012023-10-31" id="Fact000197" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,433,799</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DividendsOnPreferredShares_iN_di_msCznlq_zvQbCdWsxqKf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividends on preferred shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="alzm:DividendsOnPreferredShares" contextRef="From2024-08-012024-10-31" id="Fact000199" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,651</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0200">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="alzm:DividendsOnPreferredShares" contextRef="From2024-05-01to2024-10-31" id="Fact000201" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,651</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0202">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_mtCznlq_zFb3Z0YBrHc7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET LOSS AVAILABLE TO COMMON SHARES</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-08-012024-10-31" id="Fact000204" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,415,214</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-08-012023-10-31" id="Fact000205" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,906,033</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-05-01to2024-10-31" id="Fact000206" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,389,625</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-05-012023-10-31" id="Fact000207" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,433,799</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss per common share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--EarningsPerShareBasic_c20240801__20241031_pdd" title="Basic net loss per common share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_908_eus-gaap--EarningsPerShareDiluted_c20240801__20241031_pdd" title="Diluted net loss per common share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-08-012024-10-31" id="Fact000209" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-08-012024-10-31" id="Fact000211" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.40</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--EarningsPerShareBasic_c20230801__20231031_pdd" title="Basic net loss per common share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20230801__20231031_pdd" title="Diluted net loss per common share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-08-012023-10-31" id="Fact000213" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-08-012023-10-31" id="Fact000215" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">4.43</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--EarningsPerShareBasic_c20240501__20241031_pdd" title="Basic net loss per common share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_c20240501__20241031_pdd" title="Diluted net loss per common share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-05-01to2024-10-31" id="Fact000217" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-05-01to2024-10-31" id="Fact000219" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.11</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_c20230501__20231031_pdd" title="Basic net loss per common share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_c20230501__20231031_pdd" title="Diluted net loss per common share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-05-012023-10-31" id="Fact000221" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-05-012023-10-31" id="Fact000223" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">9.80</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Basic and diluted weighted average common shares outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240801__20241031_pdd" title="Basic weighted average common shares outstanding" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240801__20241031_pdd" title="Diluted weighted average common shares outstanding" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-08-012024-10-31" id="Fact000225" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-08-012024-10-31" id="Fact000227" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,531,702</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230801__20231031_pdd" title="Basic weighted average common shares outstanding" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230801__20231031_pdd" title="Diluted weighted average common shares outstanding" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-08-012023-10-31" id="Fact000229" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-08-012023-10-31" id="Fact000231" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">656,378</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240501__20241031_pdd" title="Basic weighted average common shares outstanding" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240501__20241031_pdd" title="Diluted weighted average common shares outstanding" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-05-01to2024-10-31" id="Fact000233" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-05-01to2024-10-31" id="Fact000235" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,154,761</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230501__20231031_pdd" title="Basic weighted average common shares outstanding" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230501__20231031_pdd" title="Diluted weighted average common shares outstanding" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-05-012023-10-31" id="Fact000237" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-05-012023-10-31" id="Fact000239" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">656,323</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these unaudited condensed financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Alzamend Neuro, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Condensed Statements of Stockholders&#8217;
Equity (Deficit)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the Three Months Ended October 31, 2024</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" summary="xdx: Statement - Condensed Statements of Stockholders' (Deficit) Equity (Unaudited)" id="xdx_304_114_zlmDzP4ckIjl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_custom--SeriesAConvertiblePreferredStockMember_zt3cqN8nUyw" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_custom--SeriesBConvertiblePreferredStockMember_zY0l9EER4U0i" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zl2j3Nshr7K7" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zNqS4li4IrXl" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_custom--NoteRecievableForCommonStockRelatedPartyMember_zaLwRIMH6O7f">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zYjqk3Zbnydc" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B9_zShXLknSZwFd" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">Series A Convertible</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">Series B Convertible</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Additional</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Preferred Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Preferred Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; white-space: nowrap; font-weight: bold; text-align: center">Paid-In</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; white-space: nowrap; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_435_c20240801__20241031_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zs7L9lsx6Mr3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 19%">BALANCES, July 31, 2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_c20240801__20241031__us-gaap--StatementEquityComponentsAxis__custom--SeriesAConvertiblePreferredStockMember_zM7JxeHpErm9" title="Beginning balance, shares" style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-07-31_custom_SeriesAConvertiblePreferredStockMember" id="Fact000249" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">188</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0241">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iS_c20240801__20241031__us-gaap--StatementEquityComponentsAxis__custom--SeriesBConvertiblePreferredStockMember_zNNCXHm2ukNf" title="Beginning balance, shares" style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-07-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000251" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,100</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0242">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_c20240801__20241031__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zeFgP6OlIyP" title="Beginning balance, shares" style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-07-31_us-gaap_CommonStockMember" id="Fact000253" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">861,332</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-07-31_us-gaap_CommonStockMember" id="Fact000243" format="ixt:numdotdecimal" decimals="0" unitRef="USD">86</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-07-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000244" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,782,414</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="color: rgb(204,238,255); width: 1%">&#160;<span style="-sec-ix-hidden: xdx2ixbrl0245">-</span></td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-07-31_us-gaap_RetainedEarningsMember" id="Fact000246" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">54,994,819</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-07-31" id="Fact000247" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,212,319</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--IssuanceOfCommonStockForCashNetOfIssuanceCosts_z2wVr6bU6ZK" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of common stock for cash, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0255">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0256">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--IssuanceOfCommonStockForCashNetOfIssuanceCostsShares_c20240801__20241031__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z51psd2cLZTc" title="Issuance of common stock for cash, net of issuance costs, shares" style="text-align: right"><ix:nonFraction name="alzm:IssuanceOfCommonStockForCashNetOfIssuanceCostsShares" contextRef="From2024-08-012024-10-31_us-gaap_CommonStockMember" id="Fact000263" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">755,888</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts" contextRef="From2024-08-012024-10-31_us-gaap_CommonStockMember" id="Fact000257" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts" contextRef="From2024-08-012024-10-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000258" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,174,148</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0260">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts" contextRef="From2024-08-012024-10-31" id="Fact000261" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,174,224</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_ztbEOb6LjBbb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of common stock for restricted stock awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0265">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0266">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240801__20241031__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHTF6FfDaTpf" title="Issuance of common stock for restricted stock awards, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-08-012024-10-31_us-gaap_CommonStockMember" id="Fact000273" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">83</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0267">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0268">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0270">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0271">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--IssuanceOfPreferredStockForCashNetOfIssuanceCosts_zEiVbqkTWkN3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of preferred stock for cash, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--IssuanceOfPreferredStockForCashNetOfIssuanceCostsShares_c20240801__20241031__us-gaap--StatementEquityComponentsAxis__custom--SeriesAConvertiblePreferredStockMember_z8FoEzM11mA" title="Issuance of preferred stock for cash, net of issuance costs, shares" style="text-align: right"><ix:nonFraction name="alzm:IssuanceOfPreferredStockForCashNetOfIssuanceCostsShares" contextRef="From2024-08-012024-10-31_custom_SeriesAConvertiblePreferredStockMember" id="Fact000283" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">550</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0275">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0276">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0277">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="alzm:IssuanceOfPreferredStockForCashNetOfIssuanceCosts" contextRef="From2024-08-012024-10-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000278" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,125,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0280">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="alzm:IssuanceOfPreferredStockForCashNetOfIssuanceCosts" contextRef="From2024-08-012024-10-31" id="Fact000281" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,125,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--ConversionOfPreferredStockToCommonStock_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Conversion of preferred stock to common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ConversionOfPreferredStockToCommonStockShares_c20240801__20241031__us-gaap--StatementEquityComponentsAxis__custom--SeriesAConvertiblePreferredStockMember_zSIcDVSGVTZ9" title="Conversion of preferred stock to common stock, shares" style="text-align: right">(<ix:nonFraction name="alzm:ConversionOfPreferredStockToCommonStockShares" contextRef="From2024-08-012024-10-31_custom_SeriesAConvertiblePreferredStockMember" id="Fact000293" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">650</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0285">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0286">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ConversionOfPreferredStockToCommonStockShares_c20240801__20241031__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zH47m3AUDGlk" title="Conversion of preferred stock to common stock, shares" style="text-align: right"><ix:nonFraction name="alzm:ConversionOfPreferredStockToCommonStockShares" contextRef="From2024-08-012024-10-31_us-gaap_CommonStockMember" id="Fact000295" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,613,951</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="alzm:ConversionOfPreferredStockToCommonStock" contextRef="From2024-08-012024-10-31_us-gaap_CommonStockMember" id="Fact000287" format="ixt:numdotdecimal" decimals="0" unitRef="USD">361</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="alzm:ConversionOfPreferredStockToCommonStock" contextRef="From2024-08-012024-10-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000288" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">361</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0290">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0291">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--StockbasedCompensationToEmployeesAndConsultants_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation to employees and consultants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0297">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0298">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0299">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="alzm:StockbasedCompensationToEmployeesAndConsultants" contextRef="From2024-08-012024-10-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000300" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81,277</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0302">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="alzm:StockbasedCompensationToEmployeesAndConsultants" contextRef="From2024-08-012024-10-31" id="Fact000303" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81,277</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_ze4DTvZcEh7d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0305">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0306">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0307">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0308">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="color: rgb(204,238,255); padding-bottom: 1pt">&#160;<span style="-sec-ix-hidden: xdx2ixbrl0309">-</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-08-012024-10-31_us-gaap_RetainedEarningsMember" id="Fact000310" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,415,214</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-08-012024-10-31" id="Fact000311" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,415,214</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_430_c20240801__20241031_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_zt5zbEjmjC6b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">BALANCES, October 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_c20240801__20241031__us-gaap--StatementEquityComponentsAxis__custom--SeriesAConvertiblePreferredStockMember_zy7xbLv6CIyb" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-10-31_custom_SeriesAConvertiblePreferredStockMember" id="Fact000321" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">88</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0313">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iE_c20240801__20241031__us-gaap--StatementEquityComponentsAxis__custom--SeriesBConvertiblePreferredStockMember_z6dE74PG1Nh2" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-10-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000323" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,100</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0314">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iE_c20240801__20241031__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYCD4dHsWq23" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-10-31_us-gaap_CommonStockMember" id="Fact000325" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,231,254</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-10-31_us-gaap_CommonStockMember" id="Fact000315" format="ixt:numdotdecimal" decimals="0" unitRef="USD">523</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-10-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000316" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,162,478</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="color: rgb(204,238,255); padding-bottom: 2.5pt">&#160;<span style="-sec-ix-hidden: xdx2ixbrl0317">-</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-10-31_us-gaap_RetainedEarningsMember" id="Fact000318" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">56,410,033</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-10-31" id="Fact000319" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,752,968</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these unaudited condensed financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Alzamend Neuro, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Condensed Statements of Stockholders&#8217;
Deficit</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the Three Months Ended October 31, 2023</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_custom--SeriesBConvertiblePreferredStockMember_zZmxEKvR4LT7" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zTifrQKEtc32" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zlnmHQvr5dpk" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_custom--NoteRecievableForCommonStockRelatedPartyMember_z64LXtoL4yv2" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_z3zkssiuyWXd" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B0_zRP5yMbPOwN3" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">Series B Convertible</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Additional</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Note Receivable for</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Preferred Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; white-space: nowrap; font-weight: bold; text-align: center">Paid-In</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; white-space: nowrap; font-weight: bold; text-align: center">Common Stock -</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; white-space: nowrap; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Related Party</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_43E_c20230801__20231031_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zA9dbbLPCK7d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">BALANCES, July 31, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_c20230801__20231031__us-gaap--StatementEquityComponentsAxis__custom--SeriesBConvertiblePreferredStockMember_zsqWpwH2MPG1" title="Beginning balance, shares" style="width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0334">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0327">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_c20230801__20231031__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdCjcp1Z129a" title="Beginning balance, shares" style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-07-31_us-gaap_CommonStockMember" id="Fact000336" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">646,268</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-07-31_us-gaap_CommonStockMember" id="Fact000328" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-07-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000329" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,370,775</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-07-31_custom_NoteRecievableForCommonStockRelatedPartyMember" id="Fact000330" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,883,295</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-07-31_us-gaap_RetainedEarningsMember" id="Fact000331" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">47,600,428</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-07-31" id="Fact000332" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">112,883</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--IssuanceOfCommonStockForCashNetOfIssuanceCosts_zV45tywwXbjb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of common stock for cash, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0338">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--IssuanceOfCommonStockForCashNetOfIssuanceCostsShares_c20230801__20231031__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4cR4dyj4rId" title="Issuance of common stock for cash, net of issuance costs, shares" style="text-align: right"><ix:nonFraction name="alzm:IssuanceOfCommonStockForCashNetOfIssuanceCostsShares" contextRef="From2023-08-012023-10-31_us-gaap_CommonStockMember" id="Fact000345" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">615</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0339">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts" contextRef="From2023-08-012023-10-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000340" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,087</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0341">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0342">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts" contextRef="From2023-08-012023-10-31" id="Fact000343" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,087</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zEnP6EjWDGv1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of common stock for restricted stock awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0347">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230801__20231031__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7lSNUqTp7Ie" title="Issuance of common stock for restricted stock awards, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-08-012023-10-31_us-gaap_CommonStockMember" id="Fact000354" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">83</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0348">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0349">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0350">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0351">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0352">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--SubscriptionReceivablePaymentReceived_iP3us-gaap--StockIssuedDuringPeriodSharesNewIssues_zvE5L9fhXIlb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Subscription receivable payment received</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0356">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0357">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="alzm:SubscriptionReceivablePaymentReceived" contextRef="From2023-08-012023-10-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000358" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,002</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="alzm:SubscriptionReceivablePaymentReceived" contextRef="From2023-08-012023-10-31_custom_NoteRecievableForCommonStockRelatedPartyMember" id="Fact000359" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,002</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0360">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0361">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--StockbasedCompensationToEmployeesAndConsultants_zEmqa9kWyAhg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation to employees and consultants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0363">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0364">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="alzm:StockbasedCompensationToEmployeesAndConsultants" contextRef="From2023-08-012023-10-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000365" format="ixt:numdotdecimal" decimals="0" unitRef="USD">318,336</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0366">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0367">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="alzm:StockbasedCompensationToEmployeesAndConsultants" contextRef="From2023-08-012023-10-31" id="Fact000368" format="ixt:numdotdecimal" decimals="0" unitRef="USD">318,336</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_zRoGJ8kqtM6h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0370">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0371">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0372">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0373">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-08-012023-10-31_us-gaap_RetainedEarningsMember" id="Fact000374" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,906,033</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-08-012023-10-31" id="Fact000375" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,906,033</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43B_c20230801__20231031_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_zdaKcQNU9BH" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">BALANCES, October 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_c20230801__20231031__us-gaap--StatementEquityComponentsAxis__custom--SeriesBConvertiblePreferredStockMember_zULXEMuZb7og" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0384">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0377">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iE_c20230801__20231031__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsY1CER0Z5Xb" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-10-31_us-gaap_CommonStockMember" id="Fact000386" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">646,966</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-10-31_us-gaap_CommonStockMember" id="Fact000378" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-10-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000379" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,700,196</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-10-31_custom_NoteRecievableForCommonStockRelatedPartyMember" id="Fact000380" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,876,293</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-10-31_us-gaap_RetainedEarningsMember" id="Fact000381" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">50,506,461</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-10-31" id="Fact000382" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,682,493</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these unaudited condensed financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Alzamend Neuro, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Condensed Statements of Stockholders&#8217;
Equity (Deficit)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the Six Months Ended October 31, 2024</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_custom--SeriesAConvertiblePreferredStockMember_zdrQoDjWrX6j" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_custom--SeriesBConvertiblePreferredStockMember_zezr2CLejvRa" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zP1nzH0FZgA9" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zy3pqz1AgOGl" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zegLWAUZ87di" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B0_zmbSWXFsMgV8" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">Series A Convertible</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">Series B Convertible</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Additional</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Preferred Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Preferred Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; white-space: nowrap; font-weight: bold; text-align: center">Paid-In</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; white-space: nowrap; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_43E_c20240501__20241031_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zlQP23Zj8n3h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 19%">BALANCES, April 30, 2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iS_c20240501__20241031__us-gaap--StatementEquityComponentsAxis__custom--SeriesAConvertiblePreferredStockMember_zDQzogg4hG9" title="Beginning balance, shares" style="width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0395">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0388">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_c20240501__20241031__us-gaap--StatementEquityComponentsAxis__custom--SeriesBConvertiblePreferredStockMember_zjX7dgkmCgQb" title="Beginning balance, shares" style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-04-30_custom_SeriesBConvertiblePreferredStockMember" id="Fact000397" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,100</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0389">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_c20240501__20241031__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlkH35OSdy15" title="Beginning balance, shares" style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-04-30_us-gaap_CommonStockMember" id="Fact000399" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">687,999</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-04-30_us-gaap_CommonStockMember" id="Fact000390" format="ixt:numdotdecimal" decimals="0" unitRef="USD">69</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-04-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000391" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,426,154</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-04-30_us-gaap_RetainedEarningsMember" id="Fact000392" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">54,020,408</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-04-30" id="Fact000393" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,594,185</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--IssuanceOfCommonStockForCashNetOfIssuanceCosts_zGYLPCxheME9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of common stock for cash, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0401">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0402">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--IssuanceOfCommonStockForCashNetOfIssuanceCostsShares_c20240501__20241031__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmWuxf93mnb5" title="Issuance of common stock for cash, net of issuance costs, shares" style="text-align: right"><ix:nonFraction name="alzm:IssuanceOfCommonStockForCashNetOfIssuanceCostsShares" contextRef="From2024-05-012024-10-31_us-gaap_CommonStockMember" id="Fact000408" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">755,888</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts" contextRef="From2024-05-012024-10-31_us-gaap_CommonStockMember" id="Fact000403" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts" contextRef="From2024-05-012024-10-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000404" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,174,148</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0405">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts" contextRef="From2024-05-01to2024-10-31" id="Fact000406" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,174,224</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zz29Yxxo9U4j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of common stock for restricted stock awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0410">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0411">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240501__20241031__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKre8lJQrxy5" title="Issuance of common stock for restricted stock awards, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-05-012024-10-31_us-gaap_CommonStockMember" id="Fact000417" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">83</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0412">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0413">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0414">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0415">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--IssuanceOfPreferredStockForCashNetOfIssuanceCosts_zLKhgYZSG0B3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of preferred stock for cash, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--IssuanceOfPreferredStockForCashNetOfIssuanceCostsShares_c20240501__20241031__us-gaap--StatementEquityComponentsAxis__custom--SeriesAConvertiblePreferredStockMember_zWu3UUgAt5Kd" title="Issuance of preferred stock for cash, net of issuance costs, shares" style="text-align: right"><ix:nonFraction name="alzm:IssuanceOfPreferredStockForCashNetOfIssuanceCostsShares" contextRef="From2024-05-012024-10-31_custom_SeriesAConvertiblePreferredStockMember" id="Fact000426" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">800</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0419">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0420">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0421">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="alzm:IssuanceOfPreferredStockForCashNetOfIssuanceCosts" contextRef="From2024-05-012024-10-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000422" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,088,644</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0423">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="alzm:IssuanceOfPreferredStockForCashNetOfIssuanceCosts" contextRef="From2024-05-01to2024-10-31" id="Fact000424" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,088,644</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--ConversionOfPreferredStockToCommonStock_zxVhKJ8UVufj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Conversion of preferred stock to common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--ConversionOfPreferredStockToCommonStockShares_c20240501__20241031__us-gaap--StatementEquityComponentsAxis__custom--SeriesAConvertiblePreferredStockMember_zKDibouvgmg9" title="Conversion of preferred stock to common stock, shares" style="text-align: right">(<ix:nonFraction name="alzm:ConversionOfPreferredStockToCommonStockShares" contextRef="From2024-05-012024-10-31_custom_SeriesAConvertiblePreferredStockMember" id="Fact000435" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">712</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0428">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0429">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ConversionOfPreferredStockToCommonStockShares_c20240501__20241031__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEcNubDJ1Faj" title="Conversion of preferred stock to common stock, shares" style="text-align: right"><ix:nonFraction name="alzm:ConversionOfPreferredStockToCommonStockShares" contextRef="From2024-05-012024-10-31_us-gaap_CommonStockMember" id="Fact000437" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,787,284</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="alzm:ConversionOfPreferredStockToCommonStock" contextRef="From2024-05-012024-10-31_us-gaap_CommonStockMember" id="Fact000430" format="ixt:numdotdecimal" decimals="0" unitRef="USD">378</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="alzm:ConversionOfPreferredStockToCommonStock" contextRef="From2024-05-012024-10-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000431" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">378</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0432">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0433">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--ConversionOfNotePayableAndInterestToPreferredStock_iP3custom--ConversionOfPreferredStockToCommonStockShares_zmLbxLZLO3N3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Conversion of note payable and interest to preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0439">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0440">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0441">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="alzm:ConversionOfNotePayableAndInterestToPreferredStock" contextRef="From2024-05-012024-10-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000442" format="ixt:numdotdecimal" decimals="0" unitRef="USD">311,356</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0443">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="alzm:ConversionOfNotePayableAndInterestToPreferredStock" contextRef="From2024-05-01to2024-10-31" id="Fact000444" format="ixt:numdotdecimal" decimals="0" unitRef="USD">311,356</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--StockbasedCompensationToEmployeesAndConsultants_zArObRlUF65l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation to employees and consultants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0446">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0447">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0448">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="alzm:StockbasedCompensationToEmployeesAndConsultants" contextRef="From2024-05-012024-10-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000449" format="ixt:numdotdecimal" decimals="0" unitRef="USD">162,554</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0450">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="alzm:StockbasedCompensationToEmployeesAndConsultants" contextRef="From2024-05-01to2024-10-31" id="Fact000451" format="ixt:numdotdecimal" decimals="0" unitRef="USD">162,554</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_z5EasPJfUuik" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0453">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0454">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0455">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0456">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-05-012024-10-31_us-gaap_RetainedEarningsMember" id="Fact000457" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,389,625</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-05-01to2024-10-31" id="Fact000458" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,389,625</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_431_c20240501__20241031_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_zgQmfsi3VMF8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">BALANCES, October 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_c20240501__20241031__us-gaap--StatementEquityComponentsAxis__custom--SeriesAConvertiblePreferredStockMember_z7l3fjnOFlLi" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-10-31_custom_SeriesAConvertiblePreferredStockMember" id="Fact000467" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">88</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0460">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_c20240501__20241031__us-gaap--StatementEquityComponentsAxis__custom--SeriesBConvertiblePreferredStockMember_zvtRlX15Qeza" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-10-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000469" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,100</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0461">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iE_c20240501__20241031__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zW2uQMO8m287" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-10-31_us-gaap_CommonStockMember" id="Fact000471" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,231,254</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-10-31_us-gaap_CommonStockMember" id="Fact000462" format="ixt:numdotdecimal" decimals="0" unitRef="USD">523</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-10-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000463" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,162,478</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-10-31_us-gaap_RetainedEarningsMember" id="Fact000464" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">56,410,033</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-10-31" id="Fact000465" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,752,968</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these unaudited condensed financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Alzamend Neuro, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Condensed Statements of Stockholders&#8217;
Equity (Deficit)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the Six Months Ended October 31, 2023</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_custom--SeriesBConvertiblePreferredStockMember_zTbWK05DVVne" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zgak1WSFUjA8" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zHG79fWCAUVg" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_custom--NoteRecievableForCommonStockRelatedPartyMember_zNVUsP9ZpbV5" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zGOSIvNwj2Ae" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B0_zPnHdmTm3kGb" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">Series B Convertible</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Additional</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Note Receivable for</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Preferred Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; white-space: nowrap; font-weight: bold; text-align: center">Paid-In</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; white-space: nowrap; font-weight: bold; text-align: center">Common Stock -</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; white-space: nowrap; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Related Party</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_43C_c20230501__20231031_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zXtPeyTt9WXl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">BALANCES, April 30, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_c20230501__20231031__us-gaap--StatementEquityComponentsAxis__custom--SeriesBConvertiblePreferredStockMember_zIqJTIT749x2" title="Beginning balance, shares" style="width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0480">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0473">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_c20230501__20231031__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfM8OtvyPyM3" title="Beginning balance, shares" style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-04-30_us-gaap_CommonStockMember" id="Fact000482" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">646,268</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-04-30_us-gaap_CommonStockMember" id="Fact000474" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-04-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000475" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,001,395</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-04-30_custom_NoteRecievableForCommonStockRelatedPartyMember" id="Fact000476" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,883,295</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-04-30_us-gaap_RetainedEarningsMember" id="Fact000477" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">44,072,662</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-04-30" id="Fact000478" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,045,503</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--IssuanceOfCommonStockForCashNetOfIssuanceCosts_zwvIZ9B5Vpo" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of common stock for cash, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0484">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--IssuanceOfCommonStockForCashNetOfIssuanceCostsShares_c20230501__20231031__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCJ2V4tJN5bj" title="Issuance of common stock for cash, net of issuance costs, shares" style="text-align: right"><ix:nonFraction name="alzm:IssuanceOfCommonStockForCashNetOfIssuanceCostsShares" contextRef="From2023-05-012023-10-31_us-gaap_CommonStockMember" id="Fact000491" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">615</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0485">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts" contextRef="From2023-05-012023-10-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000486" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,087</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0487">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0488">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="alzm:IssuanceOfCommonStockForCashNetOfIssuanceCosts" contextRef="From2023-05-012023-10-31" id="Fact000489" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,087</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zVnBwcVFIEc7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of common stock for restricted stock awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0493">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230501__20231031__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0CW1a1e2kri" title="Issuance of common stock for restricted stock awards, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-05-012023-10-31_us-gaap_CommonStockMember" id="Fact000500" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">83</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0494">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0495">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0496">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0497">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0498">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--SubscriptionReceivablePaymentReceived_zB2WsSlGB0z" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Subscription receivable payment received</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0502">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0503">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="alzm:SubscriptionReceivablePaymentReceived" contextRef="From2023-05-012023-10-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000504" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,002</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="alzm:SubscriptionReceivablePaymentReceived" contextRef="From2023-05-012023-10-31_custom_NoteRecievableForCommonStockRelatedPartyMember" id="Fact000505" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,002</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0506">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0507">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--StockbasedCompensationToEmployeesAndConsultants_z98oPI3v4o4a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation to employees and consultants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0509">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0510">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="alzm:StockbasedCompensationToEmployeesAndConsultants" contextRef="From2023-05-012023-10-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000511" format="ixt:numdotdecimal" decimals="0" unitRef="USD">687,716</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0512">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0513">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="alzm:StockbasedCompensationToEmployeesAndConsultants" contextRef="From2023-05-012023-10-31" id="Fact000514" format="ixt:numdotdecimal" decimals="0" unitRef="USD">687,716</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0516">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0517">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0518">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0519">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-05-012023-10-31_us-gaap_RetainedEarningsMember" id="Fact000520" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,433,799</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-05-012023-10-31" id="Fact000521" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,433,799</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43B_c20230501__20231031_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_zJIoYI0QgNyd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">BALANCES, October 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_c20230501__20231031__us-gaap--StatementEquityComponentsAxis__custom--SeriesBConvertiblePreferredStockMember_ztFTsBS08Cg6" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0530">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0523">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iE_c20230501__20231031__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQ4mmB9hGNoe" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-10-31_us-gaap_CommonStockMember" id="Fact000532" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">646,966</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-10-31_us-gaap_CommonStockMember" id="Fact000524" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-10-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000525" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,700,196</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-10-31_custom_NoteRecievableForCommonStockRelatedPartyMember" id="Fact000526" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,876,293</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-10-31_us-gaap_RetainedEarningsMember" id="Fact000527" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">50,506,461</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-10-31" id="Fact000528" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,682,493</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these unaudited condensed financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Alzamend Neuro, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Condensed Statements of Cash Flows</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" id="xdx_307_112_zB3ODVOwjAhh" summary="xdx: Statement - Condensed Statements of Cash Flows (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49B_20240501__20241031_zG1efC7B23Qi" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20230501__20231031_zeoHHVvj0DG9" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">For the Six Months Ended <br/> October 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zKVaZp3Yyu4a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash flows from operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_i01_maCzNHJ_zmkgnLQP0mza" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: 10pt">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-05-01to2024-10-31" id="Fact000537" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,389,625</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-05-012023-10-31" id="Fact000538" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,433,799</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zOvLMmP5ke8g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 10pt">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--Depreciation_i02_maCzNHJ_z7ikTy5cBiO4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 10pt">Depreciation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-05-01to2024-10-31" id="Fact000543" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,370</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-05-012023-10-31" id="Fact000544" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,370</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AmortizationOfDebtDiscountPremium_i02_maCzNHJ_zCCPKdNclJAa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 10pt">Interest expense - debt discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2024-05-01to2024-10-31" id="Fact000546" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,286</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0547">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ShareBasedCompensation_i02_maCzNHJ_zSrP0zvvnrK8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 10pt">Stock-based compensation to employees and consultants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-05-01to2024-10-31" id="Fact000549" format="ixt:numdotdecimal" decimals="0" unitRef="USD">162,554</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-05-012023-10-31" id="Fact000550" format="ixt:numdotdecimal" decimals="0" unitRef="USD">687,716</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zB7fzJtXXBNh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 20pt">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_msCzNHJ_zdlbe0zAIIV1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 30pt">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2024-05-01to2024-10-31" id="Fact000555" format="ixt:numdotdecimal" decimals="0" unitRef="USD">594,475</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-05-012023-10-31" id="Fact000556" format="ixt:numdotdecimal" decimals="0" unitRef="USD">134,213</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_ecustom--IncreaseDecreaseInPrepaidExpensesRelatedParty_i03N_di_msCzNHJ_zYhbdEdMq007" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 30pt">Prepaid expenses - related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0558">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="alzm:IncreaseDecreaseInPrepaidExpensesRelatedParty" contextRef="From2023-05-012023-10-31" id="Fact000559" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">247,334</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i03_maCzNHJ_zhzXX8LzsBQk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 30pt">Accounts payable and accrued liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2024-05-01to2024-10-31" id="Fact000561" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,668,953</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2023-05-012023-10-31" id="Fact000562" format="ixt:numdotdecimal" decimals="0" unitRef="USD">795,968</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_mtCzNHJ_maCz3or_zTnPq3DBKzCi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 30pt">Net cash used in operating activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-05-01to2024-10-31" id="Fact000564" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,455,843</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-05-012023-10-31" id="Fact000565" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,811,624</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zn3sRe9npKj9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash flows from investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PaymentsToAcquireMachineryAndEquipment_i01N_di_msCz2AY_zTGjOGItXuF9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-indent: 10pt">Purchase of equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireMachineryAndEquipment" contextRef="From2024-05-01to2024-10-31" id="Fact000570" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireMachineryAndEquipment" contextRef="From2023-05-012023-10-31" id="Fact000571" format="ixt:numdotdecimal" decimals="0" unitRef="USD">147,243</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtCz2AY_maCz3or_zoToRCjvvIb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 30pt">Net cash used in investing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-05-01to2024-10-31" id="Fact000573" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">90,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-05-012023-10-31" id="Fact000574" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">147,243</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_i01B_zQajSGLejEs" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ProceedsFromIssuanceOfCommonStock_i02_maCzLme_zD87fvNzTPEj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 10pt">Net proceeds from the issuance of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-05-01to2024-10-31" id="Fact000579" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,174,224</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-05-012023-10-31" id="Fact000580" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,087</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_i02_maCzLme_zOe1qT5oadk3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt">Net proceeds from the issuance of preferred stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="From2024-05-01to2024-10-31" id="Fact000582" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,088,644</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0583">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i02T_mtCzLme_maCz3or_zZo59GVPGQS3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 30pt">Net cash provided by financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-05-01to2024-10-31" id="Fact000585" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,262,868</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-05-012023-10-31" id="Fact000586" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,087</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_mtCz3or_zE91bR0JSLh2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net increase (decrease) in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2024-05-01to2024-10-31" id="Fact000588" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,717,025</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2023-05-012023-10-31" id="Fact000589" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,940,780</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_zOQJUMZcgQNe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Cash at beginning of period</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-04-30" id="Fact000591" format="ixt:numdotdecimal" decimals="0" unitRef="USD">376,048</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-04-30" id="Fact000592" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,140,859</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_zxjQVw7EZyjj" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Cash at end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-10-31" id="Fact000594" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,093,073</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-10-31" id="Fact000595" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,079</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zAK7tEoPJ5Qb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Supplemental disclosures of cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--NoncashFinancingActivitiesAbstract_i01B_zPHYWB18axce" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-cash financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--ConversionOfSeriesConvertiblePreferredStock_i02_z0sXxN9ynTT4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 10pt">Conversion of Series A convertible preferred stock</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="alzm:ConversionOfSeriesConvertiblePreferredStock" contextRef="From2024-05-01to2024-10-31" id="Fact000603" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,120,133</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0604">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--FairValueOfWarrantsIssuedInConnectionWithSeriesConvertiblePreferredStock_i02_zg4k9ahVtMJl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 10pt">Fair value of warrants issued in connection with Series A convertible preferred stock</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="alzm:FairValueOfWarrantsIssuedInConnectionWithSeriesConvertiblePreferredStock" contextRef="From2024-05-01to2024-10-31" id="Fact000606" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,635,489</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0607">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--ConversionOfNotePayableAndAccruedInterestIntoSeriesBConvertiblePreferredStock_i02_zUVHpGP0Jval" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 10pt">Conversion of note payable and accrued interest into Series B convertible preferred stock</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="alzm:ConversionOfNotePayableAndAccruedInterestIntoSeriesBConvertiblePreferredStock" contextRef="From2024-05-01to2024-10-31" id="Fact000609" format="ixt:numdotdecimal" decimals="0" unitRef="USD">311,356</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0610">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these unaudited condensed financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 9 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Alzamend Neuro, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Unaudited Condensed Financial Statements</b></p>

<ix:nonNumeric contextRef="From2024-05-01to2024-10-31" escape="true" id="Fact000612" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock"><p id="xdx_801_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_z8f1nF8Q3Bx9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>1.</b></td><td style="text-align: justify"><b><span id="xdx_826_zPuVBmwzLSg2">DESCRIPTION OF BUSINESS</span></b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>Organization</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Alzamend Neuro, Inc. (the
&#8220;Company&#8221; or &#8220;Alzamend&#8221;), is a clinical-stage biopharmaceutical company focused on developing novel products for
the treatment of Alzheimer&#8217;s disease (&#8220;Alzheimer&#8217;s&#8221;), bipolar disorder (&#8220;BD&#8221;), major depressive disorder
(&#8220;MDD&#8221;) and post-traumatic stress disorder (&#8220;PTSD&#8221;). With two current product candidates, Alzamend aims to bring
treatments or cures to market at a reasonable cost as quickly as possible. The Company&#8217;s current pipeline consists of two novel
therapeutic drug candidates: (i) a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate,
known as AL001, through two royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc.,
as licensor (the &#8220;Licensor&#8221;); and (ii) a patented method using a mutant peptide sensitized cell as a cell-based therapeutic
vaccine that seeks to restore the ability of a patient&#8217;s immunological system to combat Alzheimer&#8217;s, known as ALZN002, through
a royalty-bearing exclusive worldwide license from the same Licensor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company is devoting substantially
all its efforts towards research and development of its two product candidates and raising capital. The Company has not generated any
product revenue to date. The Company has financed its operations to date primarily through debt financings and through the sale of its
common stock, par value $<span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20241031_zzC7M8bydA91" title="Common stock, par value (in dollars per share)"><span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20241031_zp8gy3v77M9l" title="Preferred stock, par value (in dollars per share)"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-10-31" id="Fact000614" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-10-31" id="Fact000616" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> per share (&#8220;Common Stock&#8221;) and its preferred stock, par value $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240430_zq2wn0AUOCzb" title="Common stock, par value (in dollars per share)"><span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240430_zK0e3sAB2WXc" title="Preferred stock, par value (in dollars per share)"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-04-30" id="Fact000618" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-04-30" id="Fact000620" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> per share. The Company
expects to continue to incur net losses in the foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>Reverse Stock Split</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
October 27, 2023, pursuant to the authorization provided by the Company&#8217;s stockholders at a special meeting of stockholders, the
Company filed an amendment to the Certificate of Incorporation to effectuate a reverse stock split of the Company&#8217;s issued and outstanding
Common Stock by a ratio of one-for-fifteen (the &#8220;First Reverse Split&#8221;). The First Reverse Split did not affect the number
of authorized shares of Common Stock, preferred stock or their respective par value per share. As a result of the First Reverse Split,
each fifteen shares of Common Stock issued and outstanding prior to the First Reverse Split were converted into one share of Common Stock.
The First Reverse Split became effective in the State of Delaware on October 31, 2023. All share amounts in these financial statements
have been updated for all periods presented to reflect the First Reverse Split.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
July 10, 2024, pursuant to the authorization provided by the Company&#8217;s stockholders at its annual meeting of stockholders, the Company
filed an amendment to the Certificate of Incorporation to effectuate a reverse stock split of the Company&#8217;s issued and outstanding
Common Stock by a ratio of one-for-ten (the &#8220;Second Reverse Split&#8221;). The Second Reverse Split did not affect the number of
authorized shares of Common Stock, preferred stock or their respective par value per share. As a result of the Second Reverse Split, each
ten shares of Common Stock issued and outstanding prior to the Second Reverse Split were converted into one share of Common Stock. The
Second Reverse Split became effective in the State of Delaware on July 16, 2024. All share amounts in these financial statements have
been updated for all periods presented to reflect the Second Reverse Split.</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" escape="true" id="Fact000622" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock"><p id="xdx_804_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zac7UryYLn43" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>2.</b></td><td style="text-align: justify"><b><span id="xdx_821_zwl78hTbXRV3">LIQUIDITY AND GOING CONCERN</span></b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying condensed
financial statements have been prepared on the basis that the Company will continue as a going concern. As of October 31, 2024, the Company
had cash of $<span id="xdx_90F_eus-gaap--Cash_iI_pn3n3_dm_c20241031_zINjqxEAtiQ2" title="Cash"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2024-10-31" id="Fact000624" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">4.1</ix:nonFraction></span> million, working capital of $<span id="xdx_908_ecustom--WorkingCapitalDeficiency_iI_pn3n3_dm_c20241031_zrkiLXQ17Tp6" title="Working capital deficiency"><ix:nonFraction name="alzm:WorkingCapitalDeficiency" contextRef="AsOf2024-10-31" id="Fact000626" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">3.5</ix:nonFraction></span> million, an accumulated deficit of $<span id="xdx_900_eus-gaap--RetainedEarningsAppropriated_iI_pn3n3_dm_c20241031_zDXHJg9n0Hjj" title="Accumulated deficit"><ix:nonFraction name="us-gaap:RetainedEarningsAppropriated" contextRef="AsOf2024-10-31" id="Fact000628" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">56.4</ix:nonFraction></span> million and stockholders&#8217; equity of $<span id="xdx_90D_eus-gaap--StockholdersEquityBeforeTreasuryStock_iI_pn3n3_dm_c20241031_zAz756civBq8" title="Stockholders' deficit"><ix:nonFraction name="us-gaap:StockholdersEquityBeforeTreasuryStock" contextRef="AsOf2024-10-31" id="Fact000630" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">3.8</ix:nonFraction></span>
million. For the three and six months ended October 31, 2024, the Company had net losses of $<span id="xdx_903_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_dm_c20240801__20241031_zXGoiTl1GVv8" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2024-08-012024-10-31" id="Fact000632" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1.4</ix:nonFraction></span> million and $<span id="xdx_904_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_dm_c20240501__20241031_zsu2e8uj9LHi" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2024-05-01to2024-10-31" id="Fact000634" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">2.4</ix:nonFraction></span> million, respectively.
For the six months ended October 31, 2024, cash used in operating activities was $<span id="xdx_906_ecustom--CashUsedInOperatingActivities_pn3n3_dm_c20240501__20241031_z8ryH7B5IG5l" title="Cash used in operating activities"><ix:nonFraction name="alzm:CashUsedInOperatingActivities" contextRef="From2024-05-01to2024-10-31" id="Fact000636" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">4.5</ix:nonFraction></span> million. Historically, the Company has financed
its operations principally through issuances of equity and debt instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">Management
believes its current cash on hand is not sufficient to fund its planned operations through one year after the date the condensed financial
statements are issued. These factors create substantial doubt about the Company&#8217;s ability to continue as a going concern for at
least one year after the date that these condensed financial statements are issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s inability&#160;to
continue&#160;as a going concern&#160;could&#160;have a negative&#160;impact&#160;on the Company, including&#160;its ability&#160;to obtain
needed&#160;financing. The Company&#8217;s condensed financial statements do not include any adjustments relating to the recoverability
and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should it be unable to
continue as a going concern.</p>

<ix:exclude><p id="xdx_237_zkaR45NqLSze" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 10 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company expects to continue
to incur losses for the foreseeable future and needs to raise additional capital until it is able to generate revenues from operations
sufficient to fund its development and commercial operations. <span style="background-color: white">These factors create substantial doubt
about our ability to continue as a going concern</span>. However, based on the Company&#8217;s current business plan, management believes
that the Company&#8217;s cash and cash equivalents at October 31, 2024, together with the anticipated receipt of funds from its &#8220;at-the-market&#8221;
offering and from the sale of its Series A and Series B Convertible Preferred Stock pursuant to the securities purchase agreements related
thereto, will be sufficient to meet the Company&#8217;s anticipated cash requirements during the twelve-month period subsequent to the
issuance of the financial statements included in this Quarterly Report.</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" escape="true" id="Fact000639" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_80E_eus-gaap--SignificantAccountingPoliciesTextBlock_zuxoWxAHpn6g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>3.</b></td><td style="text-align: justify"><b><span id="xdx_820_zFfFfAnYehXh">SIGNIFICANT ACCOUNTING POLICIES</span></b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<ix:nonNumeric contextRef="From2024-05-01to2024-10-31" escape="true" id="Fact000641" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_842_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zI5HUlyECXMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_861_zexHZ2PszJk8">Basis of Presentation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying condensed
financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States
of America (&#8220;U.S. GAAP&#8221;) and the rules of the Securities and Exchange Commission (&#8220;SEC&#8221;) applicable to interim
reports of companies filing as a smaller reporting company. These condensed financial statements should be read in conjunction with the
audited financial statements and notes thereto contained in the Company&#8217;s Report on Form 10-K for the year ended April 30, 2024,
filed with the SEC on July 30, 2024. In the opinion of management, the accompanying condensed interim financial statements include all
adjustments necessary in order to make the condensed financial statements not misleading. The results of operations for interim periods
are not necessarily indicative of the results to be expected for the full year or any other future period. Certain notes to the condensed
financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the most recent
fiscal year as reported in the Company&#8217;s Report on Form 10-K have been omitted. The accompanying condensed balance sheet at April
30, 2024 has been derived from the audited balance sheet at April 30, 2024 contained in such Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" escape="true" id="Fact000643" name="us-gaap:UseOfEstimates"><p id="xdx_844_eus-gaap--UseOfEstimates_zGb9vUnsiA07" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_86A_zMK0CxrxZTnj">Accounting Estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.8pt">The preparation of condensed
financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the
reported amounts of expenses during the reporting period. The Company&#8217;s significant accounting policies that involve significant
judgment and estimates include stock-based compensation, warrant valuation, and valuation of deferred income taxes. Actual results could
differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" escape="true" id="Fact000645" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zCHZ7HOoD9qk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_86B_zmyOiZRjh92k">Cash and Cash Equivalents</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company considers all
highly liquid investments with a remaining maturity of three months or less when purchased to be cash equivalents. As of October 31, 2024
and April&#160;30, 2024, the Company had <span id="xdx_903_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20241031_zVxBAZTgmwR7" title="Cash equivalents"><span id="xdx_902_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20240430_zOP3iumdKFo3" title="Cash equivalents"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2024-10-31" id="Fact000647" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2024-04-30" id="Fact000649" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> cash equivalents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" escape="true" id="Fact000651" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_84A_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z6rfn6VniW7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_861_z80mgJptOpGk">Fair Value of Financial
Instruments</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial Accounting Standards
Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 820, <i>Fair Value Measurement</i>, defines fair value
as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous
market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques
used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy
is based on three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last
is considered unobservable:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Level 1: Quoted prices in
active markets for identical assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Level 2: Inputs other than
Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in
markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the
full term of the assets or liabilities.</p>

<ix:exclude><p id="xdx_237_zVeVLyOo43u2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 11 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Level 3 assumptions: Unobservable
inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including
liabilities resulting from imbedded derivatives associated with certain warrants to purchase Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair values of warrants
are determined using the Black-Scholes valuation model, a &#8220;Level 3&#8221; fair value measurement, based on the estimated fair value
of Common Stock, volatility based on the historical volatility data of similar companies, considering the industry, products and market
capitalization of such other entities, the expected life based on the remaining contractual term of the warrants and the risk free interest
rate based on the implied yield available on U.S. Treasury Securities with a maturity equivalent to the warrants&#8217; contractual life.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" escape="true" id="Fact000654" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_848_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zSWl713MMOh6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_86F_z5uJjqPqbjbl">Property and Equipment,
Net</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Property and equipment
are stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated
useful life of <span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241031_zZ1Bz5MlNSe8" title="Property and equipment estimated useful life" style="display: none"><ix:nonNumeric contextRef="AsOf2024-10-31" format="ixt-sec:duryear" id="Fact000656" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span> five years. Significant additions and improvements are capitalized, while repairs and maintenance are charged to
expense as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" escape="true" id="Fact000658" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zC6feYyBiWS6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_86F_zcWhotdCxx47">Research and Development
Expenses</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development costs
are expensed as incurred. Research and development costs consist of scientific consulting fees, clinical trial fees and lab supplies,
as well as fees paid to other entities that conduct certain research and development activities on behalf of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has acquired and
may continue to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire
license, products or rights, as well as any future milestone payments, are immediately recognized as research and development expenses,
provided that there is no alternative future use of the rights in other research and development projects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" escape="true" id="Fact000660" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_845_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zAg1t59o3Ecc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_863_z4diSl0PliNe">Stock-Based Compensation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company recognizes stock-based
compensation expense for stock options on a straight-line basis over the requisite service period and account for forfeitures as they
occur. The Company&#8217;s stock-based compensation costs are based upon the grant date fair value of options estimated using the Black-Scholes
option pricing model. To the extent any stock option grants are made subject to the achievement of a performance-based milestone, management
evaluates when the achievement of any such performance-based milestone is probable based on the relative satisfaction of the performance
conditions as of the reporting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company recognizes stock-based
compensation expense for restricted stock units on a straight-line basis over the requisite service period and account for forfeitures
as they occur. The Company&#8217;s stock-based compensation for restricted stocks is based upon the estimated fair value of the Common
Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Black-Scholes option pricing
model utilizes inputs which are highly subjective assumptions and generally require significant judgment. Certain of such assumptions
involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and the
Company uses significantly different assumptions or estimates, the Company&#8217;s stock-based compensation could be materially different.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" escape="true" id="Fact000662" name="us-gaap:ExtendedProductWarrantyPolicy"><p id="xdx_84D_eus-gaap--ExtendedProductWarrantyPolicy_zIdQEh3Qk1g4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_864_zCCyyJ0RIIj4">Warrants</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company accounts for stock
warrants as either equity instruments, derivative liabilities, or liabilities in accordance with FASB ASC 480,&#160;<i>Distinguishing
Liabilities from Equity </i>and FASB ASC 815,&#160;<i>Derivatives and Hedging</i> (&#8220;ASC 815&#8221;)<i>,</i>&#160;depending on the
specific terms of the warrant agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the terms of the
Company&#8217;s warrant agreements, the Company accounted for the warrants as equity instruments as the warrants were indexed to the Common
Stock, required settlement in shares and would be classified as equity under ASC 815.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" escape="true" id="Fact000664" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_z7zvXAL8dX0e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt"><b><i><span id="xdx_865_z1eYNnG1UOWl">Loss per Common Share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company utilizes FASB
ASC 260,&#160;<i>Earnings per Share</i>. Basic loss per share is computed by dividing loss available to common stockholders by the weighted-average
number of common shares outstanding. Diluted loss per share is computed similar to basic loss per share except that the denominator is
increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued
and if the additional common shares were dilutive. Diluted loss per common share reflects the potential dilution that could occur if convertible
preferred stock, options and warrants were to be exercised or converted or otherwise resulted in the issuance of Common Stock that then
shared in the earnings of the entity.</p>

<ix:exclude><p id="xdx_230_zyXgeGqC7RQb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 12 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since the effects of outstanding
stock options, restricted stock units and warrants are anti-dilutive in the periods presented, shares of Common Stock underlying these
instruments have been excluded from the computation of loss per common share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following sets forth the
number of shares of Common Stock underlying outstanding stock options, restricted stock units and warrants that have been excluded from
the computation of loss per common share:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<ix:nonNumeric contextRef="From2024-05-01to2024-10-31" escape="true" id="Fact000667" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><table cellpadding="0" cellspacing="0" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)" id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zBRnsDVzJUd1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B6_zaUizIxtYFC3" style="display: none">Schedule of antidilutive securities excluded from computation of earnings per share</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">For the Six Months Ended October 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Stock options (1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20241031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_fKDEp_zPOP5Pop3Wgd" title="Antidilutive securities excluded from computation of earnings per share, amount" style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-05-012024-10-31_us-gaap_StockOptionMember" id="Fact000669" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">116,999</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230501__20231031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_fKDEp_z8xDxcJcqcu1" title="Antidilutive securities excluded from computation of earnings per share, amount" style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-05-012023-10-31_us-gaap_StockOptionMember" id="Fact000671" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">121,054</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20241031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" title="Antidilutive securities excluded from computation of earnings per share, amount" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-05-012024-10-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000673" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">84</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230501__20231031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" title="Antidilutive securities excluded from computation of earnings per share, amount" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-05-012023-10-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000675" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20241031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" title="Antidilutive securities excluded from computation of earnings per share, amount" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-05-012024-10-31_us-gaap_WarrantMember" id="Fact000677" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">873,450</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230501__20231031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" title="Antidilutive securities excluded from computation of earnings per share, amount" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-05-012023-10-31_us-gaap_WarrantMember" id="Fact000679" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">67,665</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20241031_pdd" title="Antidilutive securities excluded from computation of earnings per share, amount" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-05-01to2024-10-31" id="Fact000681" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">990,533</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230501__20231031_pdd" title="Antidilutive securities excluded from computation of earnings per share, amount" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-05-012023-10-31" id="Fact000683" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">188,969</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td id="xdx_F08_zhPkSTcw221e" style="width: 0.25in">(1)</td><td id="xdx_F1B_zFMTdC2STNK5" style="text-align: justify"><ix:footnote id="Footnote000684" xml:lang="en-US">The Company has excluded 10,000 stock options for the six months ended October 31, 2024 and 2023, with
an exercise price of $0.06, from its anti-dilutive securities as these shares have been included in our determination of basic loss per
share as they represent shares issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to FASB
ASC 260-10-45-14.</ix:footnote></td></tr></table>

</ix:nonNumeric><p id="xdx_8AA_zcfCEBWffJil" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" escape="true" id="Fact000686" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zLkkA8l7RYBl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i><span id="xdx_867_zMON9y32hu3f">Recent Accounting Standards</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, new accounting
pronouncements are issued by the FASB and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact
of recently issued standards that are not yet effective are not expected to have a material impact on the Company&#8217;s financial position
or results of operations upon adoption.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management has considered
all other recently issued accounting standards and does not believe the adoption of such standards will have a material impact on its
condensed financial statements.</p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" escape="true" id="Fact000688" name="us-gaap:OtherCurrentAssetsTextBlock"><p id="xdx_800_eus-gaap--OtherCurrentAssetsTextBlock_z2EtFPlEccxe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>4.</b></td><td><b><span id="xdx_825_zHH1QrwUi9Vd">PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prepaid expenses and other
current assets were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<ix:nonNumeric contextRef="From2024-05-01to2024-10-31" escape="true" id="Fact000690" name="alzm:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"><table cellpadding="0" cellspacing="0" summary="xdx: Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)" id="xdx_888_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zp6360GtyP1a" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B9_zKCDdLZC6ae3" style="display: none">Schedule of prepaid expenses and other current assets</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20241031_zrBnMf9ZLoHl" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20240430_zfxVdxEKjD01" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">October 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">April 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_ecustom--PrepaidClinicalTrialExpenses_iI_pp0p0_maPEAOAzUiy_zu4y3rJcxvI3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Prepaid clinical trial expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right"><ix:nonFraction name="alzm:PrepaidClinicalTrialExpenses" contextRef="AsOf2024-10-31" id="Fact000692" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">490,911</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0693">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PrepaidInsurance_iI_pp0p0_maPEAOAzUiy_zruKMZL2rvCj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2024-10-31" id="Fact000695" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">163,332</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2024-04-30" id="Fact000696" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">60,523</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0_maPEAOAzUiy_zGjojI8b7Tn3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other prepaid expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2024-10-31" id="Fact000698" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">19,426</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2024-04-30" id="Fact000699" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,671</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PrepaidExpenseAndOtherAssets_iTI_pp0p0_mtPEAOAzUiy_z82835lwKRN2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssets" contextRef="AsOf2024-10-31" id="Fact000701" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">673,669</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssets" contextRef="AsOf2024-04-30" id="Fact000702" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">79,194</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 22, 2024, the Company
entered into a Study Start-up Agreement with Massachusetts General Hospital (&#8220;Mass General Agreement&#8221;) in preparation for
five clinical research trials for its AL001 product candidate. The Mass General Agreement required a prepayment of $<span id="xdx_904_ecustom--PrepaidClinicalTrialFees_c20241022__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" title="Prepaid clinical trial fees"><ix:nonFraction name="alzm:PrepaidClinicalTrialFees" contextRef="AsOf2024-10-22_custom_AL001LicenseMember" id="Fact000704" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">514,000</ix:nonFraction></span>. Prepaid clinical
trial expenses at October 31, 2024 represented the unamortized portion of clinical trial expense and will be amortized as used.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 14, 2024, the Company
purchased directors&#8217; and officers&#8217; insurance for 12 months in the amount of $<span id="xdx_90E_ecustom--InsurancePurchased_iI_pp0p0_c20240614__srt--TitleOfIndividualAxis__us-gaap--DirectorsAndOfficersLiabilityInsuranceMember_zdF59KZLaYpc" title="Insurance purchased"><ix:nonFraction name="alzm:InsurancePurchased" contextRef="AsOf2024-06-14_us-gaap_DirectorsAndOfficersLiabilityInsuranceMember" id="Fact000706" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">227,000</ix:nonFraction></span>. Prepaid insurance at October 31, 2024
represented the unamortized portion of directors&#8217; and officers&#8217; insurance.</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" escape="true" id="Fact000708" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_808_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zJ3OqgLXNDZ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>5.</b></td><td style="text-align: justify"><b><span id="xdx_828_zwjwx94Tq5la">STOCK-BASED COMPENSATION</span></b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>2016 Stock Incentive
Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 30, 2016, the Company&#8217;s
stockholders approved the Company&#8217;s 2016 Stock Incentive Plan (the &#8220;Plan&#8221;). The Plan provides for the issuance of a
maximum of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20160430__us-gaap--PlanNameAxis__custom--StockIncentivePlan2016Member_pdd" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2016-04-30_custom_StockIncentivePlan2016Member" id="Fact000710" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">83,333</ix:nonFraction></span> shares of Common Stock to be offered to the Company&#8217;s directors, officers, employees, and consultants. On March
1, 2019, the Company&#8217;s stockholders approved an additional <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20190228__20190301__us-gaap--PlanNameAxis__custom--StockIncentivePlan2016Member_pdd" title="Share-based compensation arrangement by share-based payment award, number of additional shares authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2019-02-282019-03-01_custom_StockIncentivePlan2016Member" id="Fact000712" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span> shares to be available for issuance under the Plan. Options granted
under the Plan have an exercise price equal to or greater than the fair value of the underlying Common Stock at the date of grant and
become exercisable based on a vesting schedule determined at the date of grant. The options expire between five and <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20160429__20160430__srt--RangeAxis__srt--MaximumMember__us-gaap--PlanNameAxis__custom--StockIncentivePlan2016Member_z6cq1NAsXZse" title="Share-based compensation arrangement by share-based payment award, expiration period"><ix:nonNumeric contextRef="From2016-04-292016-04-30_srt_MaximumMember_custom_StockIncentivePlan2016Member" format="ixt-sec:duryear" id="Fact000714" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">10</ix:nonNumeric></span> years from the
date of grant. Restricted stock awards granted under the Plan are subject to a vesting period determined at the date of grant.</p>

<ix:exclude><p id="xdx_23C_zA7vMvqmqUma" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 13 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>2021 Stock Incentive
Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2021, the Company&#8217;s
board of directors (the &#8220;Board&#8221;) adopted, and the stockholders approved, the Alzamend Neuro, Inc. 2021 Stock Incentive Plan
(the &#8220;2021 Plan&#8221;). The 2021 Plan authorizes the grant to eligible individuals of (1) stock options (incentive and non-statutory),
(2) restricted stock, (3) stock appreciation rights, or SARs, (4) restricted stock units, and (5) other stock-based compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Stock Subject to the 2021
Plan.</i>&#160;The maximum number of shares of Common Stock that may be issued under the 2021 Plan is 66,667 shares, which number will
be increased to the extent that compensation granted under the 2021 Plan is forfeited, expires or is settled for cash (except as otherwise
provided in the 2021 Plan). Substitute awards (awards made or shares issued by the Company in assumption of, or in substitution or exchange
for, awards previously granted, or the right or obligation to make future awards, in each case by a company that the Company acquires
or any subsidiary of the Company or with which the Company or any subsidiary combines) will not reduce the shares authorized for grant
under the 2021 Plan, nor will shares subject to a substitute award be added to the shares available for issuance or transfer under the
2021 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Restricted Stock.</i> In
May 2021, the Company issued restricted stock awards pursuant to the 2021 Plan to one employee. The restricted stock award vests over
48 months. The award requires continued service to the Company during the vesting period. The vesting provisions of individual awards
may vary as approved by the Board. Compensation expense for restricted stock is generally recorded based on its market value on the date
of grant and recognized ratably over the associated service and performance period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Stock Options.</i> All
options that the Company grants are granted at the per share fair value on the grant date. Vesting of options differs based on the terms
of each option. The Company has valued the options at their date of grant utilizing the Black Scholes option pricing model. As of the
date of issuance of these options, there was not an active public market for the Company&#8217;s shares. Accordingly, the fair value of
the underlying options was determined based on the historical volatility data of similar companies, considering the industry, products
and market capitalization of such other entities. The risk-free interest rate used in the calculations is based on the implied yield available
on U.S. Treasury issues with an equivalent term approximating the expected life of the options as calculated using the simplified method.
The expected life of the options used was based on the contractual life calculated using the simplified method. Stock-based compensation
is a non-cash expense because the Company settles these obligations by issuing shares of Common Stock from its authorized shares instead
of settling such obligations with cash payments.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A summary of stock option
activity for the six months ended October 31, 2024 is presented below:&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:nonNumeric contextRef="From2024-05-01to2024-10-31" escape="true" id="Fact000717" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details)" id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zVctCE3A4dBc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B2_zEzYp3UcWpCb" style="display: none">Schedule of share-based payment arrangement, option, activity</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Outstanding Options</b></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Shares <br/> Available <br/> for Grant</b></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Number of <br/> Shares</b></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Weighted <br/> Average <br/> Exercise <br/> Price</b></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Life (years)</b></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Aggregate Intrinsic <br/> Value</b></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Balance at April 30, 2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20240501__20241031_zZ4U65rAVeEf" title="Shares available for grant begining (in shares)" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2024-04-30" id="Fact000719" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">62,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240501__20241031_zIgJcQ3hI435" title="Number of shares begining (in shares)" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-04-30" id="Fact000721" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">98,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240501__20241031_zxhtTdR9bZZg" title="Weighted average exercise price begining (in dollars per share)" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-04-30" id="Fact000723" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">178.12</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240501__20241031_z00GzKlfDCza" title="Weighted average remaining contractual life begining (years)" style="width: 9%; text-align: right"><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" format="ixt-sec:duryear" id="Fact000725" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.22</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240501__20241031_zshmCgIsHPWj" title="Aggregate intrinsic value begining" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-04-30" id="Fact000727" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">70,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--SharesAvailableForGrantOptionsGranted_c20240501__20241031_pdd" title="Shares available for grant, Options granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0729">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240501__20241031_pdd" title="Number of shares, Options granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0731">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240501__20241031_pdd" title="Weighted average exercise price, Options granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0733">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Options exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--SharesAvailableForGrantOptionsExercised_c20240501__20241031_pdd" title="Shares available for grant, Options exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0735">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20240501__20241031_pdd" title="Number of shares, Options exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0737">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240501__20241031_pdd" title="Weighted average exercise price, Options exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0739">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Options expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--SharesAvailableForGrantOptionsExpired_c20240501__20241031_pdd" title="Shares available for grant, Options expired" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="alzm:SharesAvailableForGrantOptionsExpired" contextRef="From2024-05-01to2024-10-31" id="Fact000741" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,333</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20240501__20241031_z9XsCqWFMKIa" title="Number of shares, Options expired" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2024-05-01to2024-10-31" id="Fact000743" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,333</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20240501__20241031_pdd" title="Weighted average exercise price, Options expired" style="padding-bottom: 1pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2024-05-01to2024-10-31" id="Fact000745" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">150.00</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance at October 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_c20240501__20241031_zN1Txv3U3hPd" title="Shares available for grant end (in shares)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2024-10-31" id="Fact000747" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">65,333</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240501__20241031_zxf8EEBPqtt3" title="Number of shares end (in shares)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-10-31" id="Fact000749" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">94,667</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240501__20241031_z119PtSMDeBf" title="Weighted average exercise price end (in dollars per share)" style="padding-bottom: 2.5pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-10-31" id="Fact000751" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">179.11</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240501__20241031_z9iracl22JH4" title="Weighted average remaining contractual life end (years)" style="padding-bottom: 2.5pt; text-align: right"><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" format="ixt-sec:duryear" id="Fact000753" name="alzm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm">4.90</ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240501__20241031_zN4BreSfmOO7" title="Aggregate intrinsic value end" style="padding-bottom: 2.5pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-10-31" id="Fact000755" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,100</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Options vested and expected to vest at October 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20241031_pdd" title="Number of shares, Options vested and expected to vest at end" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2024-10-31" id="Fact000757" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">88,001</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20241031_pdd" title="Weighted average exercise price, Options vested and expected to vest at end" style="padding-bottom: 2.5pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-10-31" id="Fact000759" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">179.39</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240501__20241031_zqQk6vqYePka" title="Weighted average remaining contractual life, Options vested and expected to vest at end" style="padding-bottom: 2.5pt; text-align: right"><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" format="ixt-sec:duryear" id="Fact000761" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">4.65</ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_c20241031_pp0p0" title="Aggregate intrinsic value, Options vested and expected to vest at end" style="padding-bottom: 2.5pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="AsOf2024-10-31" id="Fact000763" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,100</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Options exercisable at October 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20241031_pdd" title="Number of shares, Options exercisable at end" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-10-31" id="Fact000765" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">87,043</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20241031_pdd" title="Weighted average exercise price, Options exercisable at end" style="padding-bottom: 2.5pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-10-31" id="Fact000767" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">178.87</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240501__20241031_zNNf3Nqwstkh" title="Weighted average remaining contractual life, Options exercisable at end" style="padding-bottom: 2.5pt; text-align: right"><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" format="ixt-sec:duryear" id="Fact000769" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">4.63</ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20241031_pp0p0" title="Aggregate intrinsic value, Options exercisable at end" style="padding-bottom: 2.5pt; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2024-10-31" id="Fact000771" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,100</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zIn33yELNdSd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The aggregate intrinsic value
in the table above represents the total pretax intrinsic value (i.e., the difference between the estimated fair value on the respective
date and the exercise price, times the number of shares) that would have been received by the option holders had all option holders exercised
their options.</p>

<ix:exclude><p id="xdx_233_zKPshflu457k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 14 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Restricted stock unit activity
for the six months ended October 31, 2024 is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<ix:nonNumeric contextRef="From2024-05-01to2024-10-31" escape="true" id="Fact000774" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zSiEgKzV0rhd" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B0_zGqDd9BGUwC3" style="display: none">Schedule of nonvested restricted stock units activity</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; white-space: nowrap">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted Average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Grant Date Fair Value</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 63%; text-align: left">Unvested at April 30, 2024</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240501__20241031_znAntT7Wjie1" title="Unvested shares, Beginning balance" style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-04-30" id="Fact000776" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">167</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20240501__20241031_z4MomUlexUCk" title="Unvested Weighted Average Grant Date Fair Value, Beginning balance" style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-04-30" id="Fact000778" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">375.00</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Granted</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240501__20241031_pdd" title="Unvested shares, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0780">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240501__20241031_pdd" title="Unvested Weighted Average Grant Date Fair Value, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0782">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Vested</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20240501__20241031_pdd" title="Unvested shares, Vested" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2024-05-01to2024-10-31" id="Fact000784" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">83</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20240501__20241031_pdd" title="Unvested Weighted Average Grant Date Fair Value, Vested" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-05-01to2024-10-31" id="Fact000786" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">375.00</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">Cancelled</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20240501__20241031_pdd" title="Unvested shares, Cancelled" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0788">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20240501__20241031_pdd" title="Unvested Weighted Average Grant Date Fair Value, Cancelled" style="padding-bottom: 1pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0790">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Unvested at October 31, 2024</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240501__20241031_zw3UdzQE05Nj" title="Unvested shares, Ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-10-31" id="Fact000792" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">84</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20240501__20241031_zD4MSBxQMKwk" title="Unvested Weighted Average Grant Date Fair Value, Ending balance" style="padding-bottom: 2.5pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-10-31" id="Fact000794" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">375.00</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_z7rL5KUS3TE1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>Performance Contingent
Stock Options Granted to Employee</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 26, 2019, the
Board granted <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20191125__20191126__us-gaap--AwardTypeAxis__custom--PerformanceContingentStockOptionsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KeyEmployeesAndDirectorMember_pdd" title="Options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2019-11-252019-11-26_custom_PerformanceContingentStockOptionsMember_custom_KeyEmployeesAndDirectorMember" id="Fact000796" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,333</ix:nonFraction></span> performance and market contingent awards to certain key employees and a director. These grants were made outside
of the Plan. These awards have an exercise price of $225.00 per share. These awards have multiple separate market triggers for vesting
based upon either (i) the successful achievement of stepped target closing prices on a national securities exchange for 90 consecutive
trading days later than 180 days after the Company&#8217;s initial public offering (&#8220;IPO&#8221;) for its common stock, or (ii) stepped
target prices for a change in control transaction. The target prices ranged from $1,500 per share to $6,000 per share. <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_c20191125__20191126__us-gaap--AwardTypeAxis__custom--PerformanceContingentStockOptionsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KeyEmployeesAndDirectorMember" title="Terms of award"><ix:nonNumeric contextRef="From2019-11-252019-11-26_custom_PerformanceContingentStockOptionsMember_custom_KeyEmployeesAndDirectorMember" id="Fact000798" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">In the event any
of the stock price milestones are not achieved within three years</ix:nonNumeric></span>, the unvested portion of the performance options will be reduced by
25%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 22, 2022, the
Compensation Committee of the Board modified the performance criteria for these awards. The target price range is now $1,500 per share
to $3,000 per share. Additionally, if the stock price milestones are now not achieved by November 27, 2026, as opposed to within three
years, the unvested portion of the portion of the performance options will be reduced by 25%. Due to the significant risks and uncertainties
associated with achieving the market-contingent awards, as of October 31, 2024, management believes that the achievement of the requisite
performance conditions is not probable and, as a result, no compensation cost has been recognized for these awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 29, 2022, the
Compensation Committee of the Board granted 13,333 performance-based stock option to the Chief Executive Officer at an exercise price
of $175.50 per share, of which 50% vest upon the completion and announcement of topline data from the Company&#8217;s Phase II clinical
trial of AL001 within three years from grant date and the remaining 50% vest upon the completion and announcement of topline data from
the Company&#8217;s Phase II clinical trial of ALZN002 within four years from the grant date. During the three months ended July 31, 2023,
management believed that it was probable that the performance condition of the completion and announcement of topline data from the Company&#8217;s
Phase II clinical trial of AL001 would be achieved and had recognized the related stock-based compensation. As of October 31, 2024, management
believed that the achievement of the second performance condition was not probable and, as a result, no compensation cost has been recognized
related to Phase I/IIA of ALZN002.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>Performance Contingent
Stock Options Granted to TAMM Net</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 23, 2021, the Company
issued performance-based stock options to certain team members at TAMM Net, Inc. (&#8220;TAMM Net&#8221;) to purchase an aggregate of
3,000 shares of Common Stock at a per share exercise price of $225.00 per share, of which 50% would vest upon the completion of Phase
I of AL001 by March 31, 2022, and the remaining 50% would vest upon completion of Phase I/IIA of ALZN002 by December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 19, 2023, the Board
modified the performance criteria for these awards. The remaining 50% of the grant will now vest upon the completion and announcement
of topline data of the first cohort from a Phase I/IIA clinical trial of ALZN002 on/or before March 31, 2024. The modified performance
criteria was not met on or before March 31, 2024 and, as a result, the remaining unvested stock options were cancelled and no compensation
cost has been recognized for these awards related to ALZN002.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>Performance Contingent
Stock Options Granted to Consultants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 14, 2021, the Company
issued performance-based stock options to two consultants to purchase an aggregate of 1,334 shares of Common Stock with an exercise price
of $363.00 per share, of which 333 vest upon completion of each of the Phase II clinical trials of AL001 for a BD indication, AL001 for
a PTSD indication, AL001 for an MDD indication and ALZN002 for an Alzheimer&#8217;s indication.</p>

<ix:exclude><p id="xdx_23A_zRsAmIBkUyhl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 15 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 19, 2023, the Board
modified the performance criteria for these awards. The revised grant will vest 25% if the Company (a) completes and announces topline
data from a Phase II clinical trial of AL001 and ALZN002, as applicable, that would support a new drug application for the drug candidate
and the indication listed below, and (b) obtained a &#8220;Study May Proceed&#8221; letter from the U.S. Food and Drug Administration
(&#8220;FDA&#8221;) for the additional Investigational New Drug (&#8220;IND&#8221;) on/or before December 31, 2023, as follows: (i) AL001
&#8211; BD; (ii) AL001- MDD; (iii) AL001 &#8211; PTSD; and (iv) ALZN002 &#8211; Alzheimer&#8217;s.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended April
30, 2024, the Company filed INDs for BD, MDD and PTSD and received a &#8220;Study May Proceed&#8221; letter for BD in October 2023, MDD
in November 2023 and PTSD in December 2023. As a result, 75% of the performance grant vested and the Company recognized stock-based compensation
related to the vesting. As of October 31, 2024, management believed that the achievement of the remaining requisite performance condition
was not probable and, as a result, no compensation cost has been recognized for these awards related to ALZN002 &#8211; Alzheimer&#8217;s.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>Stock-Based Compensation
Expense</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s results
of operations included expenses relating to stock-based compensation for three and six months ended October 31, 2024 and 2023, were comprised
as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:nonNumeric contextRef="From2024-05-01to2024-10-31" escape="true" id="Fact000801" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zt1KAqdUZDv" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span id="xdx_8B1_zS70DLh5jzc7" style="display: none">Schedule of stock-based compensation</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">For the Three Months Ended October 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">For the Six Months Ended October 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">&#160;Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20240801__20241031__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" title="Total" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0803">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20230801__20231031__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" title="Total" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0805">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_c20240501__20241031__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" title="Total" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0807">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20230501__20231031__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" title="Total" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-05-012023-10-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000809" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">142,603</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">&#160;General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20240801__20241031__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" title="Total" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-08-012024-10-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000811" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">81,277</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20230801__20231031__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" title="Total" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-08-012023-10-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000813" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">175,733</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20240501__20241031__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" title="Total" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-05-012024-10-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000815" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">162,554</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20230501__20231031__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" title="Total" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-05-012023-10-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000817" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">545,113</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20240801__20241031_pp0p0" title="Total" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-08-012024-10-31" id="Fact000819" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">81,277</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20230801__20231031_pp0p0" title="Total" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-08-012023-10-31" id="Fact000821" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">175,733</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20240501__20241031_pp0p0" title="Total" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-05-01to2024-10-31" id="Fact000823" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">162,554</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20230501__20231031_pp0p0" title="Total" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-05-012023-10-31" id="Fact000825" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">687,716</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zVAT2YRkOVUc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of October 31, 2024, total
unamortized stock-based compensation expense related to unvested employee and non-employee awards that are expected to vest was $<span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c20241031__us-gaap--IncomeStatementLocationAxis__custom--UnamortizedStockBasedCompensationMember_pp0p0" title="Unamortized stock-based compensation expense related to unvested employee and non-employee awards"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2024-10-31_custom_UnamortizedStockBasedCompensationMember" id="Fact000827" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">284,000</ix:nonFraction></span>.
The weighted-average period over which such stock-based compensation expense will be recognized was approximately <span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240501__20241031__us-gaap--IncomeStatementLocationAxis__custom--StockBasedCompensationMember_z8nrVfS0hDqk" title="Weighted-average period"><ix:nonNumeric contextRef="From2024-05-012024-10-31_custom_StockBasedCompensationMember" format="ixt-sec:duryear" id="Fact000829" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">0.9</ix:nonNumeric></span> years.</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" escape="true" id="Fact000831" name="us-gaap:ProductWarrantyDisclosureTextBlock"><p id="xdx_80B_eus-gaap--ProductWarrantyDisclosureTextBlock_zL13sjSHx1oj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>6.</b></td><td style="text-align: justify"><b><span id="xdx_821_z8aPZFuoCxta">WARRANTS</span></b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three months ended
October 31, 2024, the Company issued warrants to purchase an aggregate of <span id="xdx_902_ecustom--AggregateNumberOfStockRepurchase_c20240501__20241031__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_pdd" title="Aggregate number of stock repurchase"><ix:nonFraction name="alzm:AggregateNumberOfStockRepurchase" contextRef="From2024-05-012024-10-31_custom_Warrant2024Member" id="Fact000833" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">440,000</ix:nonFraction></span> shares of common stock at an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20241031__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_pdd" title="Exercise price (in dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-10-31_custom_Warrant2024Member" id="Fact000835" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.50</ix:nonFraction></span>
per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 36pt"/><td style="width: 22.45pt">(i)</td><td style="text-align: justify">On August 19, 2024, the Company issued a warrant to purchase <span id="xdx_903_ecustom--AggregateNumberOfStockRepurchase_c20240801__20240819__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_pdd" title="Aggregate number of stock repurchase"><ix:nonFraction name="alzm:AggregateNumberOfStockRepurchase" contextRef="From2024-08-012024-08-19_custom_Warrant2024Member" id="Fact000837" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">160,000</ix:nonFraction></span> shares of Common Stock at an exercise
price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20240819__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_pdd" title="Exercise price (in dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-08-19_custom_Warrant2024Member" id="Fact000839" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.50</ix:nonFraction></span> in connection with the sale of convertible preferred stock to Orchid Finance, LLC (&#8220;Orchid&#8221;) for $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20240801__20240819__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_zN6ksDfyqfu5" title="Value of common stock sold"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2024-08-012024-08-19_custom_Warrant2024Member" id="Fact000841" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,000,000</ix:nonFraction></span>.
Based on the terms of the Company&#8217;s warrant agreement, the Company accounted for the warrant as an equity instrument as the warrant
is indexed to the common stock, requires settlement in shares and would be classified as equity under ASC 815. The fair value of the warrant
on the date issued was $<span id="xdx_903_eus-gaap--FairValueAdjustmentOfWarrants_pp0p0_c20240801__20240819__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_zDhYlazCUQU9" title="Fair value of warrant"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-08-012024-08-19_custom_Warrant2024Member" id="Fact000843" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">571,000</ix:nonFraction></span>.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 36pt"/><td style="width: 22.5pt">(ii)</td><td style="text-align: justify">On August 21, 2024, the Company issued a warrant to purchase <span id="xdx_908_ecustom--AggregateNumberOfStockRepurchase_c20240801__20240821__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_pdd" title="Aggregate number of stock repurchase"><ix:nonFraction name="alzm:AggregateNumberOfStockRepurchase" contextRef="From2024-08-012024-08-21_custom_Warrant2024Member" id="Fact000845" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000</ix:nonFraction></span> shares of Common Stock at an exercise
price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20240821__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_pdd" title="Exercise price (in dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-08-21_custom_Warrant2024Member" id="Fact000847" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.50</ix:nonFraction></span> in connection with the sale of convertible preferred stock to Orchid for $<span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20240801__20240821__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_zRzvjrNAi55d" title="Value of common stock sold"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2024-08-012024-08-21_custom_Warrant2024Member" id="Fact000849" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,500,000</ix:nonFraction></span>. Based on the terms of the Company&#8217;s
warrant agreement, the Company accounted for the warrant as an equity instrument as the warrant is indexed to the common stock, requires
settlement in shares and would be classified as equity under ASC 815. The fair value of the warrant on the date issued was $<span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_c20240801__20240821__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_zY1ynwDN0Kkd" title="Fair value of warrant"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-08-012024-08-21_custom_Warrant2024Member" id="Fact000851" format="ixt:numdotdecimal" decimals="0" unitRef="USD">486,000</ix:nonFraction></span>.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify; text-indent: -22.5pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 36pt"/><td style="width: 22.5pt">(iii)</td><td style="text-align: justify">On September 11, 2024, the Company issued a warrant to purchase <span id="xdx_909_ecustom--AggregateNumberOfStockRepurchase_c20240901__20240911__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_pdd" title="Aggregate number of stock repurchase"><ix:nonFraction name="alzm:AggregateNumberOfStockRepurchase" contextRef="From2024-09-012024-09-11_custom_Warrant2024Member" id="Fact000853" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">80,000</ix:nonFraction></span> shares of Common Stock at an exercise
price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20240911__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_pdd" title="Exercise price (in dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-09-11_custom_Warrant2024Member" id="Fact000855" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.50</ix:nonFraction></span> in connection with the sale of convertible preferred stock to Orchid for $<span id="xdx_905_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20240901__20240911__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_zTmwf9omOlG" title="Value of common stock sold"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2024-09-012024-09-11_custom_Warrant2024Member" id="Fact000857" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,000,000</ix:nonFraction></span>. Based on the terms of the Company&#8217;s
warrant agreement, the Company accounted for the warrant as an equity instrument as the warrant is indexed to the common stock, requires
settlement in shares and would be classified as equity under ASC 815. The fair value of the warrant on the date issued was $<span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_pp0p0_c20240901__20240911__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_zaBfIB7ZJSa8" title="Fair value of warrant"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-09-012024-09-11_custom_Warrant2024Member" id="Fact000859" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">69,000</ix:nonFraction></span>.</td></tr></table>

<ix:exclude><p id="xdx_23F_zoSpV6ZKVxVg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 16 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Warrant activity for the six
months ended October 31, 2024 is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:nonNumeric contextRef="From2024-05-01to2024-10-31" escape="true" id="Fact000862" name="alzm:ScheduleOfWarrantActivityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfWarrantActivityTableTextBlock_zWMLNR3BTmk" summary="xdx: Disclosure - WARRANTS (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B1_zRpP47Cprvm9" style="display: none">Schedule of warrant activity</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; white-space: nowrap">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Number</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Outstanding</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Weighted Average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Exercise Price</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Outstanding at April 30, 2024</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20240501__20241031_zF0F44KaE1Gl" title="Class of warrant or right, outstanding, beginning" style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-04-30" id="Fact000864" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">240,449</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20240501__20241031_zZ8SJdEkcPK1" title="Weighted average exercise price, beginning" style="width: 15%; text-align: center">$<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-04-30" id="Fact000866" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">67.45</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Granted</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--ClassOfWarrantOrRightOutstandingGranted_c20240501__20241031_pdd" title="Class of warrant or right, outstanding, granted" style="text-align: right"><ix:nonFraction name="alzm:ClassOfWarrantOrRightOutstandingGranted" contextRef="From2024-05-01to2024-10-31" id="Fact000868" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">640,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_98A_ecustom--WeightedAverageExercisesPriceGranted_c20240501__20241031_pdd" title="Weighted average exercise price, granted" style="text-align: center">$<ix:nonFraction name="alzm:WeightedAverageExercisesPriceGranted" contextRef="From2024-05-01to2024-10-31" id="Fact000870" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.50</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">Cancelled/Expired</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--ClassOfWarrantOrRightOutstandingCancelledexpired_c20240501__20241031_pdd" title="Class of warrant or right, outstanding, cancelled/expired" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="alzm:ClassOfWarrantOrRightOutstandingCancelledexpired" contextRef="From2024-05-01to2024-10-31" id="Fact000872" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">6,999</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td id="xdx_98E_ecustom--WeightedAverageExercisePriceCancelledexpired_c20240501__20241031_pdd" title="Weighted average exercise price, cancelled/expired" style="padding-bottom: 1pt; text-align: center">$<ix:nonFraction name="alzm:WeightedAverageExercisePriceCancelledexpired" contextRef="From2024-05-01to2024-10-31" id="Fact000874" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">320.28</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Outstanding at October 31, 2024</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20240501__20241031_z2Cy4zu45xT" title="Class of warrant or right, outstanding, ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-10-31" id="Fact000876" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">873,450</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20240501__20241031_zdJEUTA9lwr7" title="Weighted average exercise price, ending" style="padding-bottom: 2.5pt; text-align: center">$<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-10-31" id="Fact000878" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">24.35</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_znTKJxjjQW84" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
information about Common Stock warrants outstanding and exercisable at October 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<ix:nonNumeric contextRef="From2024-05-01to2024-10-31" escape="true" id="Fact000880" name="us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_z6sfzHeW9Gh8" summary="xdx: Disclosure - WARRANTS (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; white-space: nowrap"><span id="xdx_8B4_z6R1aopOG5wb" style="display: none">Schedule of common stock warrants outstanding</span></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="13" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Number</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Number</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Life (years)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 15%; text-align: center">$<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member__srt--RangeAxis__srt--MinimumMember_pdd" title="Exercse price (in dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-10-31_custom_ExercisePrice1Member_srt_MinimumMember" id="Fact000882" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.00</ix:nonFraction></span>-$<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member__srt--RangeAxis__srt--MaximumMember_pdd" title="Exercse price (in dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-10-31_custom_ExercisePrice1Member_srt_MaximumMember" id="Fact000884" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.50</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pdd" title="Class of Warrant or Right, Outstanding" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-10-31_custom_ExercisePrice1Member" id="Fact000886" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">850,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zI8Z94sjgH3j" title="Weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="AsOf2024-10-31_custom_ExercisePrice1Member" format="ixt-sec:duryear" id="Fact000888" name="us-gaap:WarrantsAndRightsOutstandingTerm">4.7</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--WarrantOutstandingWeightedAverageExercisePrice_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pdd" title="Warrant outstanding, weighted average exercise price (in dollars per share)" style="width: 14%; text-align: right"><ix:nonFraction name="alzm:WarrantOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-10-31_custom_ExercisePrice1Member" id="Fact000890" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.38</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_ecustom--NumberOfWarrantExercisable_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pdd" title="Number of warrant exercisable" style="width: 14%; text-align: right"><ix:nonFraction name="alzm:NumberOfWarrantExercisable" contextRef="AsOf2024-10-31_custom_ExercisePrice1Member" id="Fact000892" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">850,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--WarrantExercisableWeightedAverageExercisePriceInDollarsPerShare_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pdd" title="Warrant exercisable, weighted average exercise price (in dollars per share)" style="width: 13%; text-align: right"><ix:nonFraction name="alzm:WarrantExercisableWeightedAverageExercisePriceInDollarsPerShare" contextRef="AsOf2024-10-31_custom_ExercisePrice1Member" id="Fact000894" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.38</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">$<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pdd" title="Exercse price (in dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-10-31_custom_ExercisePrice3Member" id="Fact000896" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">450.00</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pdd" title="Class of Warrant or Right, Outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-10-31_custom_ExercisePrice3Member" id="Fact000898" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,042</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_zq9JReh6gzxb" title="Weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="AsOf2024-10-31_custom_ExercisePrice3Member" format="ixt-sec:duryear" id="Fact000900" name="us-gaap:WarrantsAndRightsOutstandingTerm">1.8</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--WarrantOutstandingWeightedAverageExercisePrice_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pdd" title="Warrant outstanding, weighted average exercise price (in dollars per share)" style="text-align: right"><ix:nonFraction name="alzm:WarrantOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-10-31_custom_ExercisePrice3Member" id="Fact000902" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">450.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--NumberOfWarrantExercisable_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pdd" title="Number of warrant exercisable" style="text-align: right"><ix:nonFraction name="alzm:NumberOfWarrantExercisable" contextRef="AsOf2024-10-31_custom_ExercisePrice3Member" id="Fact000904" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,042</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_ecustom--WarrantExercisableWeightedAverageExercisePriceInDollarsPerShare_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pdd" title="Warrant exercisable, weighted average exercise price (in dollars per share)" style="text-align: right"><ix:nonFraction name="alzm:WarrantExercisableWeightedAverageExercisePriceInDollarsPerShare" contextRef="AsOf2024-10-31_custom_ExercisePrice3Member" id="Fact000906" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">450.00</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: center">$<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pdd" title="Exercse price (in dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-10-31_custom_ExercisePrice4Member" id="Fact000908" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">937.50</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pdd" title="Class of Warrant or Right, Outstanding" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-10-31_custom_ExercisePrice4Member" id="Fact000910" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">408</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_z8IiHBUXHcZd" title="Weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="AsOf2024-10-31_custom_ExercisePrice4Member" format="ixt-sec:duryear" id="Fact000912" name="us-gaap:WarrantsAndRightsOutstandingTerm">1.6</ix:nonNumeric></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_ecustom--WarrantOutstandingWeightedAverageExercisePrice_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pdd" title="Warrant outstanding, weighted average exercise price (in dollars per share)" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="alzm:WarrantOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-10-31_custom_ExercisePrice4Member" id="Fact000914" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">937.50</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--NumberOfWarrantExercisable_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pdd" title="Number of warrant exercisable" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="alzm:NumberOfWarrantExercisable" contextRef="AsOf2024-10-31_custom_ExercisePrice4Member" id="Fact000916" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">408</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_ecustom--WarrantExercisableWeightedAverageExercisePriceInDollarsPerShare_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pdd" title="Warrant exercisable, weighted average exercise price (in dollars per share)" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="alzm:WarrantExercisableWeightedAverageExercisePriceInDollarsPerShare" contextRef="AsOf2024-10-31_custom_ExercisePrice4Member" id="Fact000918" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">937.50</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; text-align: center">$<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice5Member__srt--RangeAxis__srt--MinimumMember_pdd" title="Exercse price (in dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-10-31_custom_ExercisePrice5Member_srt_MinimumMember" id="Fact000920" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.00</ix:nonFraction></span> - $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice5Member__srt--RangeAxis__srt--MaximumMember_pdd" title="Exercse price (in dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-10-31_custom_ExercisePrice5Member_srt_MaximumMember" id="Fact000922" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">937.50</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice5Member_zIQihYGkCStb" title="Class of Warrant or Right, Outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-10-31_custom_ExercisePrice5Member" id="Fact000924" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">873,450</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice5Member_zT1TcctG5qy9" title="Weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="AsOf2024-10-31_custom_ExercisePrice5Member" format="ixt-sec:duryear" id="Fact000926" name="us-gaap:WarrantsAndRightsOutstandingTerm">4.7</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--WarrantOutstandingWeightedAverageExercisePrice_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice5Member_pdd" title="Warrant outstanding, weighted average exercise price (in dollars per share)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="alzm:WarrantOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-10-31_custom_ExercisePrice5Member" id="Fact000928" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">24.35</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_ecustom--NumberOfWarrantExercisable_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice5Member_pdd" title="Number of warrant exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="alzm:NumberOfWarrantExercisable" contextRef="AsOf2024-10-31_custom_ExercisePrice5Member" id="Fact000930" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">873,450</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--WarrantExercisableWeightedAverageExercisePriceInDollarsPerShare_c20241031__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice5Member_pdd" title="Warrant exercisable, weighted average exercise price (in dollars per share)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="alzm:WarrantExercisableWeightedAverageExercisePriceInDollarsPerShare" contextRef="AsOf2024-10-31_custom_ExercisePrice5Member" id="Fact000932" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">24.35</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" escape="true" id="Fact000934" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_803_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z44mI7QlzLbg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>7.</b></td><td style="text-align: justify"><b><span id="xdx_82D_z59Kh8pHSYMg">COMMITMENTS AND CONTINGENCIES</span></b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>Contractual Obligations</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
July 2, 2018, the Company entered into two Standard Exclusive License Agreements with Sublicensing Terms for AL001 with the Licensor and
its affiliate, the University of South Florida (the &#8220;AL001 Licenses&#8221;), pursuant to which the Licensor granted the Company
a royalty bearing exclusive worldwide licenses limited to the field of Alzheimer&#8217;s, under United States Patent Nos. (i) 9,840,521,
entitled &#8220;Organic Anion Lithium Ionic Cocrystal Compounds and Compositions&#8221;, filed September 24, 2015 and granted December
12, 2017, and (ii) 9,603,869, entitled &#8220;Lithium Co-Crystals for Treatment of Neuropsychiatric Disorders&#8221;, filed May 21, 2016
and granted March 28, 2017. On February 1, 2019, the Company entered into the First Amendments to the AL001 Licenses, on March 30, 2021,
the Company entered into the Second Amendments to the AL001 Licenses and on June 8, 2023, the Company entered into the Third Amendments
to the AL001 Licenses (collectively, the &#8220;AL001 License Agreements&#8221;). The Third Amendments to the AL001 Licenses modified
the timing of the payments of the license fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
AL001 License Agreements require that the Company pay combined royalty payments of&#160;<span id="xdx_906_ecustom--PercentageOfRoyaltyPaymentsOnNetSalesOfProduct._c20180701__20180702__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pdd" title="Percentage of royalty payments on net sales of product"><ix:nonFraction name="alzm:PercentageOfRoyaltyPaymentsOnNetSalesOfProduct." contextRef="From2018-07-012018-07-02_custom_AL001LicenseMember" id="Fact000936" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.5</ix:nonFraction>%</span>&#160;on net sales of products developed from
the licensed technology for AL001.&#160;<span id="xdx_90D_ecustom--DescriptionOfLicensesAgreements_c20180701__20180702__srt--ProductOrServiceAxis__custom--AL001LicenseMember" title="Description of licenses agreements"><ix:nonNumeric contextRef="From2018-07-012018-07-02_custom_AL001LicenseMember" id="Fact000938" name="alzm:DescriptionOfLicensesAgreements">The Company has already paid an initial license fee of $<span id="xdx_903_ecustom--InitialLicenseFees_c20180701__20180702__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" title="Initial license fees"><ix:nonFraction name="alzm:InitialLicenseFees" contextRef="From2018-07-012018-07-02_custom_AL001LicenseMember" id="Fact000940" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">200,000</ix:nonFraction></span>&#160;for AL001. As an additional
licensing fee for the license of the AL001 technologies, the Licensor received&#160;14,853 shares of Common Stock. Minimum royalties for
AL001 License Agreements are $<span id="xdx_90E_eus-gaap--PaymentsForRoyalties_c20180701__20180702__srt--ProductOrServiceAxis__custom--AL001LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--FirstAnniversaryMember_pp0p0" title="Payments for royalties"><ix:nonFraction name="us-gaap:PaymentsForRoyalties" contextRef="From2018-07-012018-07-02_custom_AL001LicenseMember_custom_FirstAnniversaryMember" id="Fact000942" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">40,000</ix:nonFraction></span>&#160;on the first anniversary of the first commercial sale, $<span id="xdx_904_eus-gaap--PaymentsForRoyalties_c20180701__20180702__srt--ProductOrServiceAxis__custom--AL001LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--SecondAnniversaryMember_pp0p0" title="Payments for royalties"><ix:nonFraction name="us-gaap:PaymentsForRoyalties" contextRef="From2018-07-012018-07-02_custom_AL001LicenseMember_custom_SecondAnniversaryMember" id="Fact000944" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">80,000</ix:nonFraction></span>&#160;on the second anniversary
of the first commercial sale and $<span id="xdx_901_eus-gaap--PaymentsForRoyalties_c20180701__20180702__srt--ProductOrServiceAxis__custom--AL001LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--ThirdAnniversaryMember_pp0p0" title="Payments for royalties"><ix:nonFraction name="us-gaap:PaymentsForRoyalties" contextRef="From2018-07-012018-07-02_custom_AL001LicenseMember_custom_ThirdAnniversaryMember" id="Fact000946" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">100,000</ix:nonFraction></span>&#160;on the third anniversary of the first commercial sale and every year thereafter, for the
life of the AL001 License Agreements.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
May 1, 2016, the Company entered into a Standard Exclusive License Agreement with Sublicensing Terms for ALZN002 with the Licensor (the
&#8220;ALZN002 License&#8221;), pursuant to which the Licensor granted the Company a royalty-bearing exclusive worldwide license limited
to the field of Alzheimer&#8217;s Immunotherapy and Diagnostics, under United States Patent No. 8,188,046, entitled &#8220;Amyloid Beta
Peptides and Methods of Use,&#8221; filed April 7, 2009 and granted May 29, 2012. On August 18, 2017, the Company entered into the First
Amendment to the ALZN002 License, on May 7, 2018, the Company entered into the Second Amendment to the ALZN002 License, on January 31,
2019, the Company entered into the Third Amendment to the ALZN002 License, on January 24, 2020, the Company entered into the Fourth Amendment
to the ALZN002 License, on March 30, 2021, the Company entered into the Fifth Amendment to the ALZN002 License, on April 17, 2023, the
Company entered into the Sixth Amendment to the ALZN002 License and on December 11, 2023, the Company entered into the Seventh Amendment
to the ALZN002 License (collectively, the &#8220;ALZN002 License Agreement&#8221;). The Seventh Amendment to the ALZN002 License modified
the timing of the payments of the license fees.</p>

<ix:exclude><p id="xdx_237_zndTkOlMJTnc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 17 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
ALZN002 License Agreement requires the Company to pay royalty payments of&#160;<span id="xdx_90C_ecustom--PercentageOfRoyaltyPaymentsOnNetSalesOfProduct._c20160429__20160502__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_pdd" title="Percentage of royalty payments on net sales of product"><ix:nonFraction name="alzm:PercentageOfRoyaltyPaymentsOnNetSalesOfProduct." contextRef="From2016-04-292016-05-02_custom_ALZN002LicenseMember" id="Fact000949" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4</ix:nonFraction>%</span>&#160;on net sales of products developed from the licensed
technology for ALZN002.&#160;<span id="xdx_905_ecustom--DescriptionOfLicensesAgreements_c20160429__20160502__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember" title="Description of licenses agreements"><ix:nonNumeric contextRef="From2016-04-292016-05-02_custom_ALZN002LicenseMember" id="Fact000951" name="alzm:DescriptionOfLicensesAgreements">The Company has already paid an initial license fee of $<span id="xdx_901_ecustom--InitialLicenseFees_c20160429__20160502__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_pp0p0" title="Initial license fees"><ix:nonFraction name="alzm:InitialLicenseFees" contextRef="From2016-04-292016-05-02_custom_ALZN002LicenseMember" id="Fact000953" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">200,000</ix:nonFraction></span>&#160;for ALZN002. As an additional licensing
fee for the license of ALZN002, the Licensor received&#160;24,012 shares of Common Stock. Minimum royalties for ALZN002 are $<span id="xdx_902_eus-gaap--PaymentsForRoyalties_c20160429__20160502__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--FirstAnniversaryMember_pp0p0" title="Payments for royalties"><ix:nonFraction name="us-gaap:PaymentsForRoyalties" contextRef="From2016-04-292016-05-02_custom_ALZN002LicenseMember_custom_FirstAnniversaryMember" id="Fact000955" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,000</ix:nonFraction></span>&#160;on
the first anniversary of the first commercial sale, $<span id="xdx_90D_eus-gaap--PaymentsForRoyalties_c20160429__20160502__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--SecondAnniversaryMember_pp0p0" title="Payments for royalties"><ix:nonFraction name="us-gaap:PaymentsForRoyalties" contextRef="From2016-04-292016-05-02_custom_ALZN002LicenseMember_custom_SecondAnniversaryMember" id="Fact000957" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">40,000</ix:nonFraction></span>&#160;on the second anniversary of the first commercial sale and $<span id="xdx_900_eus-gaap--PaymentsForRoyalties_c20160429__20160502__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--ThirdAnniversaryMember_pp0p0" title="Payments for royalties"><ix:nonFraction name="us-gaap:PaymentsForRoyalties" contextRef="From2016-04-292016-05-02_custom_ALZN002LicenseMember_custom_ThirdAnniversaryMember" id="Fact000959" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000</ix:nonFraction></span>&#160;on
the third anniversary of the first commercial sale and every year thereafter, for the life of the ALZN002 License Agreement.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
November 19, 2019, the Company entered into two Standard Exclusive License Agreements with Sublicensing Terms for two additional indications
of AL001 with the Licensor (the &#8220;November AL001 License&#8221;), pursuant to which the Licensor granted the Company a royalty bearing
exclusive worldwide licenses limited to the fields of (i) neurodegenerative diseases excluding Alzheimer&#8217;s and (ii) psychiatric
diseases and disorders. On March 30, 2021, the Company entered into the First Amendments to the November AL001 License and on April 17,
2023, the Company entered into the Second Amendments to the November AL001 License (collectively, the &#8220;November AL001 License Agreements&#8221;).
The Second Amendments to the November AL001 License modified the timing of the payments for the license fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
November AL001 License Agreements require the Company to pay royalty payments of&#160;<span id="xdx_90B_ecustom--PercentageOfRoyaltyPaymentsOnNetSalesOfProduct._c20191101__20191119__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_pdd" title="Percentage of royalty payments on net sales of product"><ix:nonFraction name="alzm:PercentageOfRoyaltyPaymentsOnNetSalesOfProduct." contextRef="From2019-11-012019-11-19_custom_AdditionalAL001LicenseMember" id="Fact000961" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3</ix:nonFraction>%</span>&#160;on net sales of products developed from
the licensed technology for AL001 in those fields.&#160;The Company paid an initial license fee of $<span id="xdx_90E_ecustom--InitialLicenseFees_c20191101__20191119__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_pp0p0" title="Initial license fees"><ix:nonFraction name="alzm:InitialLicenseFees" contextRef="From2019-11-012019-11-19_custom_AdditionalAL001LicenseMember" id="Fact000963" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,000</ix:nonFraction></span>&#160;for the additional indications.
Minimum royalties for November AL001 License Agreements are $<span id="xdx_90A_eus-gaap--PaymentsForRoyalties_c20191101__20191119__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--FirstAnniversaryMember_pp0p0" title="Payments for royalties"><ix:nonFraction name="us-gaap:PaymentsForRoyalties" contextRef="From2019-11-012019-11-19_custom_AdditionalAL001LicenseMember_custom_FirstAnniversaryMember" id="Fact000965" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">40,000</ix:nonFraction></span>&#160;on the first anniversary of the first commercial sale, $<span id="xdx_903_eus-gaap--PaymentsForRoyalties_c20191101__20191119__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--SecondAnniversaryMember_pp0p0" title="Payments for royalties"><ix:nonFraction name="us-gaap:PaymentsForRoyalties" contextRef="From2019-11-012019-11-19_custom_AdditionalAL001LicenseMember_custom_SecondAnniversaryMember" id="Fact000967" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">80,000</ix:nonFraction></span>&#160;on
the second anniversary of the first commercial sale and $<span id="xdx_908_eus-gaap--PaymentsForRoyalties_c20191101__20191119__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--ThirdAnniversaryMember_pp0p0" title="Payments for royalties"><ix:nonFraction name="us-gaap:PaymentsForRoyalties" contextRef="From2019-11-012019-11-19_custom_AdditionalAL001LicenseMember_custom_ThirdAnniversaryMember" id="Fact000969" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">100,000</ix:nonFraction></span>&#160;on the third anniversary of the first commercial sale and every
year thereafter, for the life of the November AL001 License Agreements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">These
license agreements have an indefinite term that continue until the later of the date no licensed patent under the applicable agreement
remains a pending application or enforceable patent, the end date of any period of market exclusivity granted by a governmental regulatory
body, or the date on which the Company&#8217;s obligations to pay royalties expire under the applicable license agreement. Under the various
license agreements, if the Company fails to meet a milestone by its specified date, Licensor may terminate the license agreement. The
Licensor was also granted a preemptive right to acquire such shares or other equity securities that may be issued from time to time by
the Company while the Licensor remains the owner of any equity securities of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Additionally,
the Company is required to complete milestones and make payments on the due dates to the Licensor for the license of the AL001 technologies
and for the ALZN002 technology, as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Original AL001 Licenses:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b></b></p>

<ix:nonNumeric contextRef="From2024-05-01to2024-10-31" escape="true" id="Fact000971" name="srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock"><table cellspacing="0" cellpadding="0" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" id="xdx_89E_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zCMacsEn2O14" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td><span id="xdx_8B8_zpUCVNk3ZU8i" style="display: none">Schedule of contractual obligation, fiscal year maturity</span></td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap"><b>Payment</b></td>
    <td style="padding-bottom: 1pt; white-space: nowrap; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap"><b>Due Date</b></td>
    <td style="padding-bottom: 1pt; white-space: nowrap">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap"><b>Event</b></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 1%">$</td>
    <td id="xdx_985_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--PreIndMeetingMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" title="Payment" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2024-10-31_custom_PreIndMeetingMember_custom_AL001LicenseMember" id="Fact000973" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000</ix:nonFraction></td>
    <td style="width: 1%; text-align: center"><sup>*</sup></td>
    <td style="width: 49%"><span id="xdx_90F_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--PreIndMeetingMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_fKg_____znVQ4K0acZc6" title="Due date"><ix:nonNumeric contextRef="From2024-05-012024-10-31_custom_PreIndMeetingMember_custom_AL001LicenseMember" id="Fact000975" name="us-gaap:OtherCommitmentsDescription">Completed September 2019</ix:nonNumeric></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 38%">Pre-IND meeting</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>$</td>
    <td id="xdx_98A_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--IndApplicationFilingMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" title="Payment" style="text-align: right"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2024-10-31_custom_IndApplicationFilingMember_custom_AL001LicenseMember" id="Fact000977" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">65,000</ix:nonFraction></td>
    <td style="text-align: center"><sup>*</sup></td>
    <td><span id="xdx_908_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--IndApplicationFilingMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_fKg_____zShljCml5rJ5" title="Due date"><ix:nonNumeric contextRef="From2024-05-012024-10-31_custom_IndApplicationFilingMember_custom_AL001LicenseMember" id="Fact000979" name="us-gaap:OtherCommitmentsDescription">Completed June 2021</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td>IND application filing</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>$</td>
    <td id="xdx_987_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" title="Payment" style="text-align: right"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2024-10-31_custom_UponFirstDosingOfPatientInClinicalTrialMember_custom_AL001LicenseMember" id="Fact000981" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">190,000</ix:nonFraction></td>
    <td style="text-align: center"><sup>*</sup></td>
    <td><span id="xdx_90B_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_fKg_____zme72DRKSHLe" title="Due date"><ix:nonNumeric contextRef="From2024-05-012024-10-31_custom_UponFirstDosingOfPatientInClinicalTrialMember_custom_AL001LicenseMember" id="Fact000983" name="us-gaap:OtherCommitmentsDescription">Completed December 2021</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td>Upon first dosing of patient in a clinical trial</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>$</td>
    <td id="xdx_984_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" title="Payment" style="text-align: right"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2024-10-31_custom_UponCompletionOfFirstClinicalTrialMember_custom_AL001LicenseMember" id="Fact000985" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">500,000</ix:nonFraction></td>
    <td style="text-align: center"><sup>*</sup></td>
    <td><span id="xdx_905_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_fKg_____z48eF4ZqBbv" title="Due date"><ix:nonNumeric contextRef="From2024-05-012024-10-31_custom_UponCompletionOfFirstClinicalTrialMember_custom_AL001LicenseMember" id="Fact000987" name="us-gaap:OtherCommitmentsDescription">Completed March 2022</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td>Upon completion of first clinical trial</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>$</td>
    <td id="xdx_985_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInAPhaseIIIClinicalMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" title="Payment" style="text-align: right"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2024-10-31_custom_UponFirstPatientTreatedInAPhaseIIIClinicalMember_custom_AL001LicenseMember" id="Fact000989" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,250,000</ix:nonFraction></td>
    <td style="text-align: center">&#160;</td>
    <td><span id="xdx_90E_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInAPhaseIIIClinicalMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember" title="Due date"><ix:nonNumeric contextRef="From2024-05-012024-10-31_custom_UponFirstPatientTreatedInAPhaseIIIClinicalMember_custom_AL001LicenseMember" id="Fact000991" name="us-gaap:OtherCommitmentsDescription">March 2025</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td>Upon first patient treated in a Phase III clinical trial</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>$</td>
    <td id="xdx_988_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponFdaApprovalMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" title="Payment" style="text-align: right"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2024-10-31_custom_UponFdaApprovalMember_custom_AL001LicenseMember" id="Fact000993" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,000,000</ix:nonFraction></td>
    <td style="text-align: center">&#160;</td>
    <td><span id="xdx_902_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--UponFdaApprovalMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember" title="Due date"><ix:nonNumeric contextRef="From2024-05-012024-10-31_custom_UponFdaApprovalMember_custom_AL001LicenseMember" id="Fact000995" name="us-gaap:OtherCommitmentsDescription">8 years from the effective date of the agreement</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td>Upon FDA new drug application approval</td></tr>
  </table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td id="xdx_F08_zkszjVw2weqb" style="width: 9pt">*</td><td id="xdx_F11_zh3FeDOQSOg5"><ix:footnote id="Footnote000996" xml:lang="en-US">Milestone met and payment made</ix:footnote></td></tr></table>

<ix:exclude><p id="xdx_23A_ze91B6eDQd7l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><b>ALZN002 License:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap"><b>Payment</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap"><b>Due Date</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%">$</td>
    <td id="xdx_982_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponINDApplicationFilingMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_pp0p0" title="Payment" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2024-10-31_custom_UponINDApplicationFilingMember_custom_ALZN002LicenseMember" id="Fact000999" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000</ix:nonFraction></td>
    <td style="white-space: nowrap; width: 1%; text-align: center">&#160;*</td>
    <td style="width: 82%"><span id="xdx_90C_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--UponINDApplicationFilingMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_fKg_____zEp2k5XnqXz6" title="Due date"><ix:nonNumeric contextRef="From2024-05-012024-10-31_custom_UponINDApplicationFilingMember_custom_ALZN002LicenseMember" id="Fact001001" name="us-gaap:OtherCommitmentsDescription">Completed January 2022</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>$</td>
    <td id="xdx_988_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInFirstPhaseIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_pp0p0" title="Payment" style="text-align: right"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2024-10-31_custom_UponFirstDosingOfPatientInFirstPhaseIClinicalTrialMember_custom_ALZN002LicenseMember" id="Fact001003" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000</ix:nonFraction></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span id="xdx_902_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInFirstPhaseIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember" title="Due date"><ix:nonNumeric contextRef="From2024-05-012024-10-31_custom_UponFirstDosingOfPatientInFirstPhaseIClinicalTrialMember_custom_ALZN002LicenseMember" id="Fact001005" name="us-gaap:OtherCommitmentsDescription">Upon first dosing of patient in first Phase I clinical trial</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>$</td>
    <td id="xdx_989_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponCompletionOfFirstPhaseIIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_pp0p0" title="Payment" style="text-align: right"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2024-10-31_custom_UponCompletionOfFirstPhaseIIClinicalTrialMember_custom_ALZN002LicenseMember" id="Fact001007" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">500,000</ix:nonFraction></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span id="xdx_904_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--UponCompletionOfFirstPhaseIIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember" title="Due date"><ix:nonNumeric contextRef="From2024-05-012024-10-31_custom_UponCompletionOfFirstPhaseIIClinicalTrialMember_custom_ALZN002LicenseMember" id="Fact001009" name="us-gaap:OtherCommitmentsDescription">Upon completion of first Phase IIB clinical trial</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>$</td>
    <td id="xdx_980_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhaseIIIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_pp0p0" title="Payment" style="text-align: right"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2024-10-31_custom_UponFirstPatientTreatedInPhaseIIIClinicalTrialMember_custom_ALZN002LicenseMember" id="Fact001011" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,000,000</ix:nonFraction></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span id="xdx_906_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhaseIIIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember" title="Due date"><ix:nonNumeric contextRef="From2024-05-012024-10-31_custom_UponFirstPatientTreatedInPhaseIIIClinicalTrialMember_custom_ALZN002LicenseMember" id="Fact001013" name="us-gaap:OtherCommitmentsDescription">Upon first patient treated in a Phase III clinical trial</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>$</td>
    <td id="xdx_984_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponFDABLAApprovalMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_pp0p0" title="Payment" style="text-align: right"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2024-10-31_custom_UponFDABLAApprovalMember_custom_ALZN002LicenseMember" id="Fact001015" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,000,000</ix:nonFraction></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span id="xdx_904_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--UponFDABLAApprovalMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember" title="Due date"><ix:nonNumeric contextRef="From2024-05-012024-10-31_custom_UponFDABLAApprovalMember_custom_ALZN002LicenseMember" id="Fact001017" name="us-gaap:OtherCommitmentsDescription">Upon first commercial sale</ix:nonNumeric></span></td></tr>
  </table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td id="xdx_F04_zqRn9VuSZ6id" style="width: 9pt">*</td><td id="xdx_F15_zVcMtheF8a39"><ix:footnote id="Footnote001018" xml:lang="en-US">Milestone met and payment made</ix:footnote></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Additional
AL001 Licenses:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap"><b>Payment</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap"><b>Due Date</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap"><b>Event</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%">$</td>
    <td id="xdx_986_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInAPhaseIIIClinicalMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_pp0p0" title="Payment" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2024-10-31_custom_UponFirstPatientTreatedInAPhaseIIIClinicalMember_custom_AdditionalAL001LicenseMember" id="Fact001020" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,000,000</ix:nonFraction></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="width: 49%"><span id="xdx_902_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInAPhaseIIIClinicalMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember" title="Due date"><ix:nonNumeric contextRef="From2024-05-012024-10-31_custom_UponFirstPatientTreatedInAPhaseIIIClinicalMember_custom_AdditionalAL001LicenseMember" id="Fact001022" name="us-gaap:OtherCommitmentsDescription">March 2026</ix:nonNumeric></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 38%">&#160;Upon first patient treated in a Phase III clinical trial</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>$</td>
    <td id="xdx_98D_eus-gaap--ContractualObligation_c20241031__custom--LicenseEventsAxis__custom--FirstCommercialSaleMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_pp0p0" title="Payment" style="text-align: right"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2024-10-31_custom_FirstCommercialSaleMember_custom_AdditionalAL001LicenseMember" id="Fact001024" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,000,000</ix:nonFraction></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span id="xdx_903_eus-gaap--OtherCommitmentsDescription_c20240501__20241031__custom--LicenseEventsAxis__custom--FirstCommercialSaleMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember" title="Due date"><ix:nonNumeric contextRef="From2024-05-012024-10-31_custom_FirstCommercialSaleMember_custom_AdditionalAL001LicenseMember" id="Fact001026" name="us-gaap:OtherCommitmentsDescription">August 1, 2029</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td>&#160;First commercial sale</td></tr>
  </table>
</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" escape="true" id="Fact001028" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_807_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z7gA3dXwZ5d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>8.</b></td><td style="text-align: justify"><b><span id="xdx_827_zoPfkIUYLZo4">EQUITY TRANSACTIONS</span></b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Company is authorized to issue <span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_c20241031_pdd" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-10-31" id="Fact001030" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></span> shares of Preferred Stock, $<span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_c20241031_pdd" title="Preferred stock, par value (in dollars per share)"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-10-31" id="Fact001032" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> par value. The Board has designated <span id="xdx_901_ecustom--PreferredStockSharesDesignated_iI_c20241031__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zMu0nIwOihI1" title="Preferred stock shares designated"><ix:nonFraction name="alzm:PreferredStockSharesDesignated" contextRef="AsOf2024-10-31_us-gaap_SeriesAPreferredStockMember" id="Fact001034" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,000</ix:nonFraction></span> shares as Series
A Convertible Preferred Stock and <span id="xdx_90C_ecustom--PreferredStockSharesDesignated_iI_c20241031__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z62UunYPZ2Ch" title="Preferred stock shares designated"><ix:nonFraction name="alzm:PreferredStockSharesDesignated" contextRef="AsOf2024-10-31_us-gaap_SeriesBPreferredStockMember" id="Fact001036" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,000</ix:nonFraction></span> shares as Series B Convertible Preferred Stock. The rights, preferences, privileges and restrictions
on the remaining authorized <span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_c20241031__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-10-31_us-gaap_SeriesAPreferredStockMember" id="Fact001038" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,991,000</ix:nonFraction></span> shares of Preferred Stock have not been determined. The Board is authorized to create a new series
of preferred shares and determine the number of shares, as well as the rights, preferences, privileges and restrictions granted to or
imposed upon any series of preferred shares.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>Series A Convertible
Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">On
May 8, 2024, the Company and Orchid </span>entered into a securities purchase agreement (the &#8220;Orchid SPA&#8221;) for the purchase
of up to <span id="xdx_904_ecustom--NumberOfSharesPurchase_c20240501__20240508__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember_pdd" title="Number of shares purchase"><ix:nonFraction name="alzm:NumberOfSharesPurchase" contextRef="From2024-05-012024-05-08_us-gaap_SeriesAPreferredStockMember_custom_SecuritiesPurchaseAgreementsMember" id="Fact001040" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,500</ix:nonFraction></span> shares of Series A Convertible Preferred Stock and warrants to purchase shares up to 2,000,000 shares of Common Stock in
several tranche closings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 10, 2024, the Company
sold 100 shares of Series A Convertible Preferred Stock and warrants to purchase <span id="xdx_90B_ecustom--NumberOfSharesPurchase_c20240501__20240510__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember_pdd" title="Number of shares purchase"><ix:nonFraction name="alzm:NumberOfSharesPurchase" contextRef="From2024-05-012024-05-10_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementsMember" id="Fact001042" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">80,000</ix:nonFraction></span> shares of Common Stock with an exercise price
of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20240510__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember_pdd" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-05-10_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementsMember" id="Fact001044" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.50</ix:nonFraction></span>, for a total purchase price of $<span id="xdx_90B_ecustom--SharesPurchasePrice_pn3n3_dm_c20240501__20240510__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember_zgzGrOum0xV2" title="Shares purchase price"><ix:nonFraction name="alzm:SharesPurchasePrice" contextRef="From2024-05-012024-05-10_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementsMember" id="Fact001046" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1.0</ix:nonFraction></span> million. <span style="background-color: white">The purchase price was paid by the surrender
and cancellation of a term note issued by the Company to Orchid of $<span id="xdx_909_eus-gaap--DebtInstrumentIssuedPrincipal_pp0p0_c20240501__20240510__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember_zXzwQF5tCoC9" title="Principal issued"><ix:nonFraction name="us-gaap:DebtInstrumentIssuedPrincipal" contextRef="From2024-05-012024-05-10_custom_SecuritiesPurchaseAgreementsMember" id="Fact001048" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">311,356</ix:nonFraction></span>, consisting of $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20240510__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember_zMBCeTuulB4b" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-05-10_custom_SecuritiesPurchaseAgreementsMember" id="Fact001050" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">310,000</ix:nonFraction></span> of principal and $<span id="xdx_90A_eus-gaap--InterestPayableCurrent_iI_pp0p0_c20240510__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember_zpFn6H5LQAz2" title="Accrued interest"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2024-05-10_custom_SecuritiesPurchaseAgreementsMember" id="Fact001052" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,356</ix:nonFraction></span> of accrued
and unpaid interest, $<span id="xdx_901_eus-gaap--PreferredStockDiscountOnShares_iI_pp0p0_c20240510__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember_z8BGQ9STKAAh" title="Discount"><ix:nonFraction name="us-gaap:PreferredStockDiscountOnShares" contextRef="AsOf2024-05-10_custom_SecuritiesPurchaseAgreementsMember" id="Fact001054" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">100,000</ix:nonFraction></span> discount and net cash of $<span id="xdx_903_ecustom--NetCash_iI_pp0p0_c20240510__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember_zpxlSrse8SD3" title="Net cash"><ix:nonFraction name="alzm:NetCash" contextRef="AsOf2024-05-10_custom_SecuritiesPurchaseAgreementsMember" id="Fact001056" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">588,644</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 25, 2024, the Company
sold 150 shares of Series A Convertible Preferred Stock and warrants to purchase <span id="xdx_903_ecustom--NumberOfSharesPurchase_c20240601__20240625__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember_pdd" title="Number of shares purchase"><ix:nonFraction name="alzm:NumberOfSharesPurchase" contextRef="From2024-06-012024-06-25_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementsMember" id="Fact001058" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">120,000</ix:nonFraction></span> shares of Common Stock with an exercise price
of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20240625__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember_pdd" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-06-25_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementsMember" id="Fact001060" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.50</ix:nonFraction></span>, for a total purchase price of $<span id="xdx_907_ecustom--SharesPurchasePrice_pn3n3_dm_c20240601__20240625__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember_zIKQwZpJ5xqa" title="Shares purchase price"><ix:nonFraction name="alzm:SharesPurchasePrice" contextRef="From2024-06-012024-06-25_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementsMember" id="Fact001062" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1.5</ix:nonFraction></span> million. <span style="background-color: white">The purchase price was paid in cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 19, 2024, the Company
sold 200 shares of Series A Convertible Preferred Stock and warrants to purchase <span id="xdx_90A_ecustom--NumberOfSharesPurchase_c20240801__20240819__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_pdd" title="Number of shares purchase"><ix:nonFraction name="alzm:NumberOfSharesPurchase" contextRef="From2024-08-012024-08-19_custom_Warrant2024Member" id="Fact001064" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">160,000</ix:nonFraction></span> shares of Common Stock with an exercise price
of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240819__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_zafbXf1dFdg7" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-08-19_custom_Warrant2024Member" id="Fact001066" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.50</ix:nonFraction></span> to Orchid, for a total purchase price of $<span id="xdx_908_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn3n3_dm_c20240801__20240819__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_zoVbk177Zodd" title="Value of common stock sold"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2024-08-012024-08-19_custom_Warrant2024Member" id="Fact001068" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">2.0</ix:nonFraction></span> million. <span style="background-color: white">The purchase price was paid in
cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 21, 2024, the Company
sold 250 shares of Series A Convertible Preferred Stock and warrants to purchase <span id="xdx_901_ecustom--NumberOfSharesPurchase_c20240801__20240821__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_pdd" title="Number of shares purchase"><ix:nonFraction name="alzm:NumberOfSharesPurchase" contextRef="From2024-08-012024-08-21_custom_Warrant2024Member" id="Fact001070" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000</ix:nonFraction></span> shares of Common Stock with an exercise price
of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240821__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_zKAk1brOgOW8" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-08-21_custom_Warrant2024Member" id="Fact001072" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.50</ix:nonFraction></span> to Orchid, for a total purchase price of $<span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn3n3_dm_c20240801__20240821__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_zToR3gYZfe7i" title="Value of common stock sold"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2024-08-012024-08-21_custom_Warrant2024Member" id="Fact001074" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">2.5</ix:nonFraction></span> million less $100,000 discount. <span style="background-color: white">The purchase
price was paid in cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 11, 2024, the
Company sold 100 shares of Series A Convertible Preferred Stock and warrants to purchase <span id="xdx_900_ecustom--NumberOfSharesPurchase_c20240901__20240911__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_pdd" title="Number of shares purchase"><ix:nonFraction name="alzm:NumberOfSharesPurchase" contextRef="From2024-09-012024-09-11_custom_Warrant2024Member" id="Fact001076" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">80,000</ix:nonFraction></span> shares of Common Stock with an exercise
price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240911__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_z2coswCRFvrk" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-09-11_custom_Warrant2024Member" id="Fact001078" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.50</ix:nonFraction></span> to Orchid, for a total purchase price of $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn3n3_dm_c20240901__20240911__us-gaap--StatementEquityComponentsAxis__custom--Warrant2024Member_zLHblYMy2TM6" title="Value of common stock sold"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2024-09-012024-09-11_custom_Warrant2024Member" id="Fact001080" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1.0</ix:nonFraction></span> million. <span style="background-color: white">The purchase price was paid
in cash.</span></p>

<ix:exclude><p id="xdx_237_zDUjqZCbirFc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 19 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">The
</span>Series A Convertible Preferred Stock <span style="background-color: white">has a stated value of $1,000 per share and holders of
the Series A Convertible Preferred Stock are entitled to cumulative cash dividends at an annual rate of 15%, or $1,500.00 per share (&#8220;Dividend
Amount&#8221;), based on the stated value per share. Notwithstanding the foregoing, for as long as any share(s) of Series A Preferred
Stock shall remain outstanding, the Dividend Amount shall be paid either in shares of Series A Preferred Stock or cash, at Orchid&#8217;s
discretion, in each case equal to the Dividend Amount. </span>Each share of Series A Convertible Preferred Stock is convertible into shares
of Common Stock cased on the conversion price (&#8220;Series A Conversion Price&#8221;), which is defined as (a) the state value of the
Series A Preferred Stock being converted pus all accrued but unpaid dividends, divided by (b) the greater of (i) $2.50 per share (&#8220;Floor
Price&#8221;), and (ii) the lesser of (A) $15.00 and (B) 80% of the lowest closing price of the Common Stock during the three trading
days immediately prior to the date of the conversion. The Conversion Price is subject to adjustment in the event of an issuance of Common
Stock at a price per share lower than the Conversion Price then in effect, but not below the Floor Price. The Floor Price shall, however,
be adjusted for stock splits, stock dividends, combinations or similar transactions. The holders of the Series A Convertible Preferred
Stock are entitled to vote with the Common Stock as a single class on an as-converted basis, subject to applicable law provisions of the
Delaware General Corporation Law and Nasdaq, provided, however, that for purposes of complying with Nasdaq regulations, the conversion
price, for purposes of determining the number of votes the holder of Series A Convertible Preferred Stock is entitled to cast, shall not
be lower than $5.63 (the &#8220;Voting Floor Price&#8221;), which represents the closing sale price of the Common Stock on the trading
day immediately prior to the execution date of the Orchid SPA. The Voting Floor Price shall be adjusted for stock dividends, stock splits,
stock combinations and other similar transactions. Upon a liquidation event, the holders of Series A Convertible Preferred Stock receive
a liquidation preference ahead of holders of Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>Series B Convertible
Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 31, 2024, the Company
and Ault Lending, LLC (&#8220;Ault Lending&#8221;) entered into a securities purchase agreement (the &#8220;AL SPA&#8221;) for the purchase
of up to 6,000 shares of Series B Convertible Preferred Stock and warrants to purchase shares up to <span id="xdx_902_ecustom--NumberOfSharesPurchase_c20240101__20240131__us-gaap--StatementEquityComponentsAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--AultLendingMember_zhDraN3PYyU" title="Number of shares purchase"><ix:nonFraction name="alzm:NumberOfSharesPurchase" contextRef="From2024-01-012024-01-31_custom_SeriesBConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementsMember_custom_AultLendingMember" id="Fact001083" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">600,000</ix:nonFraction></span> shares of the Company&#8217;s
Common Stock. The AL SPA provides that Ault Lending may purchase up to $6 million of Series B Convertible Preferred Stock in one or more
closings. <span id="xdx_902_eus-gaap--TerminationLoansDescription_c20240101__20240131__us-gaap--StatementEquityComponentsAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--AultLendingMember" title="Termination loans description"><ix:nonNumeric contextRef="From2024-01-012024-01-31_custom_SeriesBConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementsMember_custom_AultLendingMember" id="Fact001085" name="us-gaap:TerminationLoansDescription">Ault Lending has the right to purchase up to $2 million of Series B Convertible Preferred Stock, on or before March 31, 2024,
and the right to purchase up to $4 million of Series B Convertible Preferred Stock after March 31, 2024, but on or before March 31, 2025
(the &#8220;Termination Date&#8221;). The Agreement will automatically terminate if the final closing has not occurred prior to the Termination
Date.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 31, 2024, the Company
sold <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240101__20240131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Number of common stock sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-01-012024-01-31_us-gaap_SeriesBPreferredStockMember" id="Fact001087" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,220</ix:nonFraction></span> shares of Series B Convertible Preferred Stock and warrants to purchase <span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240101__20240131__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Number of common stock sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-01-012024-01-31_us-gaap_WarrantMember" id="Fact001089" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">122,000</ix:nonFraction></span> shares of Common Stock with an exercise price
of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20240131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-01-31_us-gaap_SeriesBPreferredStockMember" id="Fact001091" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.00</ix:nonFraction></span>, for a total purchase price of $<span id="xdx_908_ecustom--SharesPurchasePrice_pn3n3_dm_c20240101__20240131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z0KEHidyU69g" title="Shares purchase price"><ix:nonFraction name="alzm:SharesPurchasePrice" contextRef="From2024-01-012024-01-31_us-gaap_SeriesBPreferredStockMember" id="Fact001093" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1.22</ix:nonFraction></span> million. <span style="background-color: white">The purchase price was paid by the cancellation
of $<span id="xdx_906_ecustom--CancellationsOfCashAdvances_pn3n3_dm_c20240101__20240131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zmnxxTkCvA54" title="Cancellations of cash advances"><ix:nonFraction name="alzm:CancellationsOfCashAdvances" contextRef="From2024-01-012024-01-31_us-gaap_SeriesBPreferredStockMember" id="Fact001095" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1.15</ix:nonFraction></span> million of cash advances made by Ault Lending to the Company between November 9, 2023 and January 31, 2024 and a subscription
receivable of $<span id="xdx_902_eus-gaap--StockholdersEquityNoteSubscriptionsReceivable_iI_pp0p0_c20240131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z9mj0Kr0NPki" title="Subscription receivable"><ix:nonFraction name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" contextRef="AsOf2024-01-31_us-gaap_SeriesBPreferredStockMember" id="Fact001097" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">70,000</ix:nonFraction></span>. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 26, 2024, the Company
sold <span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240301__20240326__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Number of common stock sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-03-012024-03-26_us-gaap_SeriesBPreferredStockMember" id="Fact001099" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">780</ix:nonFraction></span> shares of Series B Convertible Preferred Stock and warrants to purchase <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240301__20240326__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Number of common stock sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-03-012024-03-26_us-gaap_WarrantMember" id="Fact001101" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">78,000</ix:nonFraction></span> shares of Common Stock with an exercise price
of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240326__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z6yaqAszGUV3" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-03-26_us-gaap_SeriesBPreferredStockMember" id="Fact001103" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.00</ix:nonFraction></span>, for a total purchase price of $<span id="xdx_907_ecustom--SharesPurchasePrice_pp0p0_c20240301__20240326__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zkbZeq2agLX1" title="Shares purchase price"><ix:nonFraction name="alzm:SharesPurchasePrice" contextRef="From2024-03-012024-03-26_us-gaap_SeriesBPreferredStockMember" id="Fact001105" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">780,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 29, 2024, the Company
sold <span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240401__20240429__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zfveuRCKRuw6" title="Number of common stock sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-04-012024-04-29_us-gaap_SeriesBPreferredStockMember" id="Fact001107" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100</ix:nonFraction></span> shares of Series B Convertible Preferred Stock and warrants to purchase <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240401__20240429__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Number of common stock sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-04-012024-04-29_us-gaap_WarrantMember" id="Fact001109" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span> shares of Common Stock with an exercise price
of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20240429__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-04-29_us-gaap_SeriesBPreferredStockMember" id="Fact001111" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.00</ix:nonFraction></span>, for a total purchase price of $<span id="xdx_909_ecustom--SharesPurchasePrice_pp0p0_c20240401__20240429__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zkarlxSujqO" title="Shares purchase price"><ix:nonFraction name="alzm:SharesPurchasePrice" contextRef="From2024-04-012024-04-29_us-gaap_SeriesBPreferredStockMember" id="Fact001113" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">100,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">The
</span>Series B Convertible Preferred Stock <span style="background-color: white">has a stated value of $1,000 per share (&#8220;Stated
Value&#8221;) and does not accrue dividends. </span>Each share of Series B Convertible Preferred Stock is convertible into a number of
shares of Common Stock <span style="background-color: white">determined by dividing the Stated Value by $10.00</span> (the &#8220;Conversion
Price&#8221;). The Conversion Price is subject to adjustment in the event of an issuance of Common Stock at a price per share lower than
the Conversion Price then in effect, as well as upon customary stock splits, stock dividends, combinations or similar events. The holders
of the Series B Convertible Preferred Stock are entitled to vote with the Common Stock as a single class on an as-converted basis, subject
to applicable law provisions of the Delaware General Company Law and Nasdaq, provided, however, that for purposes of complying with Nasdaq
regulations, the conversion price, for purposes of determining the number of votes the holder of Series B Convertible Preferred Stock
is entitled to cast, shall not be lower than $8.73 (the &#8220;Voting Floor Price&#8221;), which represents the closing sale price of
the Common Stock on the trading day immediately prior to the Execution Date. The Voting Floor Price shall be adjusted for stock dividends,
stock splits, stock combinations and other similar transactions. Upon a liquidation event the holders of Series B Convertible Preferred
Stock receive a liquidation preference ahead of holders of Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The warrants have an exercise
price of $12.00 (the &#8220;Exercise Price&#8221;) and become exercisable on the first business day after the six-month anniversary of
issuance (the &#8220;Initial Exercise Date&#8221;) and have a five-year term, expiring on the fifth anniversary of the Initial Exercise
Date. The Exercise Price is subject to adjustment in the event of an issuance of Common Stock at a price per share lower than the Exercise
Price then in effect, as well as upon customary stock splits, stock dividends, combinations or similar events.</p>

<ix:exclude><p id="xdx_235_zSn8QfMari92" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 20 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="text-decoration: underline">At-the-Market Offering</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 3, 2024, the Company
entered into an At-the-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC (the &#8220;ATM Offering&#8221;), as sales
agent to sell shares of its Common Stock, having an aggregate offering price of up to approximately $6.5 million from time to time, through
the ATM Offering. On October 3, 2024, the Company filed a prospectus supplement with the SEC relating to the offer and sale of up to approximately
$6.5 million in shares of Common Stock in the ATM Offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The offer and sale of the
shares will be made pursuant to the Company&#8217;s effective &#8220;shelf&#8221; registration statement on Form&#160;S-3 and an accompanying
base prospectus contained therein (Registration Statement No.&#160;333-273610) filed with the SEC on August 2, 2023 and declared effective
by the SEC on August 10, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the six months ended
October 31, 2024, the Company sold an aggregate of <span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240501__20241031_pdd" title="Number of common stock sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-05-01to2024-10-31" id="Fact001116" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">755,888</ix:nonFraction></span> shares of Common Stock pursuant to the ATM Offering for gross and net proceeds
of $<span id="xdx_905_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn3n3_dm_c20240501__20241031_zuMqI5tVlFZf" title="Value of common stock sold"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2024-05-01to2024-10-31" id="Fact001118" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1.2</ix:nonFraction></span> million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><span style="text-decoration: underline">Orchid SPA</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three months ended
October 31, 2024, Orchid converted <span id="xdx_908_eus-gaap--ConversionOfStockSharesConverted1_c20240801__20241031_pdd" title="Converted shares"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2024-08-012024-10-31" id="Fact001120" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">649.5363</ix:nonFraction></span> shares of Series A Convertible Preferred Stock into <span id="xdx_900_eus-gaap--ConversionOfStockSharesIssued1_c20240801__20241031_pdd" title="Number of shares issued"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2024-08-012024-10-31" id="Fact001122" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,613,951</ix:nonFraction></span> shares of Common Stock. During
the six months ended October 31, 2024, Orchid converted <span id="xdx_90B_eus-gaap--ConversionOfStockSharesConverted1_c20240501__20241031_pdd" title="Converted shares"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2024-05-01to2024-10-31" id="Fact001124" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">712.0133</ix:nonFraction></span> shares of Series A Convertible Preferred Stock into <span id="xdx_905_eus-gaap--ConversionOfStockSharesIssued1_c20240501__20241031_pdd" title="Number of shares issued"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2024-05-01to2024-10-31" id="Fact001126" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,787,284</ix:nonFraction></span> shares
of Common Stock.</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" escape="true" id="Fact001128" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_80B_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_znkqk32mIFU3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>9.</b></td><td style="text-align: justify"><b><span id="xdx_825_zORL98nRK4Rl">RELATED PARTY TRANSACTIONS</span></b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the Orchid
SPA, the Company <span style="background-color: white">agreed to pay Ault Lending an origination fee of five percent (5%) of the total
gross proceeds we receive from Orchid upon each purchase of Series A Convertible Preferred Stock. During the three and six months ended
October 31, 2024, origination fees due to Ault Lending were $<span id="xdx_904_ecustom--OriginationFees_c20240801__20241031_pp0p0" title="Origination fees"><ix:nonFraction name="alzm:OriginationFees" contextRef="From2024-08-012024-10-31" id="Fact001130" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">275,000</ix:nonFraction></span> and $<span id="xdx_901_ecustom--OriginationFees_c20240501__20241031_pp0p0" title="Origination fees"><ix:nonFraction name="alzm:OriginationFees" contextRef="From2024-05-01to2024-10-31" id="Fact001132" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">400,000</ix:nonFraction></span>, respectively.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" escape="true" id="Fact001134" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_800_eus-gaap--SubsequentEventsTextBlock_zOIy9JIQjvhi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>10.</b></td><td style="text-align: justify"><b><span id="xdx_826_z6zCBIQAHMHk">SUBSEQUENT EVENTS</span></b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From November 1, 2024 to December
10, 2024, the Company sold an aggregate of <span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20241101__20241210_pdd" title="Number of common stock sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-11-012024-12-10" id="Fact001136" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">201,543</ix:nonFraction></span> shares of Common Stock pursuant to the ATM Offering for gross and net proceeds of $<span id="xdx_908_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20241101__20241210_pp0p0" title="Value of common stock sold"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2024-11-012024-12-10" id="Fact001138" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">280,000</ix:nonFraction></span>.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management has evaluated events
through the date the financial statement were available to be issued and determined that there have been no other events that occurred
that would require adjustment to our disclosures in the condensed financial statements.</p>

</ix:nonNumeric><p id="xdx_810_zOtDDoEpg2Jb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 21 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 1in"><b>ITEM 2.</b></td><td style="text-align: justify"><b>MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>You should read the following
management&#8217;s discussion and analysis of financial condition and results of operations in conjunction with our unaudited condensed
financial statements and notes thereto included in Part I, Item 1 of this Quarterly Report on Form 10-Q and with our audited financial
statements and related notes thereto and Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included
in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission, or the SEC, on July 30, 2024.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTE ABOUT FORWARD-LOOKING STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Quarterly Report on Form
10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities
Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). This section should
be read in conjunction with our unaudited condensed financial statements and related notes included in Part I, Item 1 of this report.
The statements contained in this report that are not purely historical are forward-looking statements within the meaning of Section 27A
of the Securities Act and Section 21E of the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These statements relate to
future events or our future financial performance. We have attempted to identify forward-looking statements by terminology including &#8220;anticipates,&#8221;
&#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221;
&#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221;
&#8220;should&#8221; or &#8220;will&#8221; or the negative of these terms or other comparable terminology. These statements are only predictions;
uncertainties and other factors may cause our actual results, levels of activity, performance or achievements to be materially different
from any future results, levels or activity, performance or achievements expressed or implied by these forward-looking statements. Although
we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels
of activity, performance or achievements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In this Quarterly Report,
unless the context requires otherwise, references to the &#8220;Company,&#8221; &#8220;Alzamend,&#8221; &#8220;we,&#8221; &#8220;our company&#8221;
and &#8220;us&#8221; refer to Alzamend Neuro, Inc., a Delaware corporation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">We
were incorporated on February 26, 2016, as Alzamend Neuro, Inc. under the laws of the State of Delaware. We were formed to acquire and
commercialize patented intellectual property and know-how to prevent, treat and potentially cure the crippling and deadly Alzheimer&#8217;s
disease (&#8220;Alzheimer&#8217;s&#8221;). With our two product candidates, we aim to bring treatment or cures not only for Alzheimer&#8217;s,
but also bipolar disorder (&#8220;BD&#8221;), major depressive disorder (&#8220;MDD&#8221;) and post-traumatic stress disorder (&#8220;PTSD&#8221;).
Existing Alzheimer&#8217;s treatments only temporarily relieve symptoms but do not, to our knowledge, slow or halt the underlying progression
of the disease. We have developed a novel approach to combat Alzheimer&#8217;s through immunotherapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Critical Accounting Policies and Estimates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Research and Development
Expenses</i>.&#160;</b>Research and development costs are expensed as incurred. Research and development costs consist of scientific consulting
fees and lab supplies, as well as fees paid to other entities that conduct certain research and development activities on behalf of our
company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have acquired and may continue
to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire license,
product or rights, as well as any future milestone payments, are immediately recognized as research and development expense, provided
that there is no alternative future use of the rights in other research and development projects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Stock-Based Compensation.&#160;</i></b>We
maintain a stock-based compensation plan as a long-term incentive for employees, non-employee directors and consultants. The plan allows
for the issuance of incentive stock options, non-qualified stock options, restricted stock units, and other forms of equity awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recognize stock-based compensation
expense for stock options on a straight-line basis over the requisite service period and account for forfeitures as they occur. Our stock-based
compensation costs are based upon the grant date fair value of options estimated using the Black-Scholes option pricing model. To the
extent any stock option grants are made subject to the achievement of a performance-based milestone, management evaluates when the achievement
of any such performance-based milestone is probable based on the relative satisfaction of the performance conditions as of the reporting
date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></p>

<!-- Field: Page; Sequence: 22 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Black-Scholes option pricing
model utilizes inputs which are highly subjective assumptions and generally require significant judgment. These assumptions include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><b><i>Risk-Free Interest Rate.</i></b>&#160;The risk-free interest rate is based on the U.S. Treasury
zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the option.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><b><i>Expected Volatility.</i></b>&#160;Because we do not have a sufficient trading history for our common
stock (&#8220;Common Stock&#8221;), the expected volatility was estimated based on the average volatility for comparable publicly traded
life sciences companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based
on the similar size, stage in life cycle or area of specialty. We will continue to apply this process until a sufficient amount of historical
information regarding the volatility of our own stock price becomes available.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><b><i>Expected Term.</i></b>&#160;The expected term represents the period that the stock-based awards
are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the
end of the contractual term), as we do not have sufficient historical data to use any other method to estimate expected term.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><b><i>Expected Dividend Yield.</i></b>&#160;We have never paid dividends on our Common Stock and have
no plans to pay dividends on our Common Stock. Therefore, we used an expected dividend yield of zero.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain of these assumptions
involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and we
use significantly different assumptions or estimates, our stock-based compensation could be materially different.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Preferred Stock Classification.</i></b>
We analyze the terms of our preferred stock using Accounting Standards Codification (&#8220;ASC&#8221;) 480, <i>Distinguishing Liabilities
from Equity</i>, to determine whether our preferred stock should be classified as a liability or equity, and if classified as equity,
permanent or temporary. Common criteria we consider are redemption provisions, conversion options, cumulative of mandatory fixed dividends,
discretionary dividends based on earning, voting rights and collateral requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Plan of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
intend to develop and commercialize therapeutics and vaccines that are better than existing treatments and have the potential to significantly
improve the lives of individuals afflicted by Alzheimer&#8217;s, BD, MDD and PTSD. To achieve these goals, we are pursuing the following
key business strategies:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Advance clinical development of AL001 for Alzheimer&#8217;s, BD, MDD and PTSD treatment;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Advance clinical development of ALZN002 for Alzheimer&#8217;s treatment;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Expand our pipeline of pharmaceuticals to include additional indications for AL001 and delivery methods;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Focus on translational and functional endpoints to efficiently develop product candidates; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Optimize the value of AL001 and ALZN002 in major markets.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
pipeline consists of two novel therapeutic drug candidates:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">AL001 - A patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate
and proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc.,
as licensor (the &#8220;Licensor&#8221;); and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">ALZN002 - A patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine
that seeks to restore the ability of a patient&#8217;s immunological system to combat Alzheimer&#8217;s through a royalty-bearing exclusive
worldwide license from the Licensor.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 23 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
most advanced product candidate (lead product) licensed and in clinical development in humans is AL001, an ionic cocrystal of lithium
for the treatment of Alzheimer&#8217;s, BD, MDD and PTSD. Based on our preclinical data involving mice models, AL001 treatment prevented
cognitive deficits, depression and irritability and is superior in improving associative learning and memory and irritability compared
with lithium carbonate treatments, supporting the potential of this lithium formulation for the treatment of Alzheimer&#8217;s, BD, MDD
and PTSD in humans. Lithium has been marketed for more than 35 years and human toxicology regarding lithium use has been well characterized,
potentially mitigating the regulatory burden for safety data.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
May 5, 2022, we initiated a multiple-dose, steady-state, double-blind, ascending dose safety, tolerability, pharmacokinetic clinical trial
of AL001 in patients with mild to moderate Alzheimer&#8217;s and healthy subjects. We completed the Phase IIA clinical trial in March
2023 and announced positive topline data in June 2023, followed by the full data set in October 2024.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
announced that we successfully identified a maximum tolerated dose (&#8220;MTD&#8221;) for development of AL001 from a multiple-ascending
dose study as assessed by an independent safety review committee. This dose, providing lithium at a lithium carbonate equivalent dose
of 240 mg 3-times daily (&#8220;TID&#8221;), is designed to be unlikely to require lithium therapeutic drug monitoring (&#8220;TDM&#8221;).
Also, this MTD is risk mitigated for the purpose of treating fragile populations, such as Alzheimer&#8217;s patients.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Lithium is a commonly prescribed
drug for manic episodes in BD type 1 as well as maintenance therapy of BD in patients with a history of manic episodes. Lithium is also
prescribed off-label for MDD, BD and treatment of PTSD, among other disorders. Lithium was the first mood stabilizer approved by the U.S.
Food and Drug Administration (&#8220;FDA&#8221;) and is still a first-line treatment option (considered the &#8220;gold standard&#8221;)
but is underutilized perhaps because of the need for TDM. Lithium was the first drug that required TDM by regulatory authorities in product
labelling because the effective and safe range of therapeutic drug blood concentrations is narrow and well defined for treatment of BD
when using lithium salts. Excursions above this range can be toxic, and below can impair effectiveness.&#160;Existing lithium drugs suffer
from chronic toxicity, poor physicochemical properties, and poor brain bioavailability. Alzamend&#8217;s novel AL001 formulation, a lithium-salicylate/L-proline
engineered ionic cocrystal, is designed to overcome the toxicities associated with conventional lithium salts, promising a next-generation
lithium treatment with an enhanced safety profile and advantageous distribution to brain and brain structures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Based
on the results from our Phase IIA MAD study, we plan to initiate five clinical trials to determine relative increased lithium levels in
the brain compared to a marketed lithium salt for healthy subject and patients diagnosed with mild to moderate Alzheimer&#8217;s, BD,
MDD and PTSD, based on published mouse studies that predict that lithium can be given at lower doses for equivalent therapeutic benefit
when treating with AL001. For example, the goal is to replace the amount of lithium needed for maintenance treatment of BD with a clinically
relevant, lower AL001 lithium carbonate equivalent lithium dose. Such lithium dose mitigation could redefine the landscape of neuropsychiatric,
neurodegenerative, and neurological treatment practices. In August 2024, we announced that we had partnered with Massachusetts General
Hospital to serve as the CRO for these clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
November 19, 2024, we announced final full data set from a nonclinical study comparing brain and plasma lithium exposures between AL001
and lithium carbonate in Alzheimer&#8217;s transgenic mice. The study was conducted at the University of South Florida and the bioanalytical
procedures for determination of lithium concentration in the brain and plasma samples were conducted under good laboratory practice standards
by Sannova Analytical LLC. The study involved administering AL001, a good manufacturing practices-quality active pharmaceutical ingredient
(&#8220;API&#8221;) to 5XFAD mice, a recognized model for Alzheimer&#8217;s research, to compare its effects against lithium carbonate,
an FDA approved and marketed API. Mice received either high or low doses scaled to humans of both AL001 and lithium carbonate over a 14-day
period to observe pharmacokinetic steady-state drug conditions. On the 15th day, the mice were analyzed to assess how the treatments affected
lithium concentrations in different brain regions and in their plasma.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the study, both treatments
had no negative impact on the mice's body weight or clinical signs during the treatment period. AL001 showed lower plasma lithium levels
than lithium carbonate, reducing the risk of adverse systemic effects, suggesting an expansion for safety of lithium&#8217;s therapeutic
index. Further, AL001 showed consistently higher lithium concentrations in brain tissues, particularly at lower doses, compared to lithium
carbonate. Finally, the study found that different brain regions absorb and retain lithium differently. This means treatments can potentially
be tailored to target specific brain areas, allowing for more precise treatment of various brain-related conditions when applied in human
studies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">These
results highlight the potential clinical advantages of AL001 for conditions like Alzheimer&#8217;s, BD, MDD and PTSD at low doses. By
reducing the systemic burden, AL001 could lessen the risk of side effects such as thyroid and kidney complications often associated with
extant lithium therapies. This positions AL001 as a promising candidate for safer long-term treatment options, without the need for TDM.
This innovation is specifically designed to address the needs of fragile populations, such as elderly and Alzheimer&#8217;s patients,
by offering a potentially more efficient and safer alternative to existing treatments. &#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; background-color: white"></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The dosing level identified
as optimal in this robust nonclinical study will serve as the foundation for advancing the evaluation of AL001 in the comprehensive &#8216;Lithium
in Brain&#8217; Phase II clinical trials. These trials, conducted in collaboration with Massachusetts General Hospital, will encompass
a diverse cohort of both healthy subjects and patients diagnosed with mild to moderate Alzheimer&#8217;s disease, BD, MDD and PTSD. &#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
September 28, 2022, we submitted an IND application to the FDA for ALZN002 and received a &#8220;study may proceed&#8221; letter on October
31, 2022. The product candidate is an immunotherapy vaccine designed to treat mild to moderate dementia of the Alzheimer&#8217;s type.
ALZN002 is a proprietary &#8220;active&#8221; immunotherapy product, which means it is produced by each patient&#8217;s immune system.
It consists of autologous DCs that are activated white blood cells taken from each individual patient so that they can be engineered outside
of the body to attack Alzheimer&#8217;s-related amyloid-beta proteins. These DCs are pulsed with a novel amyloid-beta peptide (E22W) designed
to bolster the ability of the patient&#8217;s immune system to combat Alzheimer&#8217;s, with the goal being to foster tolerance to treatment
for safety purposes while stimulating the immune system to reduce the brain&#8217;s beta-amyloid protein burden, resulting in reduced
Alzheimer&#8217;s signs and symptoms. Compared to passive immunization treatment approaches that use foreign blood products (such as monoclonal
antibodies), active immunization with ALZN002 is anticipated to offer a more robust and long-lasting effect on the clearance of amyloid.
This could provide a safer approach due to its reliance on autologous immune components, using each individual patient&#8217;s own white
blood cells rather than foreign cells and/or blood products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
April 3, 2023, we announced the initiation of a Phase I/IIA clinical trial for ALZN002 to treat mild to moderate dementia of the Alzheimer&#8217;s
type. The purpose of this trial is to assess the safety, tolerability, and efficacy of multiple ascending doses of ALZN002 compared with
that of a placebo in 20-30 subjects with mild to moderate morbidity. The primary goal of this clinical trial is to determine an appropriate
dose of ALZN002 for treatment of patients with Alzheimer&#8217;s in a larger Phase IIB efficacy and safety clinical trial. On February
13, 2024, we received notice from the company we engaged as our contract research organization (&#8220;CRO&#8221;), Biorasi, LLC (&#8220;Biorasi&#8221;)
that Biorasi was terminating our contract with them. We are currently pursuing the engagement of a replacement CRO.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
continuation of our current plan of operations with respect to initiating and conducting the series of human clinical trials for each
of our therapeutics requires us to raise additional capital to fund our operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Because
our working capital requirements depend upon numerous factors, including the progress of our preclinical and clinical testing, timing
and cost of obtaining regulatory approvals, changes in levels of resources that we devote to the development of manufacturing and marketing
capabilities, competitive and technological advances, status of competitors, and our ability to establish collaborative arrangements with
other organizations, we will require additional financing to fund future operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 25 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Results of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span style="text-decoration: underline">Results of Operations for the Three Months Ended October 31,
2024 and 2023</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
the results of our operations for the three months ended October 31, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Three Months Ended October 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$ Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">% Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">OPERATING EXPENSES</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">311,088</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,996,783</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(1,685,695</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">-84</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,046,980</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">904,939</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">142,041</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">16</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,358,068</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,901,722</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,543,654</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-53</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,358,068</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,901,722</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,543,654</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">OTHER EXPENSE, NET</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Interest expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(3,495</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(4,311</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">816</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-19</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Total other expense, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(3,495</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(4,311</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">816</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-19</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">NET LOSS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,361,563</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,906,033</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,544,468</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Dividends on preferred shares</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(53,651</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(53,651</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">*</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET LOSS AVAILABLE TO COMMON SHARES</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,415,214</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,906,033</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,490,819</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">51</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss per common share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.40</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4.43</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4.03</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">*</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Basic and diluted weighted average common&#160;shares outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,531,702</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">656,378</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">*</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 9pt">*</td><td>Not meaningful</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Revenue</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">We
currently have only two product candidates, AL001 and ALZN002. These products are in the clinical stage of development and will require
extensive clinical study, review and evaluation, regulatory review and approval, significant marketing efforts and substantial investment
before either or both of them, and any respective successors, will provide us with any revenue. </span>We did not generate any revenues
during the three months ended October 31, 2024 and 2023, and we do not anticipate that we will generate revenue for the foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 26 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development Expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development expenses
for the three months ended October 31, 2024 and 2023 were $311,000 and $2.1 million, respectively. As reflected in the table below, research
and development expenses primarily consisted of professional fees and clinical trial fees:&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Three Months Ended October 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$ Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">% Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Professional fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">181,233</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,045,212</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(863,979</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">-83</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Clinical trial fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">124,123</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">794,676</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(670,553</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-84</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">142,603</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(142,603</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">*</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other research and development expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,732</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">14,292</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(8,560</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-60</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: 20pt">Total research and development expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">311,088</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,996,783</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,685,695</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-84</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 9pt">*</td><td>Not meaningful</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Professional Fees</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three months ended
October 31, 2024 and 2023, we incurred professional fees of $181,000 and $1.0 million, respectively, which were primarily comprised of
professional fees attributed to various types of scientific services, including FDA consulting services. The decrease relates to lower
professional fees incurred related to minimal clinical trial activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Clinical Trial Fees</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three months ended
October 31, 2024 and 2023, we incurred clinical trial fees of $124,000 and $795,000, respectively. Clinical trial fees for the three months
ended October 31, 2024 were for our initial set-up for our Phase IIA brain imaging study with Massachusetts General. Clinical trial fees
for the three months ended October 31, 2023 were for our Phase IIA clinical trial for AL001 and our Phase I/IIA clinical trial for ALZN002.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Stock-Based Compensation Expense</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three months ended
October 31, 2024 and 2023, we incurred research and development stock-based compensation expense of nil and $143,000, respectively, related
to stock option grants and restricted stock grants to executives, employees and consultants. The decrease in stock-based compensation
expense for the three months ended October 31, 2024 was a result of fewer stock options vesting during the period compared to the prior
year period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Other Research and Development Expenses</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three months ended
October 31, 2024 and 2023, we incurred other fees of $6,000 and $14,000, respectively, which were primarily comprised of scientific materials
required for our clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>General and Administrative Expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses for the three months ended October 31, 2024 and 2023 were $1.0 million and $0.9 million, respectively. As reflected in the table
below, general and administrative expenses primarily consisted of the following expense categories: salaries and benefits; professional
fees; insurance; stock-based compensation expense; marketing fees; as well as board of director fees. For the three months ended October
31, 2024 and 2023, the remaining general and administrative expenses of $83,000 and $93,000, respectively, primarily consisted of payments
for filing fees, transfer agent fees, travel and entertainment and other office expenses, none of which was significant individually.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 27 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Three Months Ended October 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$ Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">% Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Salary and benefits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">325,764</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">225,934</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">99,830</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">44</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">148,669</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">283,585</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(134,916</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-48</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,239</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">88,988</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(28,749</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-32</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81,277</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">175,733</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(94,456</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-54</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Marketing fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">304,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">304,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">*</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Board of director fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other general and administrative expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">83,281</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">93,199</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(9,918</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-11</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: 20pt">Total general and administrative expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,046,980</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">904,939</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">142,041</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">16</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 9pt">*</td><td>Not meaningful</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Salaries and Benefits</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three months ended
October 31, 2024 and 2023, we incurred $326,000 and $226,000, respectively, in employee-related expenses. The increase in salaries and
benefits was due to a bonus paid to our chief executive officer. As of October 31, 2024, we had four full-time and three part-time employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Professional Fees</i>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three months ended
October 31, 2024 and 2023, we incurred professional fees of $149,000 and $284,000, respectively. During the three months ended October
31, 2024, we incurred $96,000 in audit fees, $35,000 in legal fees, $14,000 in tax preparation fees, and $2,000 in consulting fees. During
the three months ended October 31, 2023, we incurred $92,000 in audit fees, $89,000 in investor relations fees, 67,000 in legal fees,
$13,000 in tax preparation fees, $12,000 in related party consulting, and $11,000 in Sarbanes-Oxley compliance fees. The decrease in professional
fees was due mainly to lower investor relations and legal fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Insurance Expense</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three months ended
October 31, 2024 and 2023, we incurred insurance expense of $60,000 and $89,000, respectively, which was primarily directors&#8217; and
officers&#8217; insurance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Stock-Based Compensation Expense</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three months ended
October 31, 2024 and 2023, we incurred general and administrative stock-based compensation expense of $81,000 and $176,000, respectively,
related to stock option grants and restricted stock grants to executives, employees and consultants. The decrease in stock-based compensation
expense for the three months ended October 31, 2024, was a result of fewer stock options vesting during the period compared to the prior
year period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Marketing Fees</i>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended October 31, 2024
and 2023, we incurred marketing fees of $304,000 and nil, respectively. The increase was due to a marketing program launched to promote
our company and our stock during the three months ended October 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></p>

<!-- Field: Page; Sequence: 28 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span style="text-decoration: underline">Results of Operations for the Six Months Ended October 31,
2024 and 2023</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
the results of our operations for the six months ended October 31, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Six Months Ended October 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$ Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">% Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">OPERATING EXPENSES</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">517,659</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">4,362,920</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(3,845,261</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">-88</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,802,814</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,064,732</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(261,918</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">-13</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,320,473</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">6,427,652</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(4,107,179</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">-64</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,320,473</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,427,652</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,107,179</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">OTHER EXPENSE, NET</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Interest expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(15,501</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(6,147</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(9,354</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">-152</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Total other expense, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(15,501</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(6,147</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(9,354</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">-152</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">NET LOSS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,335,974</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,433,799</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,097,825</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Dividends on preferred shares</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(53,651</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(53,651</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">*</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET LOSS AVAILABLE TO COMMON SHARES</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,389,625</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(6,433,799</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,044,174</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">63</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss per common share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1.11</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(9.80</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8.69</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">*</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Basic and diluted weighted average common&#160;shares outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,154,761</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">656,323</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">*</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 9pt">*</td><td>Not meaningful</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Revenue</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">We
currently have only two product candidates, AL001 and ALZN002. These products are in the clinical stage of development and will require
extensive clinical study, review and evaluation, regulatory review and approval, significant marketing efforts and substantial investment
before either or both of them, and any respective successors, will provide us with any revenue. </span>We did not generate any revenues
during the six months ended October 31, 2024 and 2023, and we do not anticipate that we will generate revenue for the foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development Expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development expenses
for the six months ended October 31, 2024 and 2023 were $518,000 and $4.4 million, respectively. As reflected in the table below, research
and development expenses primarily consisted of professional fees and clinical trial fees:&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Six Months Ended October 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$ Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">% Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Professional fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">365,398</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,114,802</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(1,749,404</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">-83</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Clinical trials</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">124,123</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,039,794</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,915,671</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-94</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">142,603</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(142,603</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">*</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other research and development expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">28,138</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">65,721</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(37,583</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">-57</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: 20pt">Total research and development expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">517,659</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,362,920</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,845,261</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">-88</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 9pt">*</td><td>Not meaningful</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i></i></p>

<!-- Field: Page; Sequence: 29 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Professional Fees</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the six months ended
October 31, 2024 and 2023, we incurred professional fees of $365,000 and $2.1 million, respectively, which were primarily comprised of
professional fees attributed to various types of scientific services, including FDA consulting services. The decrease relates to lower
professional fees incurred related to minimal clinical trial activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Clinical Trial Fees</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the six months ended
October 31, 2024 and 2023, we incurred clinical trial fees of $124,000 and $2.0 million, respectively. Clinical trial fees for the six
months ended October 31, 2024 were for our initial set-up for our Phase IIA brain imaging study with Massachusetts General. Clinical trial
fees for the six months ended October 31, 2023 were for our Phase IIA clinical trial for AL001 and our Phase I/IIA clinical trial for
ALZN002.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Stock-Based Compensation Expense</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the six months ended
October 31, 2024 and 2023, we incurred research and development stock-based compensation expense of nil and $143,000, respectively, related
to stock option grants and restricted stock grants to executives, employees and consultants. The decrease in stock-based compensation
expense for the six months ended October 31, 2024 was a result of fewer stock options vesting during the period compared to the prior
year period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Other Research and Development Expenses</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the six months ended
October 31, 2024 and 2023, we incurred other fees of $28,000 and $66,000, respectively, which were primarily comprised of scientific materials
required for our clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>General and Administrative Expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses for the six months ended October 31, 2024 and 2023 were $1.8 million and $2.1 million, respectively. As reflected in the table
below, general and administrative expenses primarily consisted of the following expense categories: salaries and benefits; professional
fees; insurance; stock-based compensation expense; marketing fees; as well as board of director fees. For the six months ended October
31, 2024 and 2023, the remaining general and administrative expenses of $145,000 and $177,000, respectively, primarily consisted of payments
for filing fees, transfer agent fees, travel and entertainment and other office expenses, none of which was significant individually.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Six Months Ended October 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$ Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">% Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Salaries and benefits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">553,559</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">379,258</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">174,301</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">46</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">371,096</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">434,764</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(63,668</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-15</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">138,634</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">206,684</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(68,050</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-33</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">162,554</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">545,113</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(382,559</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-70</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Marketing fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">344,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">247,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">96,666</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Board of director fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">87,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other general and administrative expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">145,471</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">176,579</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(31,108</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">-18</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: 20pt">Total general and administrative expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,802,814</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,064,732</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(261,918</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">-13</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Salaries and Benefits</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the six months ended
October 31, 2024 and 2023, we incurred $554,000 and $379,000, respectively, in employee-related expenses. The increase in salaries and
benefits was due to a bonus paid to our chief executive officer. As of October 31, 2024, we had four full-time and three part-time employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i></i></p>

<!-- Field: Page; Sequence: 30 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Professional Fees</i>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the six months ended
October 31, 2024 and 2023, we incurred professional fees of $371,000 and $435,000, respectively. During the six months ended October 31,
2024, we incurred $151,000 in audit fees, $109,000 in legal fees, $86,000 in investor relations fees, $22,000 in tax preparation fees,
and $2,000 in consulting fees. During the six months ended October 31, 2023, we incurred $170,000 in audit fees, $118,000 in investor
relations fees, $69,000 in legal fees, $29,000 in tax preparation fees, $24,000 in related party consulting, and $17,000 in Sarbanes-Oxley
compliance fees. The decrease in professional fees was due mainly to lower audit, investor relations, related party consulting and Sarbanes-Oxley
compliance fees partially offset by higher legal fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Insurance Expense</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the six months ended
October 31, 2024 and 2023, we incurred insurance expense of $139,000 and $207,000, respectively, which was primarily directors&#8217;
and officers&#8217; insurance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Stock-Based Compensation Expense</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the six months ended
October 31, 2024 and 2023, we incurred general and administrative stock-based compensation expense of $163,000 and $545,000, respectively,
related to stock option grants and restricted stock grants to executives, employees and consultants. The decrease in stock-based compensation
expense for the six months ended October 31, 2024, was a result of fewer stock options vesting during the period compared to the prior
year period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Marketing Fees</i>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the six months ended
October 31, 2024 and 2023, we incurred marketing fees of $344,000 and $207,000, respectively. The increase was due to a marketing program
launched to promote our company and our stock during the six months ended October 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Liquidity and Capital Resources</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying condensed
financial statements have been prepared assuming that we will continue as a going concern. We have incurred recurring net losses and operations
have not provided sufficient cash flows. We believe that we will continue to incur operating and net losses each quarter until at least
the time we are able to generate revenues from operations. <span style="background-color: white">We believe our current cash on hand is
insufficient to fund our planned operations through one year after the date the condensed financial statements are issued. These factors
create substantial doubt about our ability to continue as a going concern for at least one year after the date that our condensed financial
statements are issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our inability&#160;to continue&#160;as
a going concern&#160;could&#160;have a negative&#160;impact&#160;on our company, including&#160;our ability&#160;to obtain needed&#160;financing.
We intend to finance our future development activities and our working capital needs largely through the sale of equity securities with
some additional funding from other sources, including debt financing, until such time as funds provided by operations are sufficient to
fund working capital requirements. Our condensed financial statements do not include any adjustments relating to the recoverability and
classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should we be unable to continue
as a going concern. As of October 31, 2024, we had cash of $4.1 million, working capital of $3.5 million, an accumulated deficit of $56.4
million and stockholders&#8217; equity of $3.8 million. For the three and six months ended October 31, 2024, we had net losses of $1.4
million and $2.4 million, respectively. For the six months ended October 31, 2024, cash used in operating activities was $4.5 million.
Historically, we have financed our operations principally through issuances of equity and debt instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will need to obtain substantial
additional funding in the future for our clinical development activities and continuing operations. If we are unable to raise capital
when needed or on favorable terms, we would be forced to delay, reduce, or eliminate our research and development programs or future commercialization
efforts. Our future capital requirements will depend on many factors, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 36pt"/><td style="width: 22.4pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">successful enrollment in and completion of clinical trials;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 36pt"/><td style="width: 22.4pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">our ability to establish agreements with third-party manufacturers for clinical supply for our clinical
trials and, if our product candidates are approved, commercial manufacturing;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 31 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 36pt"/><td style="width: 22.4pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">our ability to maintain our current research and development programs and establish new research and development
programs;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 36pt"/><td style="width: 22.4pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">addition and retention of key research and development personnel;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 36pt"/><td style="width: 22.4pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">our efforts to enhance operational, financial, and information management systems, and hire additional
personnel, including personnel to support development of our product candidates;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 36pt"/><td style="width: 22.4pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter
and performing our obligations in such collaborations;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 36pt"/><td style="width: 22.4pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">the timing and amount of milestone and other payments we may receive under our collaboration arrangements;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 36pt"/><td style="width: 22.4pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">our eventual commercialization plans for our product candidates;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 36pt"/><td style="width: 22.4pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">the costs involved in prosecuting, defending, and enforcing patent claims and other intellectual property
claims; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 36pt"/><td style="width: 22.4pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">the costs and timing of regulatory approvals.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A change in the outcome of
any of these or other variables with respect to the development of any of our product candidates could significantly change the costs
and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we
may need additional funds to meet operational needs and capital requirements associated with such operating plans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529"><span style="background-color: white"><b><i>Series
B Preferred Financing</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white; color: #212529">On
January 31, 2024, we entered into a securities purchase agreement (&#8220;AL SPA&#8221;) with Ault Lending, LLC (&#8220;Ault Lending&#8221;)
whereby Ault Lending may purchase of up to 6,000 shares of series B convertible preferred stock (&#8220;Series B Convertible Preferred
Stock&#8221;) and warrants to purchase shares up to 600,000 shares of our common stock. The AL SPA provides that Ault Lending may purchase
up to $6 million of Series B Convertible Preferred Stock in one or more closings. Ault Lending has the right to purchase up to $2 million
of Series B Convertible Preferred Stock, on or before March 31, 2024, and the right to purchase up to $4 million of Series B Convertible
Preferred Stock after March 31, 2024, but on or before March 31, 2025 (the &#8220;Termination Date&#8221;). The Agreement will automatically
terminate if the final closing has not occurred prior to the Termination Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white; color: #212529">During
the year ended April 30, 2024, we sold an aggregate of 2,100 shares of Series B Convertible Preferred Stock and warrants to purchase 210,000
shares of common stock with an exercise price of $12.00, for a total purchase price of $2.1 million.&#160;<span style="background-color: white">The
purchase price was paid by the cancellation of $1.15 million of cash advances made by Ault Lending to us between November 9, 2023 and
January 31, 2024 and the remaining $950,000 in cash. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white; color: #212529"><span style="background-color: white">The&#160;</span>Series
B Convertible Preferred Stock&#160;<span style="background-color: white">has a stated value of $1,000 per share (&#8220;Series B Stated
Value&#8221;) and does not accrue dividends.&#160;</span>Each share of Series B Convertible Preferred Stock is convertible into a number
of shares of common stock&#160;<span style="background-color: white">determined by dividing the Series B Stated Value by $10.00</span>&#160;(the
&#8220;<span style="background-color: white">Series B&#160;</span>Conversion Price&#8221;). The&#160;<span style="background-color: white">Series
B&#160;</span>Conversion Price is subject to adjustment in the event of an issuance of common stock at a price per share lower than the&#160;<span style="background-color: white">Series
B&#160;</span>Conversion Price then in effect, as well as upon customary stock splits, stock dividends, combinations or similar events.
The holders of the Series B Convertible Preferred Stock are entitled to vote with the common stock as a single class on an as-converted
basis, subject to applicable law provisions of the Delaware General Corporation Law and Nasdaq, provided however, that for purposes of
complying with Nasdaq regulations, the conversion price, for purposes of determining the number of votes the holder of Series B Convertible
Preferred Stock is entitled to cast, shall not be lower than $8.73 (the &#8220;Voting Floor Price&#8221;), which represents the closing
sale price of the common stock on the trading day immediately prior to the date of execution of the AL SPA. The Voting Floor Price shall
be adjusted for stock dividends, stock splits, stock combinations and other similar transactions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white; color: #212529">The
warrants have an exercise price of $12.00 (the &#8220;<span style="background-color: white">Series B&#160;</span>Exercise Price&#8221;)
and become exercisable on the first business day after the six-month anniversary of issuance (the &#8220;<span style="background-color: white">Series
B&#160;</span>Initial Exercise Date&#8221;) and have a five-year term, expiring on the fifth anniversary of the&#160;<span style="background-color: white">Series
B&#160;</span>Initial Exercise Date. The&#160;<span style="background-color: white">Series B&#160;</span>Exercise Price is subject to
adjustment in the event of an issuance of common stock at a price per share lower than the&#160;<span style="background-color: white">Series
B&#160;</span>Exercise Price then in effect, as well as upon customary stock splits, stock dividends, combinations or similar events.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529"></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><b><i>Series A Preferred Financing</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">On
May 8, 2024, we and Orchid Finance, LLC (&#8220;Orchid&#8221;)</span>, entered into a securities purchase agreement (the &#8220;Orchid
SPA&#8221;) for the purchase of up to 2,500 shares of Series A Convertible Preferred Stock (&#8220;Series A Convertible Preferred Stock&#8221;)
and warrants to purchase shares up to 2,500,000 shares of common stock in several tranche closings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 10, 2024, we sold 100
shares of Series A Convertible Preferred Stock and warrants to purchase 80,000 shares of common stock with an exercise price of $12.50,
for a total purchase price of $1.0 million. <span style="background-color: white">The purchase price was paid by the surrender and cancellation
of a term note issued by us to Orchid of $311,356, consisting of $310,000 of principal and $1,356 of accrued and unpaid interest, $100,000
discount and net cash of $588,644. </span>On June 25, 2024, we sold 150 shares of Series A Convertible Preferred Stock and warrants to
purchase 120,000 shares of common stock with an exercise price of $12.50, for a total purchase price of $1.5 million. <span style="background-color: white">The
purchase price was paid in cash. On August 19, 2024, we sold 200 shares of Series A Convertible Preferred Stock and warrant to purchase
160,000 shares of common stock with an exercise price of $12.50, for a total purchase price of $2.0 million. The purchase price was paid
in cash. On August 21, 2024, we sold 250 shares of Series A Convertible Preferred Stock and warrant to purchase 200,000 shares of common
stock with an exercise price of $12.50, for a total purchase price of $2.5 million less $100,000 discount. The purchase price was paid
in cash. On September 11, 2024, we sold 100 shares of Series A Convertible Preferred Stock and warrant to purchase 80,000 shares of common
stock with an exercise price of $12.50, for a total purchase price of $1.0 million. The purchase price was paid in cash. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Pursuant
to the Orchid SPA, Orchid has agreed to purchase the remaining 1,700 Preferred Shares based on our achievement of the milestones set forth
below (the &#8220;Milestones&#8221;):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 8%">&#160;</td>
    <td style="width: 3%">&#8226;</td>
    <td style="width: 89%; text-align: justify">200 Preferred Shares, for $2,000,000, within 60 days of the effectiveness of the resale registration statement (the &#8220;Registration Statement&#8221;) and the execution of a partnership agreement with a nationally renowned research facility for a clinical trial (the &#8220;Fourth Tranche&#8221;); and</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 8%">&#160;</td>
    <td style="width: 3%">&#8226;</td>
    <td style="width: 89%; text-align: justify">100 Preferred Shares, for $1,000,000, on each monthly anniversary of the effectiveness of the resale registration statement, which was declared effective on July 9, 2024, until all remaining 1,500 Preferred Shares have been sold (each, a &#8220;Final Tranche&#8221;).</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Notwithstanding
the foregoing Milestones, Orchid has the ability to invest any amount in its sole discretion in advance of the dates that the foregoing
Milestones shall have been met. In the event that the average closing price of the common stock during the three trading days preceding
the date of a tranche closing shall not be equal to or greater than $2.50 a share (the &#8220;Floor Price&#8221;), then the applicable
closing shall be delayed until such time as the price meets the required threshold. <span style="background-color: white">We agreed to
pay Ault Lending an origination fee of five percent (5%) of the total gross proceeds we receive from Orchid upon each purchase of Series
A Convertible Preferred Stock. We also agreed to pay Orchid a fee of $100,000 upon the first closing, which occurred on May 10, 2024,
$100,000 upon the third closing, which occurred on August 21, 2024, and the fourth, eighth and thirteenth closings constituting parts
of the Final Tranche.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Registration Statement registering for resale the shares of common stock issuable upon conversion of the Series A Convertible Preferred
Stock and exercise of the warrants was declared effective on July 9, 2024. In addition, we agreed to use our best efforts to hold a special
meeting of our stockholders within 90 days of the execution date of the Orchid SPA for purposes of seeking stockholder approval of the
issuance of all the shares of common stock issuable upon conversion of the Series A Convertible Preferred Stock and the exercise of the
warrants in excess of the &#8220;Nasdaq Limit,&#8221; which is 19.99% of our shares of common stock issued and outstanding on the execution
date of the Orchid SPA. We held a special meeting of stockholders on July 8, 2024, at which time, the stockholders approved the issuance
of all the shares of common stock issuable upon conversion of the Series A Convertible Preferred Stock and the exercise of the warrants
in excess of the &#8220;Nasdaq Limit.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 33 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">The
</span>Series A Convertible Preferred Stock <span style="background-color: white">has a stated value of $10,000 per share (&#8220;Series
A Stated Value&#8221;) and accrues dividends </span>at the rate of 15% per annum, payable quarterly in arrears in cash or paid-in-kind
shares, in Orchid&#8217;s sole discretion. Each share of Series A Convertible Preferred Stock is convertible into a number of shares of
common stock <span style="background-color: white">determined by dividing the Series A Stated Value <span style="color: #212529">by&#160;</span></span>(y)
the greater of (i) the Floor Price and (ii) the lesser of (A) $15.00 and (B) 80% of the lowest closing price of our common stock during
the three trading days immediately prior to the date of conversion into conversion shares (the &#8220;<span style="background-color: white">Series
A </span>Conversion Price&#8221;). The <span style="background-color: white">Series A </span>Conversion Price is subject to adjustment
in the event of an issuance of common stock at a price per share lower than the <span style="background-color: white">Series A </span>Conversion
Price then in effect, as well as upon customary stock splits, stock dividends, combinations or similar events. The holders of the Series
A Convertible Preferred Stock are entitled to vote with the common stock as a single class on an as-converted basis, subject to applicable
law provisions of the Delaware General Corporation Law and Nasdaq, provided however, that for purposes of complying with Nasdaq regulations,
the conversion price, for purposes of determining the number of votes the holder of Series B Convertible Preferred Stock is entitled to
cast, shall not be lower than $5.63 (the &#8220;Series A Voting Floor Price&#8221;), which represents the closing sale price of the common
stock on the trading day immediately prior to the date of execution of the Orchid SPA. The Series A Voting Floor Price shall be adjusted
for stock dividends, stock splits, stock combinations and other similar transactions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The warrants have an exercise
price of $12.50 (the &#8220;<span style="background-color: white">Series A </span>Exercise Price&#8221;) and are exercisable upon issuance
and have a five-year term, expiring on the fifth anniversary of issuance. The <span style="background-color: white">Series A </span>Exercise
Price is subject to adjustment in the event of an issuance of common stock at a price per share lower than the <span style="background-color: white">Series
A </span>Exercise Price then in effect, as well as upon customary stock splits, stock dividends, combinations or similar events. The warrants
are exercisable on a cashless basis in the event that there is not then an effective resale registration statement for the common stock
issuable upon exercise of the warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>At-the-Market Offering</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">On October 3, 2024, we entered
into an At-the-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC (the &#8220;ATM Offering&#8221;), as sales agent to
sell shares of our common stock, having an aggregate offering price of up to approximately $6.5 million from time to time, through the
ATM Offering. On October 3, 2024, we filed a prospectus supplement with the SEC relating to the offer and sale of up to approximately
$6.5 million in shares of common stock in the ATM Offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The offer and sale of the
shares will be made pursuant to our effective &#8220;shelf&#8221; registration statement on Form&#160;S-3 and an accompanying base prospectus
contained therein (Registration Statement No.&#160;333-273610) filed with the SEC on August 2, 2023 and declared effective by the SEC
on August 10, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">During the six months ended
October 31, 2024, we sold an aggregate of 755,888 shares of common stock pursuant to the ATM Offering for gross and net proceeds of $1.2
million. From November 1, 2024 to December 10, 2024, we sold an aggregate of 201,543 shares of common stock pursuant to the ATM Offering
for gross and net proceeds of $280,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Cash Flows</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
our cash flows for the six months ended October 31, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Six Months Ended October 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Net cash provided by (used in):</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">(4,455,843</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">(4,811,624</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(90,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(147,243</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">8,262,868</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">18,087</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net increase (decrease) in cash and cash equivalents</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,717,025</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,940,780</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Operating Activities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the six months ended
October 31, 2024, net cash used in operating activities was $4.5 million. This consisted primarily of a net loss of $2.4 million and a
decrease in our net operating assets and liabilities of $2.3 million, partially offset by non-cash charges of $197,000. The non-cash charges
primarily consisted of stock-based compensation expense. The decrease in our net operating assets and liabilities was due to a decrease
in accounts payable and accrued liabilities and an increase in prepaid expenses and other current assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Investing Activities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the six months ended
October 31, 2024, net cash used in investing activities was $90,000 from the purchase of equipment. We purchased equipment, which measures
lithium levels in the brain, to be used in the AL001 clinical trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i></i></p>

<!-- Field: Page; Sequence: 34 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Financing Activities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the six months ended
October 31, 2024, net cash provided by financing activities was $8.3 million. This consisted of $7.1 million from the sale of Series A
Convertible Preferred Stock and $1.2 million from the sale of common stock from our ATM Offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Contractual Obligations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 2, 2018, we entered
into two Standard Exclusive License Agreements with Sublicensing Terms for AL001 with the Licensor and its affiliate, the University of
South Florida (the &#8220;AL001 Licenses&#8221;), pursuant to which the Licensor granted us a royalty bearing exclusive worldwide licenses
limited to the field of Alzheimer&#8217;s, under United States Patent Nos. (i) 9,840,521, entitled &#8220;Organic Anion Lithium Ionic
Cocrystal Compounds and Compositions,&#8221; filed September 24, 2015 and granted December 12, 2017, and (ii) 9,603,869, entitled &#8220;Lithium
Co-Crystals for Treatment of Neuropsychiatric Disorders,&#8221; filed May 21, 2016 and granted March 28, 2017. On February 1, 2019, we
entered into the First Amendments to the AL001 Licenses, on March 30, 2021, we entered into the Second Amendments to the AL001 Licenses
and on June 8, 2023, we entered into the Third Amendments to the AL001 Licenses (collectively, the &#8220;AL001 License Agreements&#8221;).
The Third Amendments to the AL001 Licenses modified the timing of the payments of the license fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The AL001 License Agreements
require that we pay combined royalty payments of 4.5% on net sales of products developed from the licensed technology for AL001. We have
already paid an initial license fee of $200,000 for AL001. As an additional licensing fee for the license of the AL001 technologies, the
Licensor received 14,853 shares of our common stock. Minimum royalties for AL001 License Agreements are $40,000 on the first anniversary
of the first commercial sale, $80,000 on the second anniversary of the first commercial sale and $100,000 on the third anniversary of
the first commercial sale and every year thereafter, for the life of the AL001 License Agreements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 1, 2016, we entered
into a Standard Exclusive License Agreement with Sublicensing Terms for ALZN002 with the Licensor (the &#8220;ALZN002 License&#8221;),
pursuant to which the Licensor granted us a royalty bearing exclusive worldwide license limited to the field of Alzheimer&#8217;s Immunotherapy
and Diagnostics, under United States Patent No. 8,188,046, entitled &#8220;Amyloid Beta Peptides and Methods of Use,&#8221; filed April
7, 2009 and granted May 29, 2012. On August 18, 2017, we entered into the First Amendment to the ALZN002 License, on May 7, 2018, we entered
into the Second Amendment to the ALZN002 License, on January 31, 2019, we entered into the Third Amendment to the ALZN002 License, on
January 24, 2020, we entered into the Fourth Amendment to the ALZN002 License, on March 30, 2021, we entered into the Fifth Amendment
to the ALZN002 License, on April 17, 2023, we entered into the Sixth Amendment to the ALZN002 License and on December 11, 2023, we entered
into the Seventh Amendment to the ALZN002 License (collectively, the &#8220;ALZN002 License Agreement&#8221;). The Seventh Amendment to
the ALZN002 License modified the timing of the payments of the license fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ALZN002 License Agreement
requires us to pay royalty payments of 4% on net sales of products developed from the licensed technology for ALZN002. We have already
paid an initial license fee of $200,000 for ALZN002. As an additional licensing fee for the license of ALZN002, the Licensor received
24,012 shares of our common stock. Minimum royalties for ALZN002 are $20,000 on the first anniversary of the first commercial sale, $40,000
on the second anniversary of the first commercial sale and $50,000 on the third anniversary of the first commercial sale and every year
thereafter, for the life of the ALZN002 License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 19, 2019, we entered
into two Standard Exclusive License Agreements with Sublicensing Terms for two additional indications of AL001 with the Licensor (the
&#8220;November AL001 License&#8221;), pursuant to which the Licensor granted us a royalty bearing exclusive worldwide licenses limited
to the fields of (i) neurodegenerative diseases excluding Alzheimer&#8217;s and (ii) psychiatric diseases and disorders. On March 30,
2021, we entered into the First Amendments to the November AL001 License and on April 17, 2023, we entered into the Second Amendments
to the November AL001 License (collectively, the &#8220;November AL001 License Agreements&#8221;). The Second Amendments to the November
AL001 License modified the timing of the payments of the license fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The November AL001 License
Agreements require us to pay royalty payments of 3% on net sales of products developed from the licensed technology for AL001 in those
fields. We paid an initial license fee of $20,000 for the additional indications. Minimum royalties for November AL001 License Agreements
are $40,000 on the first anniversary of the first commercial sale, $80,000 on the second anniversary of the first commercial sale and
$100,000 on the third anniversary of the first commercial sale and every year thereafter, for the life of the November AL001 License Agreements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These license agreements have
an indefinite term that continue until the later of the date no licensed patent under the applicable agreement remains a pending application
or enforceable patent, the end date of any period of market exclusivity granted by a governmental regulatory body, or the date on which
the licensee&#8217;s obligations to pay royalties expire under the applicable license agreement. Under our various license agreements,
if we fail to meet a milestone by its specified date, Licensor may terminate the license agreement. The Licensor was also granted a preemptive
right to acquire such shares or other equity securities that may be issued from time to time by us while the Licensor remains the owner
of any equity securities of our company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 35 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, we are required
to complete milestones and make payments on the due dates to the Licensor for the license of the AL001 technologies and for the ALZN002
technology, as follows:&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Original AL001 Licenses:</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap"><b>Payment</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap"><b>Due Date</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap"><b>Event</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%">$</td>
    <td style="width: 10%; text-align: right">50,000</td>
    <td style="white-space: nowrap; width: 1%">*</td>
    <td style="width: 44%">&#160;Completed September 2019</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 43%">Pre-IND meeting</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>$</td>
    <td style="text-align: right">65,000</td>
    <td style="white-space: nowrap">*</td>
    <td>&#160;Completed June 2021</td>
    <td>&#160;</td>
    <td>IND application filing</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>$</td>
    <td style="text-align: right">190,000</td>
    <td style="white-space: nowrap">*</td>
    <td>&#160;Completed December 2021</td>
    <td>&#160;</td>
    <td>Upon first dosing of patient in a clinical trial</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>$</td>
    <td style="text-align: right">500,000</td>
    <td style="white-space: nowrap">*</td>
    <td>&#160;Completed March 2022</td>
    <td>&#160;</td>
    <td>Upon completion of first clinical trial</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>$</td>
    <td style="text-align: right">1,250,000</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>March 2025</td>
    <td>&#160;</td>
    <td>Upon first patient treated in a Phase III clinical trial</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>$</td>
    <td style="text-align: right">10,000,000</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>8 years from the effective date of the agreement</td>
    <td>&#160;</td>
    <td>Upon FDA new drug application approval</td></tr>
  </table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 9pt">*</td><td>Milestone met and payment made</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>ALZN002 License:</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap"><b>Payment</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap"><b>Due Date</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%">$</td>
    <td style="width: 15%; text-align: right">50,000</td>
    <td style="white-space: nowrap; width: 1%">*</td>
    <td style="width: 83%">&#160;Upon IND application - completed January 2022</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>$</td>
    <td style="text-align: right">50,000</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>Upon first dosing of patient in first Phase I clinical trial</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>$</td>
    <td style="text-align: right">500,000</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>Upon completion of first Phase IIB clinical trial</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>$</td>
    <td style="text-align: right">1,000,000</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>Upon first patient treated in a Phase III clinical trial</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>$</td>
    <td style="text-align: right">10,000,000</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>Upon first commercial sale</td></tr>
  </table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 9pt">*</td><td>Milestone met and payment made</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Additional AL001 Licenses:</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap"><b>Payment</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap"><b>Due Date</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap"><b>Event</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%">$</td>
    <td style="width: 10%; text-align: right">2,000,000</td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 44%">&#160;March 2026</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 43%">&#160;Upon first patient treated in a Phase III clinical trial</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>$</td>
    <td style="text-align: right">16,000,000</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;August 1, 2029</td>
    <td>&#160;</td>
    <td>&#160;First commercial sale</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recent Accounting Standards</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 1in"><b>ITEM 3.</b></td><td style="text-align: justify"><b>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because we are a smaller reporting
company, this section is not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 36 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 1in"><b>ITEM 4.</b></td><td style="text-align: justify"><b>CONTROLS AND PROCEDURES</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Evaluation of Disclosure
Controls and Procedures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have established disclosure
controls and procedures designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange
Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms and is accumulated and communicated
to management, including the principal executive officer and principal financial officer, to allow timely decisions regarding required
disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our principal executive officer
and principal financial officer, with the assistance of other members of the Company&#8217;s management, have evaluated the effectiveness
of the design and operation of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under
the Exchange Act) as of the end of the period covered by this quarterly report. Based upon our evaluation, each of our principal executive
officer and principal financial officer has concluded that the Company&#8217;s internal control over financial reporting was not effective
as of the end of the period covered by this Quarterly Report on Form 10-Q because the Company has not yet completed its remediation of
the material weakness previously identified and disclosed in the Company&#8217;s Annual Report on Form 10-K for the year ended April 30,
2024, the end of its most recent fiscal year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Specifically, management has
<span style="background-color: white">identified the following material weaknesses:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">1.</td><td style="text-align: justify">we do not have sufficient resources in our accounting function, <span style="background-color: white">which
restricts our ability to perform sufficient reviews and approval of manual journal entries posted to the general ledger and to consistently
execute review procedures over general ledger account reconciliations, financial statement preparation and accounting for non-routine
transactions</span>; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">2.</td><td style="text-align: justify">our <span style="background-color: white">primary user access controls (i.e., provisioning, de-provisioning,
privileged access and user access reviews) to ensure appropriate authorization and segregation of duties that would adequately restrict
user and privileged access to the financially relevant systems and data to appropriate personnel were not designed and/or implemented
effectively. We did not design and/or implement sufficient controls for program change management to certain financially relevant systems
affecting our processes</span>.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A material weakness is a control
deficiency or combination of control deficiencies that result in more than a remote likelihood that a material misstatement of the annual
or interim financial statements will not be prevented or detected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Planned Remediation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are implementing measures
designed to improve our internal control over financial reporting to remediate material weaknesses, including the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 40.6pt"/><td style="width: 22.4pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Continue to formalize our internal control documentation and strengthening supervisory reviews by our
management; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 40.6pt"/><td style="width: 22.4pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Developing plans to add additional accounting personnel and segregating duties amongst accounting personnel.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management continues to work
to improve its controls related to our material weaknesses, specifically relating to user access and change management surrounding our
information technology systems and applications. Management will continue to implement measures to remediate material weaknesses, such
that these controls are designed, implemented, and operating effectively. The remediation actions include: (i) enhancing design and documentation
related to both user access and change management processes and control activities; and (ii) developing and communicating additional policies
and procedures to govern the area of information technology change management. In order to achieve the timely implementation of the above,
management has commenced the following actions and will continue to assess additional opportunities for remediation on an ongoing basis:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 40.6pt"/><td style="width: 22.4pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Engaging a third-party specialist to assist management with improving the Company&#8217;s overall control
environment, focusing on change management and access controls; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 40.6pt"/><td style="width: 22.4pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Implementing new applications and systems that are aligned with management&#8217;s focus on creating strong
internal controls.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are currently working to
improve and simplify our internal processes and implement enhanced controls, as discussed above, to address the material weaknesses in
our internal control over financial reporting and to remedy the ineffectiveness of our disclosure controls and procedures. These material
weaknesses will not be considered to be remediated until the applicable remediated controls are operating for a sufficient period of time
and management has concluded, through testing, that these controls are operating effectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 37 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Despite the existence of these
material weaknesses, we believe that the condensed financial statements included in the period covered by this Quarterly Report on Form
10-Q fairly present, in all material respects, our financial condition, results of operations and cash flows for the periods presented
in conformity with U.S. generally accepted accounting principles.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Changes in Internal Control</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as detailed above,
during the quarter ended October 31, 2024, there was no change in our internal control over financial reporting that materially affected,
or is reasonably likely to materially affect, our internal control over financial reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 38 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART II &#8212; OTHER INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 1in"><b>ITEM 1.</b></td><td style="text-align: justify"><b>LEGAL PROCEEDINGS</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
be subject to legal proceedings. We are not currently a party to or aware of any proceedings that we believe will have, individually or
in the aggregate, a material adverse effect on our business, financial condition or results of operations. Regardless of the outcome,
litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 1in"><b>ITEM 1A.</b></td><td style="text-align: justify"><b>RISK FACTORS</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The risks described in Part
I, Item&#160;1A, &#8220;Risk Factors,&#8221; in our 2024 Annual Report on Form 10-K, could materially and adversely affect our business,
financial condition and results of operations, and the trading price of our Common Stock could decline. These risk factors do not identify
all risks that we face; our operations could also be affected by factors that are not presently known to us or that we currently consider
to be immaterial to our operations. Due to risks and uncertainties, known and unknown, our past financial results may not be a reliable
indicator of future performance and historical trends should not be used to anticipate results or trends in future periods. The Risk Factors
section of our&#160;2024&#160;Annual Report on Form 10-K remains current in all material respects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 1in"><b>ITEM 2.</b></td><td style="text-align: justify"><b>UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">On
August 19, 2024, we sold 200 shares of Series A Convertible Preferred Stock and warrants to purchase 160,000 shares of common stock with
an exercise price of $12.50, for a total purchase price of $2.0 million. The purchase price was paid in cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">On
August 21, 2024, we sold 250 shares of Series A Convertible Preferred Stock and warrants to purchase 200,000 shares of common stock with
an exercise price of $12.50, for a total purchase price of $2.5 million less $100,000 discount. The purchase price was paid in cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">On
September 11, 2024, we sold 100 shares of Series A Convertible Preferred Stock and warrants to purchase 80,000 shares of common stock
with an exercise price of $12.50, for a total purchase price of $1.0 million. The purchase price was paid in cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 1in"><b>ITEM 3.</b></td><td style="text-align: justify"><b>DEFAULTS UPON SENIOR SECURITIES</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 1in"><b>ITEM 4.</b></td><td style="text-align: justify"><b>MINE SAFETY DISCLOSURES</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 1in"><b>ITEM 5.</b></td><td style="text-align: justify"><b>OTHER INFORMATION</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_908_eecd--Rule10b51ArrAdoptedFlag_dbF_c20240501__20241031_z2P8XVX9Y2il" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_90E_eecd--NonRule10b51ArrAdoptedFlag_dbF_c20240501__20241031_zO15Crflkd2a" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_90B_eecd--Rule10b51ArrTrmntdFlag_dbF_c20240501__20241031_zqClqsBhxh91" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_909_eecd--NonRule10b51ArrTrmntdFlag_dbF_c20240501__20241031_zwt8IUO3Wqfa" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" format="ixt:booleanfalse" id="Fact001139" name="ecd:Rule10b51ArrAdoptedFlag"><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" format="ixt:booleanfalse" id="Fact001140" name="ecd:NonRule10b51ArrAdoptedFlag"><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" format="ixt:booleanfalse" id="Fact001141" name="ecd:Rule10b51ArrTrmntdFlag"><ix:nonNumeric contextRef="From2024-05-01to2024-10-31" format="ixt:booleanfalse" id="Fact001142" name="ecd:NonRule10b51ArrTrmntdFlag">None</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span></span></span></span>&#160;of the Company&#8217;s
directors and officers adopted, modified, or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during
the Company's fiscal quarter ended October 31, 2024 (each as defined in Item 408 of Regulation S-K under the Securities Exchange Act of
1934, as amended).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 39 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 1in"><b>ITEM 6.</b></td><td style="text-align: justify"><b>EXHIBITS</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 7%"><b><span style="text-decoration: underline">Exhibit<br/>
No.</span></b></td>
    <td style="white-space: nowrap; width: 2%">&#160;</td>
    <td style="white-space: nowrap; width: 91%"><b><span style="text-decoration: underline">Exhibit&#160;Description</span></b></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="white-space: nowrap; text-align: justify">3.1</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1677077/000161577416006901/filename3.htm">Certificate of Incorporation (incorporated by reference to Exhibit&#160;2.1 of Form DOS filed with the SEC on August&#160;19, 2016).</a></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="white-space: nowrap; text-align: justify">3.2</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1677077/000121465923016500/ex3_2.htm">Certificate of Amendment to the Certificate of Incorporation, filed with the Delaware Secretary of State on June 10, 2016 (incorporated by reference to Exhibit 3.2 of the Quarterly Report on Form 10-Q filed with the SEC on December 15, 2023).</a></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="white-space: nowrap; text-align: justify">3.3</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1677077/000121465923016500/ex3_3.htm">Certificate of Amendment to the Certificate of Incorporation, filed with the Delaware Secretary of State on December 22, 2020 (incorporated by reference to Exhibit 3.3 of the Quarterly Report on Form 10-Q filed with the SEC on December 15, 2023).</a></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="white-space: nowrap; text-align: justify">3.4</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1677077/000121465923014086/ex3_1.htm">Certificate of Amendment to the Certificate of Incorporation, filed with the Delaware Secretary of State on October 27, 2023 (incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed with the SEC on October 30, 2023).</a></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="white-space: nowrap; text-align: justify">3.5</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1677077/000121465924004200/ex3_1.htm">Amended and Restated Certificate of Designations of Preferences, Rights and Limitations of Series B Convertible Preferred Stock, filed with the Delaware Secretary of State on March 1, 2024 (incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed with the SEC on March 7, 2024).</a></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="white-space: nowrap; text-align: justify">3.6</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1677077/000121465924005032/ex3_1.htm">Certificate of Amendment to the Amended and Restated Certificate of Designations of Preferences, Rights and Limitations of Series B Convertible Preferred Stock, filed with the Delaware Secretary of State on March 21, 2024 (incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed with the SEC on March 22, 2024).</a></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="white-space: nowrap; text-align: justify">3.7</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1677077/000121465924008833/ex3_1.htm">Certificate of Designations of Preferences and Rights of Series A Preferred Stock, as filed with the Delaware Secretary of State on May 9, 2024 (incorporated by reference to Exhibit 3.1 of the amended Current Report on Form 8-K/A filed with the SEC on May 10, 2024).</a></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="white-space: nowrap; text-align: justify">3.8</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1677077/000110465921063812/tm2039434d6_ex3-2.htm">Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 of the registration statement on Form S-1 filed with the SEC on May 10, 2021).</a></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="white-space: nowrap; text-align: justify">10.1</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1677077/000121465924017141/ex10_1.htm">At-The-Market Issuance Sales Agreement, dated October 3, 2024, with Ascendiant Capital Markets, LLC (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the SEC on October 3, 2024).</a></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="white-space: nowrap; text-align: justify">31.1*</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="ex31_1.htm">Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a).</a></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="white-space: nowrap; text-align: justify">31.2*</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="ex31_2.htm">Certification of Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a).</a></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="white-space: nowrap; text-align: justify">32.1**</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="ex32_1.htm">Certification of Chief Executive and Financial Officer required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code.</a></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="white-space: nowrap; text-align: justify">101.INS*</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">XBRL Instance Document. The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="white-space: nowrap; text-align: justify">101.SCH*</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">Inline XBRL Taxonomy Extension Schema Document.</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="white-space: nowrap">101.CAL*</td>
    <td>&#160;</td>
    <td>Inline XBRL Taxonomy Extension Calculation Linkbase Document.</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="white-space: nowrap">101.DEF*</td>
    <td>&#160;</td>
    <td>Inline XBRL Taxonomy Extension Definition Linkbase Document.</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="white-space: nowrap">101.LAB*</td>
    <td>&#160;</td>
    <td>Inline XBRL Taxonomy Extension Label Linkbase Document.</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="white-space: nowrap">101.PRE*</td>
    <td>&#160;</td>
    <td>Inline XBRL Taxonomy Extension Presentation Linkbase Document.</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="white-space: nowrap">104</td>
    <td>&#160;</td>
    <td>Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">*Filed herewith.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">** This certification will not be deemed &#8220;filed&#8221;
for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section. Such certification will not be
deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the
extent specifically incorporated by reference into such filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 40 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td colspan="3" style="text-align: justify"><b>ALZAMEND NEURO, INC.</b></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 55%; text-align: justify">&#160;</td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 43%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">Date: December&#160;11, 2024</td>
    <td style="text-align: justify">By:</td>
    <td style="text-align: justify">&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">/s/ Stephan Jackman</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stephan Jackman<br/>
    Chief Executive Officer (principal executive officer)</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 55%; text-align: justify">Date: December&#160;11, 2024</td>
    <td style="width: 1%; text-align: justify">By:</td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 43%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">/s/ David J. Katzoff</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">David J. Katzoff<br/>
    Chief Financial Officer (principal financial and accounting officer)</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="text-align: center; margin-top: 0; margin-bottom: 0">41</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="text-align: left; margin-top: 3pt; margin-bottom: 3pt"><div style="border-top: Black 2px solid; font-size: 1pt; width: 100%">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</body>
</html>
